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Abstract
The pharmacological complexity of the now numerous subtypes of neuronal nicotinic 
acetylcholine receptors (nAChRs) has been increasingly refined through the appearance of 
greater numbers of pharmacological agents, derived from both natural and synthetic 
sources. This large structural data base of agonist and antagonist molecules harbours 
information required to refine the present model of the nicotinic pharmacophore - a unifying 
structural model for ligands active at the nicotinic receptor. Exploration of the relationships 
between structure and biological activity of such ligands is essential to the resolution of such 
a model, and consequently to the design of future ligands that may prove useful tools in 
subsequent receptor characterisation, or even have therapeutic use.
Biological descriptors of agonist molecules taken from structurally diverse families were 
generated through both a biochemical and physiological route. The former avenue, 
employing competition binding assays, established relative potencies of ligands at two 
subtypes of neuronal nAChR, and monitored the initial effects of structural modification. The 
latter method determined the functional activity of molecules at a reconstituted receptor 
expressed in the Xenopus oocyte system. Allied to these investigations was an exploration 
of feasible molecular geometries of ligands, examined using theoretical computational 
chemistry techniques. Through studying the biological effects of various molecules and their 
analogues, and the molecular features and geometries of these small ligands, the structural 
requirements of the nicotinic pharmacophore have further evolved.
Much attention in the project has focused on (+)anatoxin-a, a natural ligand found to be the 
most potent agonist at neuronal nicotinic acetylcholine receptors. The rigidity of this molecule 
and chemically modifiable nature, made it an attractive structure from which to explore 
structure-activity relationships of the neuronal nicotinic receptor. Rational design and 
synthesis of novel analogues of anatoxin-a to determine the bioactive configuration, revealed 
that extension of the sidechain retained, or possibly improved, activity yet had little influence 
on preferred geometry. These synthetic analogues provide an insight into the constraints 
imposed on the pharmacophore and those imposed by the receptor binding pocket, and 
represent important structures from which to further investigate the bioactive conformation of 
this ligand. The extended sidechain of the active analogues bestows potential for their use 
as affinity ligands for the nicotinic receptor.
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11.Introduction
Acetylcholine (ACh) functions as a neurotransmitter in many regions of the mammalian 
peripheral and central nervous systems by activating two structurally distinct classes of cell surface 
receptors: those activated by the mushroom alkaloid muscarine - the muscarinic receptors 
(mAChRs), and those by the tobacco alkaloid nicotine - the nicotinic receptors (nAChRs). Binding of 
ACh to mAChRs elicits responses mediated by GTP-binding proteins which modulate various 
effector molecules such as enzymes and ion channels. nAChRs are Ligand-Gated Ion Channels 
(LGICs) prevalent in the membrane of nerve and muscle which facilitate cation flux in response to 
the binding of effector molecules (e.g. ACh and nicotine), resulting in depolarisation of the excitable 
cell membrane. Such effects are made possible by transient conformational changes in the complex 
architecture of the receptor induced by the binding of effector molecules (agonists) many thousands 
of times smaller in size. This structural perturbation creates a temporary channel through the protein 
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Figure 1.1: The Ligand-gated Ion Channel (LGIC). Stylised representation of the receptor which traverses 
the membrane of excitable cells and is responsible for the creation of an ion conducting pathway in response 
to the binding of small agonist molecules. The protein possesses all the elements required for agonist 
recognition through to the complex structural features responsible for channel opening and desensitisation.
nAChRs are prevalent at the neuromuscular junction where they mediate contraction of muscle 
fibres. This contraction event serves as a convenient means of directly measuring receptor function 
and it is this, coincident with the abundance of the receptor in the electric organs of certain fish, and 
the availability of certain highly selective probes for the receptor, which has made the nAChR the 
most extensively studied of membrane receptors to date. Much more recently attention has focused 
on the physiological role of this receptor in the brain and its relevance to the addictive and 
behavioural effects associated with the use of tobacco-derived nicotine. Such motivations have 
catalysed extensive advances in the biochemical, molecular biological, ultrastructural and
3
physiological approaches to the understanding of the complex structure-function relationships 
associated with this receptor.
1.1 The neurotransmitter-gated receptor family
The nAChR is currently regarded as the prototypical Ligand-Gated Ion Channel (LGIC) 
receptor. This growing family of neurotransmitter-gated channels includes those found at excitatory 
synapses (nAChR, serotonin- (5HT3) and glutamate-sensitive receptors) which gate the passage of 
cations, and those found at inhibitory synapses (GABAa- and Glycine-sensitive channels) which are 
anion selective. All these proteins share the common function of regulated opening and closing of an 
integral ion channel.
Two subfamilies exist within this LGIC classification based on amino acid sequence identity. The 
subunits of nACh, 5HT3, GABAa and Glycine channels are homologous, particularly in their 
membrane-spanning segments (see below), whereas this family shares no overall homology with 
the glutamate-gated family which consists of AMPA- (a-amino-3-hydroxy-5-methyl-4-isoxazole 
proprionic acid), NMDA- (N-methyl-D-aspartate) and kainate-sensitive receptors - these channels, 
like certain members of the nAChR family, are cation selective. Homology between the subunits of 
different members of these two families is between 20% and 40%, whereas in the different subunits 
which create the individual channels of each family homology is generally at least 40%.
Despite the lack of overall homology among ACh- and glutamate-gated channel families, many 
conserved features are evident, among them the presence of four significant hydrophobic segments 
(Figure 1.2) which, although not yet unambiguously determined, are presumed to correspond to
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Figure 1.2: Subunits of the LGIC family members. Represented are the ACh family (first 5 
subunits) and the glutamate family (remainder) aligned at the pore forming M2 region - lengths 
correspond directly to amino acid numbers. Membrane-spanning regions common to all subunits 
are shown (M1-M4). N-terminal domains are longest, noticeably so in the glutamate family (-450 cf. 
-200 for ACh). A possible folding arrangement for the subunit is shown (inset) - an expanded 
representation is given in section 1.4.3.
membrane-spanning regions (M1-M4) which create the conduction pathway (see section 1.4.3). 
Among other conserved features are an extracellular N-terminal signal sequence, a long hydrophilic
4
N-terminal domain harbouring the agonist and competitive antagonist binding sites, conserved 
residues in the proposed pore-lining M2 region where non-competitive antagonists interact, and a 
large intracellular loop (located between M3 and M4) accommodating phosphorylation sites. This 
conserved topology and evident sequence similarity are sufficient to suggest that the LGIC channels 
may be based on similar 3-dimensional motifs.
Although these proteins are relatives in the same gene superfamily, they differ significantly in 
pharmacology, ion selectivity and response to allosteric modulators. The features that underlie these 
differences are beginning to emerge principally through the application of molecular biological 
techniques. Genes corresponding to the subunits of these receptors are being discovered and 
cloned with great rapidity, and are providing the foundations for the rigorous biochemical and 
pharmacological characterisation required to gain insight into the actual constitution of the different 
receptors found in situ. As will be demonstrated in section 1.3, the neuronal nAChRs are no 
exception, there now being at least ten different subunit genes, some of which contribute to the 
subtypes observed in neuronal tissue.
1.2 Torpedo electric organ nAChR - a LGIC prototype
Release of ACh into the synaptic cleft at the neuromuscular junction results in the rapid 
contraction of muscle fibres. Initial work on the characterisation of the nAChR mediating these 
events was performed on the electric organs of the electric eel, Electrophorus, and electric ray, 
Torpedo. These tissues are extremely rich in cells called electrocytes (or electroplax) which develop 
from muscle cells in the embryonic fish and are innervated by cholinergic neurons and therefore are 
an abundant source of nAChR - it is the summation of ACh-induced depolarisation of these cells 
which gives rise to the large electrical discharges associated with electric organs. Considered, 
therefore, to be an amenable model of the neuromuscular junction, the muscle-type nAChR of 
electric organ has been an invaluable tool for purification and characterisation studies on the nAChR 
protein. An additional factor which facilitated these studies is the occurrence of polypeptide toxins in 
certain snake venoms. Of these so-called a-toxins, a-bungarotoxin (aBgt) from the venom of 
Bungarus muiticinctus, (the Taiwan banded krait), proved to be an almost irreversible antagonist of 
the muscle-type receptor, and can be radiolabelled to a high specific activity. These attributes make 
this toxin an extremely useful affinity ligand and have proved instrumental in the localisation, and 
isolation of the nACh receptor, and as such has established this protein complex as the LGIC 
benchmark.
1.3 Heterogeneity of the nACh receptor family
Before introducing the pharmacological subtypes of native nAChRs and functional array of 
cloned putative cholinergic receptors found in neuronal tissue, it is perhaps pertinent to briefly 
mention some of the more homologous attributes of the muscle-type and neuronal receptors - a 
detailed structural picture of the receptor will be presented in section 1.4.
5
Subunit composition
Highly purified detergent extracts of Electrophorus and Torpedo electric organ reveal a strong 
a-toxin binding component. When reconstituted in lipid bilayers, this 290kDa glycoprotein mimics the 
ligand binding, ion channel function and ligand-induced desensitisation phenomena associated with 
functional nAChR in situ (Galzi e ta l 1991). Electrophoretic studies using protein from all vertebrate 
species analysed to date, reveal this molecule to be composed of four distinct polypeptide subunits 
assembled into a heterooligomeric pentamer (Figure 1.3). The subunits, a, p, 7  and 5, are all 
glycosylated with apparent molecular weights of 39, 48, 58 and 64kDa respectively (Schmidt & 
Raftery 1973), and form into a complex with a 2p78  stoichiometry. Reconstitution of the protein in 
frog oocytes following injection of subunit mRNAs shows that the a 2p78  oligomer contains all the 
structural elements required for the physiological response. In contrast to the muscle-type receptor, 
there are just two types of neuronal receptor subunits designated a  and non-a (alias p), of which 
multiple subtypes have been described: a2-a9 and p2-p4 (see section 1.3.1). In the case of both 
the muscle-type and neuronal receptor the a  subunits are characterised by the presence of two 
disulphide bridged cysteine residues located at positions 192 and 193 (Torpedo numbering), and 
form part of the principal ACh binding surface of the nAChR (see section 1.4.3.1). Non-a subunits 
are primarily structural though some amino acid residues are implicated in the formation of effector 
binding site(s) (see section 1.4.3.3).
Figure 1.3: Associations of the 
muscle-type nAChR complex in 
its membrane environment. The
heterooligomeric protein and ion 
channel results from the union of 
five subunits - a, p, 7 and 8 in 
muscle, but only a  and p in 
neuronal tissue - at least two a 
subunits are required. In the native 
membrane environment the 
receptor is anchored via contact 
with a 43kDa protein and 
cytoskeletal elements. Unique to 
muscle nAChR is the formation of 
dimers via disulphide bridging of 
adjacent 8 subunits (inset).
Variations in subunit composition of the receptor affect its physiological function. In adult muscle the 
e subunit replaces 7 , modifying both conductance and kinetic characteristics (Camacho et al 1993). 
In order to be functionally effective, muscle-type receptors require a  and either just two (Sine & 
Claudio 1991) or even one (Golino & Hamill 1992) other subunit type. However, the pentameric 
complex is essential to maintain function: for example, omission of 7 creates receptors of a 2pS2 
stoichiometry (Charnet et al 1992b). The capacity for heterogeneity is accentuated among the 
neuronal proteins as combinations of a2, a3 or a4 subunits with either p2 or p4, manifest functional 




1.3.1.5). Neuronal receptors also form pentamers (see section 1.3.1.5) but may contain more than 
one type of a  subunit, with, or without a p subunit. Forr instance the a 7 subtype, a feature of this 
project, readily forms functional homomeric channels (Couturier et al 1990a) of a pentameric 
stoichiometry (Anand eta! 1993).
Homology among the nAChR subunit sequences
The four polypeptide subunits of Torpedo share 54%  homology overall (Noda et al 1983) and 
are therefore likely to have arisen from gene duplication.. Human muscle and electric fish a  subunits 
show 80% sequence homology (Numa et al 1983) emphiasising the strong evolutionary conservation 
of this receptor subunit. Mammalian and avian neuronal nAChR subunit sequences are equally 
homologous: comparisons of all a  and p subunits from rat, chicken and human (see tablel of 
Sargent 1993) reveals amino acid sequence homologies of 40-60%, and corresponding sequences 
from rat and chicken are highly homologous (>70%). Even the subunit genes isolated from insects 
(Housefly and cockroach) and goldfish share signifficant homology with their more evolved 
counterparts. It should be pointed out that although neuronal non-a subunits are named p, this does 
not imply they are homologous to muscle-type p subunits, for they are not. In fact they are as similar 
to each other as they are to some of the neuronal a  subunits.
Putative membrane spanning regions are indicated by strong conservation of stretches of 
hydrophobic amino acids (see section 1.4.1). Althouglh overall amino acid sequence homology 
between gene products from neuronal and muscle sounces from the same species is 40-55%, this 
may increase to nearly 100% in the transmembrane regions (especially M1-M2), and in certain 
regions of the ligand binding N-terminal domain.
1.3.1 Neuronal nAChR subtypes present in situ
Although the muscle nAChR is now relatively well defined much less is known about nAChR 
in the nervous system. Extensive genetic characterisation of the neuronal nicotinic receptor has 
recently been possible using the knowledge gained from work on the muscle subtype, primarily 
through the use of monoclonal antibody (MAb) and complementary DNA (cDNA) probes. Hampered 
by a lack of suitable ligand probes, a paucity of the receptor in neuronal tissue and the paradox of 
non-functional aBgt binding proteins (see section 1.3.1.2) in brain, the genetic makeup of neuronal 
nAChR did not become apparent until the mid to late 1980's (rev. Clarke 1992). As mentioned 
above, ten genes have since been identified in rat and chicken neuronal tissue that are homologous 
to the muscle nAChR genes - eight putative agonist binding subunits (a2-a9) and 3 structural 
subunits (p2-p4) (see Deneris et al 1991: Elgoyhen et a l 1995). Before the functional implications of 
these subunits is considered the pharmacologically distinct native nAChR subtypes found in situ will 
be reviewed.
Three classes of pharmacological agents are recognised as affecting the behaviour of the 
nAChR as defined by pharmacological studies and radioligand binding experiments. Agonists (e.g. 
ACh, (-)nicotine, (-)cytisine, (-)lobeline, (+)anatoxin-a) initiate the mechanism(s) which open the
7
receptor channel. Antagonists, which prevent signal transduction events, are classified as either 
competitive (e.g. snake venom atoxins, dihydroperythroidine (DHpE) or methyllycaconitine (MLA)) 
which block the receptor response by binding to a site(s) overlapping with the agonist site, or non­
competitive (e.g. d-tubocurarine (d-TC) and local anaesthetics such as hexamethonium and 
mecamylamine). The latter group operate by binding directly in the channel pore thus sterically 
hindering ion flow (hence the term 'channel blocker'), but alternatively may bind to distinct regulatory 
sites (see section 1.4.4.1 & 1.4.4.2). Comparative analysis of the interaction of these ligands with 
muscle and neuronal nAChR reveals the presence of pharmacologically distinct receptor 
populations.
1.3.1.1 Native neuronal nAChR subtypes identified by [3H]-(-)-nicotine
[3H]-(-)-nicotine binding to mammalian brain preparations were first carried out some 20 years 
ago (Schleiffer & Eldefrawi 1974). The advent of commercially available [3H]-(-)-nicotine of high 
specific activity initiated a series of studies describing its binding to brain sites (rev. Wonnacott 
1987a). Most extensively studied has been the rodent brain (see Romano & Goldstein 1980: Marks 
& Collins 1982: Yamada et al 1985: Lipiello et al 1987: Martino-Barrows & Kellar 1987) which 
demonstrates saturable, high affinity binding (Kd 2-60nM) of [3H]-(-)-nicotine to what is now 
recognised to be a single receptor site - reported disparities in binding affinities have been attributed 
to the differences between protocols used for membrane preparation and binding assays. Although 
all nAChR recognise nicotine by definition, only those that bind nicotine with nanomolar affinity are 
labelled with the radiolabelled agonist. [3H]-(-)-nicotine binding to brain is strongly stereospecific; (-) 
nicotine is some 10-60 times more effective than its isomer. Pharmacologically, the [3H]-(-)-nicotine 
labelled sites show high affinities for cholinergic agonists and competitive antagonists, but lower 
affinities for non-competitive antagonists - see Wonnacott 1990. aBungarotoxin (see section 1.3.1.2) 
is unable to inhibit high affinity [3H]-(-)-nicotine up to high micromolar concentrations.
The less stable, though no less effective, [3H]ACh has also been used in the study of nAChRs. 
Irrefutable evidence from pharmacological studies (Schwartz et al 1982: Martino-Barrows & Kellar 
1987), autoradiographic and biochemical studies reveal that the site recognised by [3H]-(-)-nicotine 
and [3H]ACh in the brain are the same - see section 1.3.1.3. Similarly, [3H]cytisine and 
[3H]methylcarbamylcholine label the same receptor population as [3H]-(-)-nicotine (Wonnacott 1990).
1.3.1.2 Native neuronal nAChR labelled by snake atoxins 
[125l]a  Bungarotoxin (a  Bgt)
There exist many functional nACh proteins in mammalian, avian, amphibian and insect 
neuronal tissue which exhibit a binding site for abungarotoxin (aBgt). These sites, referred to as a  
bungarotoxin binding proteins (aBgtBPs), were for some time thought to be distinct from functional 
neuronal nAChRs (rev. Clarke 1992), despite exhibiting a nicotinic pharmacology, and being 
coincident on the same neurons as functional [3H]-(-)-nicotine labelled nAChR (Jacob & Berg 1983: 
Smith et al 1986). Many features of neuronal aBgtBPs paralleled those of the muscle homologue: a  
Bgt binding could be blocked by the affinity reagents 4-(N-maleimido)-benzyltrimethylammonium
8
(MBTA) and bromoacetylcholine (Lukas & Bennett 1980), and sulphydral reduction (Marks et al 
1986), whilst preincubation with non-competitive nicotinic antagonists enhanced the inhibition of [125l] 
aBgt binding by ACh (Lukas & Bennett 1979). Although a successful probe for the muscle-type 
receptor, the usefulness of aBgt in identifying nAChRs of mammalian brain and ganglia was 
considered to be limited, given its failure to antagonise most nicotinic responses (Schmidt et al 
1980). This was all the more confusing given the very good evidence for aBgt binding to a 
physiologically functional nAChR of the insect nervous system, and the isolation of a locust protein, 
(of comparable weight to that found in Torpedo), using a monoclonal antibody raised against nAChR 
from electric organ (Breer et al 1985). Despite these conflicting reports, work with this stable atoxin, 
amenable to iodination, has continued (see Clarke 1992) and the persistence has been rewarded by 
the now conclusive evidence that mammalian neuronal aBgtBPs do represent functional nAChR 
(see section 1.3.1.7).
I 125!] neuronal bungarotoxin (nBgt)
A minor component of Bungarus multicinctus venom, and variously referred to as K-Bgt, toxin
3.1 or toxin F, neuronal bungarotoxin (nBgt) specifically blocks the functional cholinergic responses 
associated with nAChRs of autonomic ganglia at concentrations of 5-100nM (Ravdin & Berg 1979: 
Chiappinelli 1983: Loring et al 1984). For instance [125l]nBgt demonstrates high affinity for chick 
ciliary ganglia nAChR (Kd=5-6nM) being displaced by micromolar concentrations of ACh and 
nicotine, but not by aBgt (Halvorsen & Berg 1986) - ganglionic nAChRs, with the exception of a7- 
and a 8-containing proteins, have greater affinity for nBgt (Kd=300nM for a3) than aBgt, which 
generally fails to block most ganglionic receptors up to 1jaM concentrations.
[125l]nBgt identifies two high affinity sites in the chick ciliary ganglion (Halvorsen & Berg 1986), one 
shared by aBgt (which binds extrasynaptically in ganglia) and another, synaptic site that is not. At 
the latter site, [125l]nBgt binding is inhibited by nicotinic antagonists such as tubocurarine and DHpE, 
and nicotinic agonists such as DMPP. However, the affinities of these cholinergic agents 
(micromolar) contrasts with the nM affinities displayed by [3H]-(-)-nicotine sites, an observation 
consistent with the absence of high affinity [3H]agonist binding to ganglionic neurons. Distributions of 
[125l]nBgt- and [125l]aBgt-labelled sites on ciliary ganglia differ considerably - aBgt receptors are 
uniformly distributed whereas the nBgt site not recognised by aBgt is concentrated at synaptic 
membranes (see Loring & Zigmond 1988). This coincides with the localisation of a3, a5  and p2 
subunits immunopurified from the same tissue (Conroy et al 1992) using mAb35, a monoclonal 
antibody raised against Torpedo nAChR and confirmed to identify functional receptors (rev. Loring & 
Zigmond 1988). Therefore in ganglia at least nBgt labels a distinct cholinergic receptor, whose 
distribution and number is essentially mirrored by mAb35.
It is unfortunate that the difficulty of obtaining isolated, pure toxin from snake venom has raised 
questions about the validity of the receptors identified using nBgt as specific probes for the nAChR, 
as with many other LGICs, are few and far between.
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1.3.1.3 Distribution of high affinity [3H]-(-)-nicotine and [125l]aBgt receptor sites
Autoradiographic analysis of rat brain sections labelled with [3H]-(-)-nicotine and [3H]ACh 
reveal an identical pattern of distribution of binding of these ligands (Clarke et al 1985). The 
strongest presence is revealed in the interpeduncular nucleus, superior colliculus, medial hebenular 
and thalamus. This distribution is very different from that observed for [125l]ocBgt (Clarke et al 1985) 
which is high in the cerebral cortex, hypothalamus, hippocampus, inferior colliculus and some 
regions of the brain stem. A more refined picture is revealed by Swanson and co-workers (1987) 
through immunohistochemical studies of avian and mammalian CNS. If the pharmacological profiles 
of these two distinct sites are also compared, little correlation is evident (Figure 1.4).
Figure 1.4: Regional
distribution (a) and 
pharmacological specificity 
(b) of nicotinic cholinergic 
binding sites in rat brain, (a)
binding site numbers
(fmol/mg protein) in different 
brain regions relate to
radiolabelled ligands - data 
is taken from Marks et al 
(1986). Sites labelled by 
nicotine and ACh are highly 
correlated (r=0.99), the 
same cannot be said of 
nicotine and aBgt (r=0.33). 
This pattern is mirrored in 
the pharmacological
correlations of these sites 
(b): nicotine/ACh (red),
r=0.98: nicotine/aBgt (blue), 
r=0.14. Agonists (O ) are 
more potent than 
antagonists (a ). Figure 
redrawn from Wonnacott 
(1990).
Consideration of immunocytochemical studies using monoclonal antibodies specific for particular 
subunits corroborates the distinctness of [3H]-(-)-nicotine and [125l]cxBgt labelled brain nAChRs and 
in general confirms the oc4 subunit to associate mainly with [3H]-(-)-nicotine/[3H]ACh binding and a7 
and a 8 with aBgt (rev. Lindstrom et al 1987: Sargent 1993).
The pattern of gene expression for the subunits has refined speculation as to the putative subunit 
composition of the nAChRs identified by radioligands. In situ hybridisation assays show that at least 
one nAChR gene is expressed in numerous areas within rat brain and that each gene is expressed 
in a distinct pattern (Wada et al 1989: Seguela et al 1992). The anatomical distribution of rat brain 
regions expressing nAChR genes correlates fairly well with the distribution of high affinity [3H]-(-)- 
nicotine and [3H]ACh sites (Clarke e ta l 1985) and with anti-AChR antibody binding (Swanson et al 
1987). As such these observations, and those resulting from heterologous expression of subunit
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genes in various cell lines (see section 1.3.1.4), have confirmed the heterogeneity of the nAChR and 
the probable subunit composition of principle receptors identified by radioligands.
1.3.1.4 Heterologous expression of cloned neuronal nAChR subunits
Many lines of evidence support the notion that the genes identified, cloned and sequenced 
from mammalian and avian nervous tissue could be those that encode nAChR subunits. As 
discussed above, the pattern of expression of these genes in autonomic neurons and brain nuclei 
closely resembles that of high affinity [3H]-(-)-nicotine/ACh and [125l]cxBgt sites, and is consistent with 
nicotinic responses in the same regions. Perhaps the most solid support for these genes 
representing nAChR subunit sequences is apparent when they are transfected, or the corresponding 
cDNAs/mRNAs injected, into non-neuronal cells and are able to form fully functional receptors 
responsive to cholinergic ligands.
Following injection of mRNAs of the rat a2, a3  or a4 subunits in combination with either the 02 or 
04 gene into Xenopus oocytes (Boulter et al 1987: Wada et al 1988: Deneris et al 1989) functional 
nAChRs are expressed and appear in the membrane (Figure 1.5). Only the a4 subunit, of these 
clones, is able to form, albeit unstable, homomeric channels. This picture is repeated for the 
equivalent chicken subunits following cDNA injection into the oocyte nucleus (Ballivet et al 1988: 
Couturier et al 1990b). This suggests that these genes do indeed encode valid nAChR subunits and 
that specific combinations of a  and 0 coassemble to form individual functional nAChRs, 
complementing the immunocytochemical and autoradiographic findings (see Sargent 1993).
The rat a5 and a 6 cDNAs are unable to form functional channels in oocytes even when injected 
with several other a  and 0 clones (Boulter et al 1990). Similarly, rat 03 does not form channels 
when coinjected as mRNA with a2, a3 and a4 clones (Deneris et al 1989). These subunits may be 
required to coassemble with as yet undiscovered subunits in the formation of the channel or, as with 
a5, which has been found to be assembled with a4 and 02 in the same complex (Conroy et al 
1992), require more than one different subunit type. Of course there is always the possibility that the 
'non-functional' subunits are members of another family of LGICs or are incorrectly, or insufficiently, 
modified following their translation in the amphibian oocyte. It is evident that the stably expressed 
nAChRs in mouse fibroblasts (M10) transfected with chicken a4 and 02 cDNAs (Whiting et al 1991), 
are pharmacologically very similar to those in chicken brain where both a4 and 02 predominate 
(Morris e ta l 1990).
Agonists and antagonists distinguish proteins with distinct choiinergic pharmacologies
Pairwise injection of a2, a3  or a4 with either 02 or 04 yields six pharmacologically distinct 
nAChRs as demonstrated by their unique rank order of potency to the agonists nicotine, ACh, 
cytisine and DMPP (Luetje & Patrick 1991). Both a  and 0 subunits contribute significantly to the 
observed potencies. Notably cytisine sensitivity is radically affected depending on the nature of the 0 
subunit: 04-containing nAChRs are more sensitive to cytisine than other agonists, while 02- 























Figure 1.5: Subunits represented in muscle and principle brain nAChRs following injection 
into non-neuronal cells. Both muscle and neuronal nAChR form as pentameric complexes as 
represented. [125l]aBgt binds with high affinity to receptors in muscle and electric organ, complexes 
that comprise a p 7/e and 5 subunits (a). Injection of cloned neuronal subunit mRNA or cDNA into 
Xenopus oocytes in various combinations (b) reveals that pharmacologically equivalent receptors to 
those labelled in situ by [3H]-(-)-nicotine, [125l]nBgt and [125l]aBgt are expressed (c): the principle 
brain receptor (labelled by [3H]-(-)-nicotine) comprises oc4p2 subunits, the nAChR of autonomic 
ganglia (that labelled by [125l]nBgt), constitutes a3p4, and receptors identified by [125l]ocBgt comprise 
a7 (and/or a8) subunits which are functional as homomeric channels, though this may not 
necessarily represent their native form. Cell line models of these various receptors are given in 
parenthesis.
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nAChR are equally affected by the nature of the a  submit. a4p2 heterooligomers have higher 
affinity for ACh and desensitise to a lesser extent than do a3p2 nAChRs (Gross et al 1991). Species 
differences are also apparent between equivalent nAChR subunits because the differences 
observed for the chicken a4p2 and a3p2 receptors are not apparent for the equivalent 
heterooligomers of rat (Luetje & Patrick 1991). The a7 honomeric receptor is very different again 
from chicken a4p2 and rat a4p2 demonstrating a higher affinity for nicotine than ACh and more 
extensive desensitisation (Couturier et al 1990b).
Oocyte expression of heterologous subunits has confirmed the existence of the nAChR subtype 
sensitive to nBgt and has identified the a3 subunit as responsible for conferring this specificity. nBgt 
(100nM) completely abolishes ACh-induced currents of receptors formed on injection of a3  and p2 
mRNAs in oocytes (Luetje et al 1990). The a4p2 nAChR is less sensitive and a2p2 are completely 
insensitive to this toxin. As with the agonist sensitivities, antagonists are also differentially influenced 
by the nature of the p subunit and a3p4 nAChRs are completely insensitive to nBgt (Duvoisin et al
1989). The aBgt binding protein component a7 is the only subunit whose ACh-induced currents are 
functionally blocked by aBgt (IC50=0.9nM), and it does so as a homomeric receptor (Couturier et al 
1990a).
1.3.1.5 Electrophysiological diversity of reconstituted receptors
Combinations of a2, a3  or a4 mRNA with p2 generate cell surface proteins in the oocyte 
which have unique single channel properties, and in the case of a2p2 and a3p2 two conductance 
states are observed (Papke et al 1989) - Charnet and co-workers (1992a) report three 
electrophysiologically distinct channels following a4 and p2 injection. This latter phenomenon raises 
the question of how more than one distinct nAChR population appears in the oocyte following 
injection of a single a  and single p subunit? There may be two explanations for this:
• subunit coassembly is a promiscuous event: for instance subunit stoichiometry may vary (e.g. 
a 2p2, a 3p2, a 2p3, a 3p3), as might the subunit order around the pore (e.g. a p a p p , a a p p p  etc.). 
Present opinion favours an a :p  stoichiometry of 2:3 for the neuronal nAChRs. Besides activation 
characterised by Hill coefficients greater than unity and a size (~300kDa) indicative of a 
pentameric structure, a4p2 nAChRs have also been 35S-methionine labelled (Anand et al 1991) 
and indeed the ratio of a :p  subunits was 1:1.46 implying a a 2p3 stoichiometry. The a4p2 
nAChR stably transfected into M10 mouse fibroblast corroborates this (Whiting et al 1991), as do 
the channel conductance studies of Cooper and co-workers (1991).
• channels of the same subunit arrangement may undergo different post-translational 
modifications in the oocyte.
Whatever the reason, these multiple conductance states are also apparent in p4-containing 
receptors (Papke & Heinemann 1991), though mean conductances are again distinct from p2- 
containing proteins.
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1.3.1.6 Correlations of native and expressed receptors
One goal of expression studies is to be able to interpret experimental observations in terms of 
native receptors. However caution must be emphasised. For example heterologously expressed a3 
(32 and oc3|34 nAChRs have higher affinities for ACh (Bertrand eta l 1991: Gross et al 1991) than the 
native chick ciliary ganglion receptors of the same constitution (Margiotta et al 1987). Likewise the 
channel conductance of reconstituted a4(34 nAChRs does not match that of the native channels in 
the interpeduncular nucleus (IPN). This brain region also shows the presence of a2, a3, a4, a5, (32 
and (34 subunit genes (although not necessarily on the same neuron) - the nicotinic receptors of IPN 
neurons have a channel conductance of 35pS (Mulle et al 1991), a value very close to that exhibited 
by the predominant nAChR, a2(32, found in these neurons (34pS: Papke et al 1989). This 
correlation may indicate that a2 and P2 subunits form the principal nAChR of IPN neurons.
This latter case currently represents the only situation where there is direct correlation between the 
native nAChR and that observed upon expression of subunit genes in the oocyte. If more 
physiological attributes are considered then the number of variables defined for the match markedly 
reduces the hit rate. Even considering simply agonist rank order of potency and conductance 
characteristics can reduce the coincidence. For example in the rat medial hebenular and the 
autonomic ganglion cell model (PC12 cell), conductance states (26pS) indicate the presence of 
a3p4 channels (22pS), yet the agonist rank order of potency of these same channels resembles 
that of no other heterologously expressed nAChR subtype (Luetje & Patrick 1991: Mulle e ta l 1991). 
As mentioned previously, these anomalies may be a consequence of factors alluded to earlier: poor 
processing by the oocyte or a requirement for different subunits, which may as yet be unidentified.
1.3.1.7 Functional role of abungarotoxin Binding Proteins
aBgtBPs of chick optic lobe (Wong & Schmidt 1976) and retina (Betz 1981), and goldfish 
brain (Henley & Oswald 1987), exhibit high (nM) affinity for [125l]aBgt and demonstrate a nicotinic 
pharmacology (i.e. low micromolar affinity for agonists, ACh and nicotine). The isolated protein 
complexes are similar in size (with sedimentation coefficients ~11S) to those of electric organ, 
muscle and brain, though antigenic complementarity is limited (see Lindstrom et al 1987). That these 
aBgtBPs are members of the same nAChR gene family is apparent when it is realised that the 
lighter (48kDa) of the 4 to 5 polypeptides that constitute the aBgtBP complex, shows considerable 
homology with the N-terminal sequence of electric organ and muscle derived nAChR subunits 
(Conti-Tronconi et al 1985), and furthermore by the presence of homologous cysteines 192 and 193 
(Norman et al 1982). Unequivocal support for the function of aBgtBPs as Ligand-Gated Ion 
Channels has since been demonstrated in the chick ciliary ganglion (Zhang e ta l 1994), where these 
proteins appear responsible for increasing levels of intracellular calcium.
Rodent brain aBgtBPs have also been extensively investigated (Marks & Collins 1982: Lukas 
1986: Marks et al 1986), and as with their insect, fish and avian counterparts have a distinctly 
nicotinic pharmacology. As mentioned earlier, these proteins are distinct from those neuronal nAChR 
which bind nicotine and ACh with high affinity, exhibiting a quite different distribution pattern in brain
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(see section 1.3.1.3). Limited antigenic and structural homology is evident between electric organ 
and muscle nAChRs, and neuronal aBgtBPs (Morley e ta l 1983: Mills & Wonnacott 1984). Affinity 
chromatography purification of a rat brain aBgtBP (Whiting & Lindstrom 1987) identifies a complex 
of four polypeptides (MW: 45, 52, 56 and 65 kDa). [3H]MBTA and [3H]-bromoacetylcholine (BAC) 
alkylate a 55kDa component which is presumed to be an a  subunit for the aBgtBP (Norman et al 
1982: Kemp et al 1985). As many as four additional components have been reported to copurify with 
this subunit (Conti-Tronconi et al 1985) but it is unclear whether these may be artefactual or 
represent other subunits that form an aBgtBP heterooligomer.
Two groups (Couturier e ta l 1990a: Schoepfer e ta l 1990) have since unequivocally demonstrated 
the presence of two subunits (a7 and a 8) in chick brain able to bind aBgt with high affinity. 
Furthermore a7 appears as a 57kDa protein in denaturing gels, concurrent with the size of the 
subunit affinity alkylated by [3H]MBTA and [3H]-BAC. The a7 subunit is predominant among the [125l] 
aBgt binding sites - an a7-specific MAb immunoprecipitates >90% of the aBgt sensitive nAChRs. 
Rat (Seguela et al 1992) and human (Peng et al 1994) brain a7  subunit genes have also been 
identified. Use of an antisense probe to supress the expression of the a3 subunit in chick 
sympathetic neurons provides strong evidence that this subunit may be associated in the same 
complex with a7  (Listerud et al 1991). The rat a9  subunit also exhibits high affinity for aBgt and, as 
with a7  and a 8 subunits, is able to form functional homomeric proteins gated by nicotinic, but also 
muscarinic, ligands (Elgoyhen efa/1995).
1.4 Structural features of the nicotinic receptor complex
Section 1.3 briefly outlined the themes that underlie the 3-dimensional structure of the muscle­
like and neuronal nicotinic receptors. These features (Figure 1.6) stem from a series of conserved 
motifs among the constituent subunits and will be reviewed in more detail in the ensuing sections 
with a view to mapping the locations of the various effector sites and understanding how the 
associations impart the functional character of the receptor. Emphasis will be placed on the residues 
implicated in, and nature of, the ligand binding site(s) as it is this region which is most crucial to 
receptor activation events via interaction with ligands which dictate the nature of the nAChR 
pharmacophore.
1.4.1 Motifs of subunit primary structure
The following observations have been widely reviewed (see Galzi et al 1991a: Sargent 1993). 
Four distinct regions of hydrophobic amino acids are obvious on alignment of Torpedo, muscle and 
neuronal derived subunit sequences (Figure 1.6c & d). These putative membrane-spanning regions 
(M1-M4), some 20-30 amino acids in length, are presumed to fold into mainly a  helix (Noda et al
1983) as they span the ~32A hydrophobic portion of the bilayer (Figure 1.4e). M2 lines and gates the 
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Figure 1.6: Model of transmembrane topology and organisation of the nAChR subunits.
Possible arrangement of the five subunits about the axis of pseudosymmetry of the receptor (a) in 
the creation of the ion pore (b). Models of the subunit topology, largely based on hydrophobicity 
profiles of the amino acid sequence and antibody studies, reveal the presence of four 
transmembrane regions (M1-M4) per subunit which associate non-covalently as they cross the 
membrane with the M2 portion (purple) facing the channel lumen (b). Each subunit (c) & (d) is 
characterised by a large extracelluiary located N-terminal domain bearing glycosylation sites and, in 
a  subunits, a pair of conserved cysteines (CC). Between M3 and M4 is an intracellular loop 
containing potential phosphorylation sites through which receptor function can be modulated. 
Channel lining residues of M2 have periodicity indicative of a  helical structure while the remainder 
may be p-barrel (e) (Unwin 1993) - this may be reflected in the other transmembrane sequences.
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All nAChR subunit sequences have a large hydrophilic N-terminal domain oriented toward the 
synaptic cleft which bears an N-glycosylation site (N141 - Torpedo labelling). Hydrophobic M1, M2 
and M3 regions separate this domain from a smaller but similarly hydrophilic variable cytoplasmic 
loop which carries consensus sites for phosphorylation. Modulation of the receptor through 
phosphorylation of these sites by protein kinases influences the desensitisation characteristics of the 
receptor. M4 connects this loop to the short C-terminal region, creating a model whereby both N- 
and C-terminus are extracellularly located (DiPaola et al 1989). The agonist binding site is confined 
to the N-terminal domain (see section 1.4.3) with the ion channel in the axis of pseudosymmetry of 
the protein complex, as revealed by electron microscopy (see section 1.4.2). It is apparent from the 
remoteness of effector site and channel that indirect or 'allosteric' interactions must occur in order for 
effective signal transduction to take place.
A stretch of -40 amino acids is also rigorously conserved in all muscle and neuronal nAChR 
subunits. Characteristically amphipathic and with the periodicity of an a  helix (Finer-Moore & Stroud 
1984: Guy 1984), this sequence does not appear in subunits of other LGIC family members. Its 
original designation as a transmembrane segment lining the channel has now been discounted but 
its role is still an enigma.
1.4.2 Electron microscopic structure of the receptor
The subunits of the nAChR protein complex are intimately associated by non-covalent 
interactions and in Torpedo the receptor predominately occurs as a dimer of oligomers (Figure 1.3). 
This association, unique among LGICs, occurs through disulphide cross-linking of cysteine residues 
at the carboxy terminus of the adjacent 5 subunits (Dunn et al 1986). The quaternary structure of the 
nAChR is unknown, but a rudimentary picture is emerging through studies on tubular crystals of 
Torpedo membranes densely packed with nAChR using electron microscopy (Unwin 1993). A 
consensus representation of the membrane-bound configuration is as drawn in Figure 1.1. At 9A 
resolution the receptor appears perpendicular to the membrane being some 120A in length with 
subunits arranged rosette-like in a left-handed twist around a central axis. The conduction pathway 
consists of a narrow pore across the bilayer some 30A long, with the narrowest diameter, around 7k, 
representing the gating site and ion selectivity filte r. Much of the receptor is extracellular with protein 
extending some 55A above the membrane. These extracellular domains of each of the five subunits 
form a cylindrical vestibule which accounts for -20% of the solvent accessible surface area of the 
extracellular region. A protein wall some 25A thick insulates this entrance cavity from changes in the 
membrane potential field, having dimensions indicative of p-barrel structure. Analysis of aligned 
sequences predicts a net charge of -50mV for this extracellular domain (residues 1-228) at pH7 
(Stroud et al 1990). If evenly distributed the vestibule could contain at least 10 negative charges thus 
concentrating cations at the mouth of the channel (Dani & Eisenmann 1987). Notably, anion 
conducting GABAa and glycine receptors have excess positive charge in this same region.
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Disposition of agonist and non-competitive antagonist sites.
The distance between the agonist and channel sites is estimated to be 20-40A according to 
studies using the fluorescent agonist dansyl choline (Waksman et al 1980), and the competitive 
antagonist bis(choline)-N-(4-nitrobenzo-2-oxa-1,3-diazol-7-yl)-iminodipropionate (BCNI: Bolger e ta ! 
1984). More recent fluorescence lifetime and energy transfer experiments (Herz et al 1989) place 
the acetylcholine binding site 20-30A from the membrane, a finding consistent with electron 
microscopy results of the whole receptor (Unwin 1993) - the reconstituted image of the receptor 
reveals distinct bulges at this point and even at quite low resolution (Toyoshima & Unwin 1990) a 
cleft and internal cavity are evident suggesting that this binding pocket is as close to the membrane 
as to the top of the protein. Therefore, the allosteric interaction between ACh binding sites and 
channel occurs over considerable distances, suggesting an intricate model of the binding site 
required to bring about such long-range interactions.
The 43kDa receptor-associated entity
Another prominent feature of the membrane bound muscle receptor which is revealed through 
electron microscopy is the presence of a large cytoplasmic element which intimately associates with 
the receptor (Figure 1.3). Various cytoskeletal and regulatory molecules, including protein kinases 
(Huganir & Greengard 1990) converge here, in particular a so-called '43kDa protein' which may 
represent the receptor associated entity revealed by EM images. Several indirect lines of evidence 
suggest that this protein may be involved in the establishment and/or maintenance of nAChR 
clusters at synaptic junctions.
1.4.3 Structure of the acetylcholine binding site
Three classes of pharmacological agents are recognised as affecting the nAChR as defined 
by pharmacological studies and radioligand binding experiments (see section 1.3.1). Agonists initiate 
the mechanism(s) which open the receptor channel. Competitive antagonists prevent signal 
transduction events by occluding the agonist site. Non-competitive antagonists operate by binding 
directly in the channel pore thus sterically hindering ion flow (hence the term 'channel blocker'), but 
alternatively may bind to distinct regulatory sites (see section 1.4.4.1). The pharmacologically distinct 
nAChR populations of muscle and neuronal tissue are united by the fact that the agonists and 
competitive antagonists impinging on them exert their effects by binding to overlapping site(s) 
carried principally by the a  subunits (rev. Lindstrom et al 1987). The residues implicated in the 
recognition and binding phenomena leading up to activation (and desensitisation), or inhibition are 
described below.
1.4.3.1 Residues labelled using cholinergic affinity probes
The agonist molecules that bind to and activate the nicotinic receptor complex are very small 
in comparison to the protein. This suggests that the binding site itself need only be a small region of 
the protein, the remainder of the complex providing the architecture required for the channel and for 
transducing the long-range conformational changes between the topographically remote agonist and 
channel sites. The changes leading up to channel opening may be initiated through a local
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disturbance on agonist binding which could be envisaged through a complex 3-dimensional 
architecture around the agonist molecule. Indeed acetylcholinesterase hydrolyses ACh through a 
spatially complex site consisting of a narrow gorge lined by some 14 aromatic residues (Sussman et 
al 1991), though conformational changes are not prerequisite for this latter case.
Although there is evidence that the nAChR binding site may lie, at least partially, between the 
interface of the a  subunit and its neighbour (see section 1.4.3.3), many residues of the a  subunit 
contribute to the ACh binding region. The disulphide-linked adjacent cysteines at positions a192 and 
a193 of native nAChR from all species and tissues, when reduced, are the site of incorporation of 
the affinity label MBTA (4-(N-maleimido)-benzyltrimethylammonium) (Kao et al 1984). A variety of 
studies based on snake atoxin binding to regions including these residues, and mutagenesis 
experiments, have confirmed that the region containing cysteines 192 and 193 contributes to the 
binding site for nicotinic ligands (see Galzi et al 1991 a).
The intimate molecular organisation of the ACh-binding site has been probed most extensively and 
successfully using the photoaffinity probe DDF (N,N-(dimethylamine) benzenediazonium 
flouroborate). This molecule acts as a reversible competitive antagonist of the nAChR of 
Electrophorus and the C2 mouse cell line (Langenbuch-Cachet et al 1988) under light-excluding 
conditions. Photoactivation of this ligand via an excited tryptophan residue in the binding site, 
improves the labelling specificity with no need for prior reduction, and reveals that DDF strongly 
labels the agonist/competitive antagonist binding site with one molecule being incorporated per aBgt 
binding site (Langenbach-Cachet e ta l 1988). Residues labelled by [3H]DDF, in a carbamylcholine-
sensitive manner, are identified in three distinct regions of the a  subunit (Dennis et al 1986).
Five residues are strongly labelled by DDF: Tyrosine 93, Tryptophan 149, Tyrosine 190 and the two 
cysteines 192 and 193 (Torpedo numbering). Additionally, some weak affinity is also demonstrated 
for Tryptophan 86, Tyrosine 151 and Tyrosine 198 of the a  subunit (Dennis et al 1988: Galzi et al
1990). DDF labelling of these regions is competitive with both atoxin and carbamylcholine. Thus it 
seems that the architecture of the binding site on the a  subunit is indeed complex involving a cavity 
created by at least three loops of amino acids in the N-terminal hydrophilic domain (Figure 1.7). 
Complexity is extended by the confirmation that as yet unidentified residue(s) of the 7 subunit are 
also labelled by [3H]DDF (Langenbuch-Cachet et al 1988), providing direct support for the 
involvement of non-a subunit residues in the building of the site (see section 1.4.3.3).
Any preconceptions that these DDF labelled residues may be artefactual or coincidental can be 
discounted for a number of reasons:
• Cysteines 192 and 193 are labelled both by DDF and MBTA.
• Tyrosine 190 reacts covalently with the competitive antagonist lophotoxin from marine coral 
(Abramson eta l 1989).
• All the residues labelled by DDF are conserved at homologous positions in all a  subunits from 
muscle and neuronal sources from all species examined to date, including humans. The only
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exception being the neuronal a5 subunit, which lacks Tyr93 and Tyr190, but this subunit is 
unable to form functional nAChR with any non-a subunits when expressed in the Xenopus 
oocyte system (Boulter etal 1990).
• Muscle-type non-a subunits (i.e. (31, 7  and 5) lack the principal five amino acids labelled by 
DDF.
Figure 1.7: Model of the
agonist/competitive antagonist 
binding site. Represented are the key 
residues in the a  subunit of the nAChR 
identified by the photoactivatable 
competitive antagonist DDF. Black 
balls represent amino acids most 
strongly labelled and include those 
labelled by lophotoxin (Y190) and 
MBTA (C192/193) - Torpedo
numbering. The site appears to consist 
of three loops of amino acids which are 
mainly hydrophobic in character. The 
conserved 'Cys-loop' (see section 
1.4.3.2) is also shown containing 
potential interaction sites yet no 
residues of this sequence are 
identified by the photolabel. 
Unidentified residues (X) in the 7 and 8 
subunits of muscle nAChR are also 
identified by DDF and may be a 
negative subsite.
Neuronal nAChR non-a subunits have however conserved two of the DDF residues, namely: Tyr93 
and Trp149 (Deneris eta l 1988: Nef e ta l 1988: Duvoisin e ta l 1989: Isenberg & Meyer 1989). This 
conservation of some a-like features implies that these subunits may have a function in neuronal 
tissue. This is not altogether surprising given that 7 and 8  subunit equivalents appear to be absent in 
neuronal receptors and that the a  subunit seems only to provide part of the binding site (see section 
1.4.3.3).
The evidence is therefore very clear. Residues labelled by DDF, MBTA and lophotoxin, all molecules 
which demonstrate a clear nicotinic cholinergic pharmacology, are highly conserved through
evolution and must therefore be strong candidates in the formation of the ACh binding site of the a
subunits. More recently, a further region encompassing Trp54 of the a  subunit has been implicated 
in the binding of cholinergic ligands to the a7 homomeric receptor (Corringer et al 1995), a position 
which is analogous to Trp residues labelled by d-TC in the 7 and 8  subunits of the Torpedo receptor, 
supporting a role for non-a subunits in the formation of the site (see section 1.4.3.3).
1.4.3.2 Contribution of other sequences on the a  subunit to the site - the 'Cys-loop*
Two additional cysteine residues, 128 and 142, are conserved in the subunits of all nAChR 
subunits, as well as GABAa and Glycine receptors. These residues have been proposed to form a
’Cys loop'
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disulphide bridge in vivo generating a highly conserved 15-residue loop, termed the 'Cys-loop' (Kao 
& Karlin 1986). A synthetic peptide of this region interacts with ACh and aBgt (McCormick & Atassi
1984) and sequential mutation of all the residues to serine totally abolishes ACh-induced responses 
in the native receptor (Mishina et al 1985). As regards the brain receptor, high affinity nicotine 
binding is specifically inhibited by antibodies raised to a peptide encompassing positions 3-12 of the 
neuronal a  subunit loop.
It has long been a widely held belief that carboxylate anions (side chains of aspartic and glutamic 
acids) are the principal species which interact with the cationic headgroup of nicotinic ligands. Good 
candidates for this anionic site exist in the 5 subunit of the muscle-type receptor (see section 1.4.3.3 
and 1.4.3.5) and also at position 11 of the 'Cys loop' (Figure 1.8), an invariant aspartate, one of only 
two invariant acidic residues in the whole of the N-terminal hydrophilic domain of LGIC subunits. 
Theoretically modelled as forming a rigid (3-hairpin (Cockcroft et al 1990), the loop has inherited a 
number of additional features which are proposed to account for neurotransmitter specificities of the 
various ligand-gated channels and provision of binding surface residues. More specifically, 
conserved hydrophobic and hydrophilic residues are positioned such that the structure assumes an 
amphipathic character, the hydrophilic face containing four invariant or strongly conserved residues 
which includes the anionic and specificity residues. Although the theoretical picture being painted is 
a very neat one, unfortunately none of the residues in this loop are labelled by photoaffinity reagents, 
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Figure 1.8: Energy minimised model of the 'Cys-loop' structure of the chick a2 
subunit. Containing many attractive features of a potential binding surface this 
conserved 15 residue sequence has been modelled (Cockcroft et al 1990) as a proline 
turn-induced (position 9) amphipathic (3-hairloop structure which is stabilised by a 
disulphide bridge. A conserved anionic residue at position 11 creates a natural charge 
interaction site for all LGIC effectors, with a specificity residue at position 6 which varies 
to accommodate ligands of the particular LGIC. Although highly conserved among LGICs 
there is little experimental evidence which supports this region as a major contributor to 




Thus this conserved motif may play a subsidiary role in the creation of the binding pocket or may 
serve an as-yet unknown purpose.
1.4.3.3 Contribution of non-a subunits to the ACh binding site 
a  Subunit binding sites are non-equivaient
As described, the a  subunit of the nAChR contains principle elements of the ligand binding 
site. Each receptor contains two copies of this subunit and hence has two binding sites (Reynolds & 
Karlin 1978). Both sites are required to be occupied for effective activation and interact in a positive, 
co-operative manner (rev. Changeux 1990). However, although a1 subunits are encoded by a 
single gene in Torpedo (Klarsfeld et al 1984) and mouse (Merlie e ta l 1983), the two agonist binding 
sites are not equivalent. The most probable cause of this non-equivalence is due to the contribution 
of additional subunits to the binding surface for agonist and competitive antagonist molecules. 
Evidence for this is apparent in the association and dissociation kinetics of atoxin binding, which 
occurs in two steps (Ratnam e ta l 1986) indicating the presence of two sites with different affinities 
for the same ligand. Furthermore, dissociation of bound toxin occurs at different rates in the 
presence of competing cholinergic ligand. Many other lines of evidence support this view including 
equilibrium binding experiments with the antagonists [3H]d-tubocurarine and lophotoxin, and affinity 
reagents MBTA or bromoacetylcholine, all of which bind to both sites with different affinities (see 
Galzi et al 1991 a).
Both the 7 and 8 subunits contribute to the ligand binding surface of the muscle receptor. Irradiation 
of the [3H]atoxin-receptor complex results in the covalent incorporation of radioactivity in 7 and 8 
subunits in addition to a  (Oswald & Changeux 1982). Also DDF, demonstrated to covalently label 
specific residues of the a  subunit, is also incorporated in a carbamyl-sensitive manner into the 7 
subunit (Langenbach-Cachet et al 1988). Likewise, a  and 7 subunits, and a  and 8 subunits, are 
photoaffinity labelled by [3H]-(-)d-tubocurarine when bound to its low- and high-affinity site 
respectively (Pederson & Cohen 1990). Binding sites consistent with a 7 and a 8 association are 
also observed when these subunit combinations from mouse muscle are expressed in fibroblast 
cells revealing different high-affinity binding sites for d-tubocurarine (Blount & Merlie 1989) - 
omission of 7 or 8 generates receptors which have poor affinity and cooperativity for nicotinic ligands 
(Karlin 1991).
Notably, affinity labelling, (using MBTA and BAC), of neuronal aBgtBPs produces a monophasic 
concentration curve indicating either labelling at a single site, or at more than one site with the same 
affinity (Ratnam et al 1986). Thus it could be that the ACh binding subunits of certain neuronal 
nAChRs create a more symmetrical environment than muscle-type which is unsurprising given that 
only a  and (3 subunits constitute the protein complex.
Order of subunits around the channel
The p1 subunit of muscle nAChR has failed to be identified as contributing to the binding site(s) and 
is consequently regarded to have a purely structural role - this contradicts previous observations
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(Kubalek et al 1987) that placed the (3 subunit adjacent to a  subunits. The evidence for the 
involvement of the 7 and 5 subunits in the formation of the effector site(s) concurs with the current 
model which supports a cyyocpS arrangement for the muscle-type receptor. Neuronal receptors are 
possibly simplified by the presence of only the a  and p subunits.
1.4.3.4 An aromatic preference
As discussed in section 1.4.3.1, the conserved residues that are labelled by photoaffinity 
labels are aromatic in character. This is consistent with a model where either the lone pair of 
electrons of the phenolic oxygen of tyrosine and/or the n  electron system associated with the 
hydrophobic ring provide the principal electronegative character required for association with the 
cationic head, the prerequisite of all cholinergic ligands. Indeed synthetic analogues of the receptor 
binding pocket in the guise of hydrophobic macrocycles and macrocyclic polyphenoxides, 
demonstrate micromolar affinity for methyl-substituted ammonium groups (see Dougherty & Stauffer
1990), observations consistent with the need for electrostatic and hydrophobic interactions in the 
binding pocket.
More recently NMR techniques have pin-pointed Trp184 in the Torpedo sequence a184-200 as 
interacting through its aromatic protons with the N(CH3)3+ and CH3 groups of ACh (Fraenkel et al
1991). Cross-peaks indicated that the interaction occurred over a distance of less than 5k.
1.4.3.5 Negative subsite of the binding pocket
It would be fool-hardy to discount the presence of a negatively charged subsite, created by 
anion residues, which may provide the opportunity for significant charge-charge interactions to occur 
between the nicotinic receptor and its ligand(s). Although aromatics seem to be prevalent and the 
Cys-loop aspartate seems not to react with affinity reagents, more recent evidence lends credence 
to a binding site model that incorporates a negative subsite.
Aspartates and glutamates are present in much larger numbers in the 8 subunit of muscle-type 
receptor. It is known that a subsite binding the quaternary ammonium of ACh exists some 10A from 
Cys192/193 (Karlin 1991). Carboxyl groups within the Torpedo 8 subunit specifically react with a 9A 
crosslinker designed to interact with carboxyl groups at one end and sulphydryls at the other 
(Czajkowski & Karlin 1991). Greatest reactivity is observed for the 8164-224 fragment which in 
mouse contains four aspartates and eight glutamates. Mutation of these residues to asparagine or 
glutamine (Czajkowski e ta l 1992) reveals that residues 8Asp180 and SGIu189 reduce the affinity of 
the receptor for ACh by 100- and 10-fold respectively. Asp and Glu residues in analogous positions 
are present in 8 ,7  and e subunits. This conservation is consistent with the location of these residues 
within the agonist binding sites formed by a 8, a y  and ae subunit interfaces (see section 1.4.3.3). In 
the p 1 subunit, which is not implicated in contributing to a binding site, the equivalent residues at 
these positions are histidine, or asparagine, and glutamine respectively (see Karlin 1993). The a1 
subunit lacks these two residues (Blount & Merlie 1989) but paradoxically so does neuronal a7 
which forms a functional homomeric channel (Couturier et al 1990a).
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1.4.3.6 Holistic model of ACh binding to the whole receptor
All the key residues so far identified to interact closely with cholinomimetic ligands are 
represented in possible binding site model in figure 1.9. DDF predominantly labels residues 
exclusive to the a  subunit. The unknown residues that are also labelled by DDF on the 7 and 5 
subunits may correspond to the anionic residues at positions 8180 and 8189 - however it should be 
born in mind that the affinity label acetylcholine mustard, which is capable of reacting with 
carboxylates, labels only aTyr93 (Cohen e ta l 1991). Given that the muscle subunits probably have 
similar folding arrangements, and the fivefold symmetry of the complex, an equivalent negative 
subsite may be formed by Asp174 and Glu183 of the 7 subunit (which align with 8Asp180 and 8 
Glu189) on the 0C7 interface of the second a  subunit. Thus, although the two ACh binding sites 
associated with the receptor are non-equivalent, experimental evidence implicates the same key 
residues as possibly participating in the creation of the site (Figure 1.9). Perhaps then the orientation 
and reactivity of these residues is quite different in their individual local environment associated with 
each site, manifesting the non-equivalence.
1.4.4 The competitive antagonist binding site - abungarotoxin
Curarimimetic snake toxins, such as aBgt, also bind in the vicinity of aCys192/193. aBgt has 
been used extensively to distinguish different nAChR subtypes (Deneris e ta l 1991), being a potent 
inhibitor of nAChRs containing the a1 subunit (see section 1.3.1.2) and neuronal a7  and a 8 
subunits (Schoepfer eta l 1990: Couturier et al 1990a). Isolated Torpedo a1 subunit is able to bind a  
Bgt, even after denaturation, indicating that many of the determinants for toxin binding are contained 
on the a  subunit (Haggerty & Froehner 1981). Some overlap of the binding site for this large toxin 
must occur with that for ACh. However, because aBgt is specific only for functional neuronal 
receptors which contain the a7 or a 8 subunit, additional regions must also be involved in the 
formation of the aBgt site. Indeed high affinity toxin binding diminishes considerably when key 
fragments of the a  subunit are considered individually, suggesting the involvement of multiple 
domains in the organisation of the toxin binding area.
Regions of the a  subunit implicated in the formation of the a  toxin binding site
Many techniques have been used in attempts to clarify which part(s) of the receptor sequence 
react with aBgt. Among the most successful have been those which have assessed toxin binding to 
proteolytic fragments, bacterially expressed fusion proteins and synthetic peptides of specific 
regions of the a  subunit. Assimilation of results from peptide mapping studies defines the region a  
174-204 of Torpedo as forming the main aBgt binding 'prototope1 (see McLane et al 1991a, b & c), & 
1994). A homologous region is also found in the vertebrate muscle a1 subunit of several species, 
and the avian brain a7  and a 8 subunits (McLane et al 1991a & b), suggesting this region as a 
potential universal aBgt binding site (Figure 1.10).
Other regions of the Torpedo a1 subunit are also recognised to interact with aBgt, among them 
positions 55-74 (Conti-Tronconi e ta l 1990), and additionally regions between 1-16, 23-49 and 122- 




A Tyr93 A Tyr190, Cys192/193, Tyr198
A Trp149 Asp180(174)
A Trp184 A Glu189(183)
Figure 1.9: Holistic model of the muscle nAChR binding site. Viewed from the top, agonist 
binding sites are represented at the interface between 017 and a5  subunits of the muscle receptor 
with the channel in the centre. Main contributions to the site (represented by the ACh molecule) in 
the a  subunit are from multiple loops of hydrophobic residues. A possible anionic site, which may 
interact with the cationic headgroup of all nAChR ligands, might originate from aspartate and/or 
glutamate residues in the 7 (180 & 189) and 8  (174 & 183) subunits. Due to the local environments 
associated with the formation of the sites at subunit interfaces the ligand sites are not equivalent 
though they do interact in a positive co-operative manner.
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Figure 1.10: The residues of the abungarotoxin binding surface. Summary of the effect of 
conservative amino acid substitutions on the binding of aBgt to the a181-200 sequence of Torpedo 
nAChR (a) - modified from McLane et al 1994. Indicated are the mutations of the original peptide 
sequence (centre) which are tolerated ( I) , i.e. aBgt binding activity is the same or slightly reduced, 
and those which are not (T). The '3-fingered' structure of aBgt derived from x-ray crystallographic 
measurements (b) is shown interacting via its variable loop extremities with the residues indicated in 
(a) and an a50-70 sequence which seems to be common to both long and short aneurotoxins. 
Although not as strongly implicated as residues in the a181-200 peptide, additional regions of the a  
subunit also interact with this long snake toxin. (The receptor peptide structures are entirely notional 
whereas the structure of aBgt is derived from x-ray data.)
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region in the same subunit sequence conveys a picture, concurrent with that for the agonist binding 
site, of a complex 3-dimensional contact region. The p subunits of neuronal receptors may also be 
important. Neuronal bungarotoxin (nBgt), a toxin closely related to aBgt, is proposed to be a 
selective competitive antagonist for a3p2 nAChR of brain and sympathetic ganglia (see Lindstrom 
et al 1987). However, an a3p4 complex is not inhibited by nBgt (Duvoisin et al 1989: Luetje et al
1990) suggesting, as with the agonist site, that other non-a subunits may help generate the binding 
site for snake toxins.
The aneurotoxins isolated from the Elapidae family of snakes (e.g. krait, cobra, mamba) are 
distinguished on the basis of a 'short' (<60 residues) or a 'long' (<70 residues) polypeptide chain. 
Despite there being numerous sequence differences between the atoxins (mainly deletions and 
mutations) their 3-demensional structures are similar (see Dufton & Harvey 1989). X-ray 
crystallographic maps of long (aBgt and acobratoxin) and short (erabutoxin b) toxins, and a 
cytotoxin, reveal a common '3-fingered' folding motif throughout (Figure 1.10b). Major residue 
differences occur in the surface regions, especially the loop extremities. Conversely, the 
pharmacological action of these toxins are quite different (Loring & Zigmond 1988). The conserved 
shape and extent of rearrangement of loop residues would imply that probably at least three contact 
zones interact with the receptor which could account for the specificity and pseudo-irreversible 
nature of the binding. Possibly, one loop remains relatively conserved in some atoxins, which is why 
although erabutoxin b does not bind a181-200 of Torpedo it will bind with high affinity to a56-71, 
and a 1 00-115 (Ruan et al 1991). These partially conserved residues of a particular loop may 
provide the initial recognition event between toxin and receptor. The other more variable loops may 
confer the specificity by interacting with residues that overlap the agonist binding site. Another 
common binding site (a122-138) is also evident for some short and long neurotoxins in both human 
(Ruan et al 1990) and Torpedo (Mulac-Jericevic & Atassi 1987) a1 subunit sequences.
Experimental evidence
The full complement of conserved residues in all a  subunits from muscle and neuronal 
sources labelled by MBTA and DDF are not essential for conferring aBgt affinity as, until recently, all 
cloned neuronal nAChRs expressed in Xenopus oocytes were insensitive to aBgt (Boulter et al 
1987: Deneris e ta l 1988: Wada e ta l 1988). These same affinity labelled residues are present in the 
two aBgt-sensitive neuronal receptor subunits a7 and a 8 (see section 1.4.3.1), an observation 
consistent with a model where aBgt interacts with many more amino acid residues than those 
strictly involved in agonist binding. Despite this, certain residues in and adjacent to the ACh site 
seem crucial to the aBgt sensitivity of the receptor.
Conserved or conservatively substituted residues in the 181-200 fragment of aBgt-sensitive 
neuronal a  subunits are Lys185, Tyr189, Tyr190, Pro194, Asp195, Pro197 and Tyr198 (McLane et 
al 1991c). These residues are almost entirely conserved among nAChR a1 subunit sequences from 
different species (>75% amino acid identity). In attempts to identify the crucial residues of the aBgt 
binding interface, Conti-Tronconi and co-workers (1991) have employed synthetic single substitution
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peptide analogues of the a181-200 Torpedo sequence. Non-conservative glycine substitution found 
residues at positions Val188, Tyr189, Tyr190, Cys192/193 and Pro194 were critical to aBgt binding. 
Other residues were less strongly implicated (Trp184, Lys185, Trp187, Asp195, Tyr196, Pro197 and 
Tyr198). A later, more refined conservative substitution approach on the same sequence aimed to 
identify some of the more physicochemical and structural attributes important in binding (McLane et 
al 1994). In summary, crucial residues in the formation of the aBgt interaction site appear to be 
Tyr189, Tyr190 and Cys192/193 as replacement of these amino acids by physicochemically 
equivalent residues dramatically reduced affinities (Figure 1.10a). Also, although experiments were 
performed using only the 20 residue peptides, when proline residues at a194 and a197 were 
removed toxin affinity decreased, indicating a structural role for these residues.
Attempts to construct a 3-dimensional model of human nAChR toxin binding site using information 
gleaned from peptide binding, predict a conical cavity ~30A in depth, with most favourable energetic 
interactions occurring in the a125-136 region, which are not coincident with any of the residues of 
the ACh binding site (McCormick & Atassi 1984). This provision of a deep cavity fits with a model 
involving few electrostatic and primarily hydrophobic and possibly hydrogen bonding interactions.
1.4.4.1 Ion conducting pathway of the nicotinic receptor
The permeability response associated with the activation of muscle and neuronal nAChR 
agonists can be inhibited by non-competitive blockers. As their name suggests their action is via a 
site remote from the agonist site (rev. Heidman et al 1983 (muscle-like): Rapier et al 1987: Ramoa et 
al 1990 (neuronal)). Structurally diverse, this group of pharmacological agents includes hydrophobic 
local anaesthetics, the anticonvulsant MK801, the hallucinogen phencyclidine and the tree frog toxin 
histrionicotoxin (HTX) (see Galzi et al 1991a). Functional responses in other LGICs (Albuquerque et 
al 1988) are also blocked by some of these compounds.
Two main categories of sites exist: a single high affinity site, sensitive to HTX, and low affinity sites, 
insensitive to HTX, which considering their number (10-30 per complex) and lipid-dependent 
location, may be resident at the receptor-membrane interface. The former site is located in the ion 
channel, an environment concordant with the voltage sensitivity of the block such as occurs with 
QX222 (Neher & Steinbach 1978: Cohen eta l 1992).
1.4.4.2 A structural view of the channel
Affinity labelling agents were, as in the case with the ACh site, pivotal in the identification of 
key channel residues. Four of the subunits of Torpedo nAChR are specifically labelled by 
[3H]chlorpromazine (Heidman & Changeux 1984). The only place where this is feasible is the 
narrowest part along the axis of pseudosymmetry of the receptor, namely the channel. Indeed all the 
interactions are common to the transmembrane M2 segment of each subunit (Giraudat et al 1986, 
1987 & 1989: Revah et al 1990). A series of experiments using different affinity labels and 
recombinant DNA technology (rev. Deviellers-Thiery et al 1993) refined the channel model to its 
current status (see Figure 1.6) whereby:
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• M2 segments are arranged symmetrically about the channel
• labelling appears, in part at least, to be consistent with an a  helical organisation (see Akabas et
al 1992).
• homologous residues from each subunit line the channel lumen forming five important rings: the
Threonine, Serine, equatorial Leucine, Valine and outer Leucine rings. Additional rings of
negatively charged residues flank the luminal rings.
The functional roles of the residues forming the rings have been explicitly demonstrated through 
mutagenesis experiments and the effects are comprehensively reviewed (see Deviellers-Theiry et al 
1993). In simple summary it seems that the NCI site is formed mainly by the Serine ring and that the 
channel gate is carried by the hydrophobic Leucine and Valine, and polar Serine rings. Ion selectivity 
filters appear to be provided by the Threonine ring and can be switched from cationic to anionic in a  
7 by mutation of the residues Glu237 and Val251. The negatively charged rings at the extremes and 
outer Leucine ring have significant roles in the permeability of the receptor to Ca++.
1.5 Pharmacophore of the nicotinic acetylcholine receptor.
Central to the rationalisation of the wealth of pharmacological data for the many ligands which 
have now been characterised at the nAChR, is the notion of the pharmacophore - the specific 3- 
dimensional configuration of essential chemical groups common to active molecules that is 
recognised by a single receptor inducing a pharmacological effect. Although potential nAChR 
binding site-forming residues have been identified, the dynamic nature of the large transmembrane 
nAChR protein has precluded detailed analysis of the molecular organisation of the ligand site at an 
atomic level. As such the current description of the site gleaned through affinity labelling and 
mutagenesis studies can be married with observations of structural and physicochemical features of 
ligands interacting at the receptor. Inactive ligands should be equally informative as active and 
delineating the features which confer activity, or inactivity, for a range of structurally diverse 
molecules should, at least in part, reflect the structural nature of the complementary receptor binding 
pocket. However, because the events of receptor activation are complex there will probably exist 
pharmacophore modes for recognition, binding and subsequent activation and desensitisation 
phases. Alternatively, different elements of the pharmacophore may be required for each step. 
Therefore, in attempting to correlate observed pharmacology with a set of interacting groups, it must 
be understood that the actual number of effective pharmacophore modes may not be trivial. This 
said, the initial barrier is the recognition event between ligand and receptor so this mode will be, 
initially at least, the most pertinent.
A pharmacophore model applies to a single receptor type. The heterogeneity of neuronal nAChR 
(see section 1.3) makes the task of finding a single model for each subtype very large. The 
approach has been to consider structure-activity relationships of ligands at many nAChR and thus to 
generate a unifying pharmacophore model which both identifies common features of active ligands
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at all nAChR types, and identifies aspects of this model which may be flexible and thus generate 
some receptor subtype specificity.
1.5.1 Principle features of the nicotinic pharmacophore
The tetramethylammonium ion is the minimum essential structure that activates the nAChR 
complex. Potency is enhanced by the presence of an aliphatic hydrocarbon chain (e.g. 
decamethonium) or an atom with unshared electrons (e.g. ACh and nicotine). The atom bearing the 
unshared electrons (a carbonyl oxygen in most agonists) is proposed to form a hydrogen bond with 
the receptor.
'Beers-Reich' model
The first cogent model of the pharmacophore for ligands active at the nAChR was introduced by 
Beers & Reich (1970) who compared semi-rigid agonists (mainly cytisine and nicotine) and some 
competitive antagonists. Briefly, they concluded that in order for ligands to have cholinergic activity 
they must possess a centre of positive charge (a cationic head) and a hydrogen bond acceptor 
group (usually a carbonyl oxygen) which are disposed in a particular geometrical relationship 
characterised by a separating distance of 4.8A (±0.3A) - the 'Beers-Reich' distance - and the angle 
between the cationic centre and the C=0 bond (Figure 1.11a).
The Sheridan 'triangle'
This model generally corroborates observations by previous authors (Wasserman e ta l 1979), each 
recognising the two hydrophilic centres required for effective receptor-agonist interaction. A 
somewhat different approach was applied to the problem by Sheridan et al (1986) who treated the 
four structurally diverse agonists (-)-nicotine, (-)-cytisine, (-)-ferruginine methiodide and (-)- 
muscarone, collectively as an ensemble, identifying a pharmacophore triangle (Figure 1.11b). This 
comprised a cationic centre (A), an electronegative atom (B) and an atom (C) which forms a dipole 
with (B). The model agrees well with that of Beers & Reich, including an exact 4.8A distance, but 
differs in its selection of template molecules opting for a conformational search approach of semi­
rigid agonists and using rigid antagonists such as strychnine and dihydro-p-erythroidine (DHpE) to 
confirm the model. Additionally, the angle between the cationic head, the centre of the hydrogen 
bond acceptor, and the line through the carbonyl bond (or its equivalent) directed toward the donor, 
is around 137°, a little larger than that associated with the Beers-Reich model (120°). Studies with 
stereospecific molecules revealed that active isomers have the bulk of their volumes on one specific 
side of the plane defined by the cationic head and the carbonyl oxygen and its associated carbon, or 
in the case of nicotine and analogues, the cationic head and centre point of the pyridine ring.
'Flexibility' model
As the structure set has become larger through the products of synthetic chemistry, so the 
pharmacophore model has been progressively modified. Consequently, an alternative 
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Figure 1.11: Unified nAChR pharmacophore models. Salient features common to molecules active at the 
nicotinic receptor are schematically represented. The omnipresent cationic headgroup is a prerequisite for all 
active ligands and appears as an amine function. Models are as follows: (A) 'Beers-Reich' model, (Beers & 
Reich 1970), (B) 'pharmacophore triangle' (examples of how the triangle points apply to active ligands are 
shown (inset)) (Sheridan et al 1986), (C) 'Flexibility' model which better explains the large potency differences 
observed for active ligands (Barlow & Johnson 1989). Descriptions of each model are given in the text.
| (-)nicotine |
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specific groups in the active molecules being involved, activity at the receptor depends on a more 
generalised theme, that being the possession of a flat area containing double bonds, or double bond 
systems, and a cationic binding group some 4.5-6.5A from the flat area (Figure 1.11c). This model 
although skeletal, at least goes some way to explaining the activity of pharmacologically important 
molecules possessing unsaturated systems such as nicotine, cytisine, 1,1-dimethyl-4- 
phenylpiperazinium (DMPP).
1.5.2 Additional factors to consider in the pharmacophore model
These models, while independently derived and complementary, are insufficient to explain the 
pharmacological profiles of all the ligands and their analogues assayed against the nAChR to date. 
Additional factors must be considered to explain disparities, such as
•  small deviations from optimal conformation
•  deviations in electrostatic potentials about the cationic head and carbonyl group
•  presence of bulky groups a  to the carbonyl carbon.
Quantitation of how the introduction of a single, isolated discrete change to the structure of a ligand 
effects the physicochemical character of that ligand is complex. For example modification intended 
to demonstrate the influence of inductive effects will concomitantly shuffle the ground state, steric 
effects, solvation and have other subtle effects.
1.5.3 3-Dimensional structure of active nicotinic agonists
The spatial arrangement of atoms about the crucial pharmacophore points is important in 
dictating potency of a particular ligand, as demonstrated by the stereoselectivity of the [3H]-(-)- 
nicotine and [125l]aBgt labelled neuronal receptors in favour of (-)nicotine (10-60-fold) and 
(+)anatoxin-a (>200-fold) (see Wonnacott 1987a) for example. Therefore, although the 
pharmacophore model may be a useful template, it is insufficient to predict potency, thus a 3- 
dimensional view of ligands is necessary to attempt to explain these differences. However, 
determination of bioactive conformation is not trivial. For example, ACh is very conformationally 
labile and the number of conformations varies depending on the environment - the receptor bound 
conformation of ACh is very different from that in solution (Behling et al 1988), as are conformations 
determined in vacuo and from crystal scattering data. Once possible stable bioactive conformations 
are found not all of the pharmacophore features are necessarily fulfilled: e.g. anatoxin-a and the 
closely related ferruginines in the cis conformation fit the Beers-Reich distance but not the 
associated angle. The same can be said of arecolone methiodide.
Synthetic chemistry has provided the means to investigate the structure of the nicotinic cholinergic 
pharmacophore, most notably through modifications to active, semi-rigid molecules such as 
piperazines (Spivak et al 1986 & 1989) and anatoxins (see Swanson et al 1991: Wonnacott et al




In order that a biological macromolecule, such as a receptor protein, may be characterised 
and understood, there must exist a means by which the specific protein, or class of proteins, can be 
targeted and identified among the tissue milieu in which it exists. In 1905, when Langley observed 
that nicotine excited the contraction of skeletal muscle, he proposed that the interaction of the 
exogenous agent with 'receptive substances' was responsible for the observed physiological 
reaction. The concept of a receptor for nicotine was thus born and set into motion experiments to 
identify, isolate and characterise this physiologically important protein.
it has already been described how the densely packed muscle-like receptors of the electric organs 
of certain fish were invaluable in laying the foundations for the understanding of the nicotinic 
receptor (see section 1.2). Of equal importance, especially since the investigative field was 
broadened to include neuronal tissue where the same protein is less abundant, has been the 
concurrent use of receptor specific ligands. These molecules (which are mainly natural toxins) have, 
through their high affinity and specificity for certain subtypes of the nAChR, been used to target 
native nAChR proteins in situ, thus facilitating extensive pharmacological characterisation. The now 
familiar abungarotoxin (aBgt) is one such ligand which specifically binds with high affinity to the 
muscle-like receptor, and certain neuronal subtypes - nicotine itself binds to the predominant 
neuronal nAChR (see section 1.3.1.1). Unfortunately only one other ligand, neuronal bungarotoxin 
(nBgt), has so far been able to identify a different nAChR subtype.
This shortfall emphasises the current restriction imposed on neuronal nAChR classification, namely 
a paucity of suitable, specific molecular probes. Given the extensive number of subunits that have 
now been cloned from neuronal cholinergic proteins, and the potential for heterogeneity, there exists 
a need for more ligands able to distinguish pharmacologically distinct nicotinic receptor subtypes in 
the anatomically complex wiring system that is the brain. The primary focus of this study has been to 
attempt to underpin some of the structural attributes of cholinergic agonist molecules which confer 
activity at two receptor populations. This has involved making novel chemical modifications in certain 
instances, modifications which may concurrently introduce selectivity features into these molecules. 
If successful this would go some way towards redressing the imbalance of selective neuronal 
nicotinic ligands.
Focus of the radioligand binding assay experiments
In summary, the strategy has involved the establishment of pharmacological profiles for the 
[3H]-(-)-nicotine and [125l]aBgt labelled brain acetylcholine receptors to compare with profiles in the 
literature. The potencies of many classical and novel agonists have been assessed in competition 
binding experiments. Much attention has focused on the potent anatoxin ligand whose structure we 
have synthetically modified (Paul Brough and Timothy Gallagher, Univ. Bristol). The initial line of 
attack has been through competition binding assays, used to monitor the effects of structural 
modifications on the affinity or selectivity demonstrated by these ligands for the receptors - this is 
delt with in this chapter. We speculate that perhaps certain features of agonist molecules bestow
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functional potency, (as distinct from those that bestow binding affinity), and so have reinforced the 
pharmacological properties of some of the agonists used by concurrently assessing potency profiles 
at the functional a l  homomeric receptor expressed in Xenopus oocytes - this is the subject of 
chapter 3. A theoretical modelling approach has also been applied to agonist molecules as an aid to 
predicting spatial orientation of atoms with a view to understanding the pharmacophore model, which 
in its present form is insufficient to explain the diversity of pharmacological activity of agonists at 
neuronal nicotinic receptors - this theoretical aspect is presented in chapter 4.
Before going any further it is perhaps pertinent to introduce the diverse array of ligands active at the 
nAChR. Attention, like that of the project, is drawn largely to the small agonist molecules which bind 
to and activate the receptor, though it also seems useful to mention some of the antagonist 
molecules which have such profound inhibitory affects.
2.1.1 Common cholinergic agonists 
Examples and features
The tetramethylammonium (TMA) ion is the simplest nicotinic agonist and serves to 
demonstrate the fundamental role of the cationic head (see below) in the nicotinic pharmacophore. 
More complex structures generally enhance potency, though this is not always the case: for 
example, the relative potencies of nornicotine and ferruginine, as assayed by contracture of frog 
muscle, are lower than that for TMA (see table 1 of Gund & Spivak 1991). The structure of TMA and 
some of the more complex, widely studied agonists are represented in figure 2.1. The neuronal 
nAChRs are stereoselective for certain molecules, e.g. (-)nicotine and (+)anatoxin (see section 
2.3.5). The geometrical displacement of supporting atoms around the basic pharmacophore points is 
crucial for activity in these ligands.
All agonists are small in size, (generally around 30 atoms), when compared to competitive 
antagonists, which are presumed to overlap the agonist site on the receptor. This size and volume 
limitation imposed on these agonist molecules is very strict. For instance, although competitive 
antagonists share the pharmacophore features of agonists (see section 2.1.2), their inability to 
activate the receptor is most likely dictated by their larger structure. This would imply that the basic 
pharmacophore features of agonists are primarily for recognition, whereas activation may only be 
initiated through further interactions with other aspects of the molecule, which can only occur 
through tighter association in a pocket or cavity designed for small ligands. This may also explain the 
partial agonist properties of slightly smaller molecules like phenyltrimethylammonium (PTMA), 
though the reasons for some agonists being only partially active are difficult to ascertain.
A cationic head, be it ammonium, sulphonium or phosphonium, is essential for activity. Quaternary 
amines are most common (e.g. ACh, DMPP), but secondary (e.g. AnTx, cytisine) and tertiary (e.g. 
nicotine, lobeline) amines have activity in cyclic compounds. The active non-quaternary amines are 
expected to be overwhelmingly protonated at physiological pH, e.g. anatoxin-a is >99% protonated 
at pH7 (Koshkinen & Rapoport 1985). Increasing bulk around the cationic head through N-
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methylation diminishes activity among simple alklyammonium compounds (R-N(CH3)3). The same 
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Figure 2.1: Structural representations of some common agonists active at the nicotinic 
receptor. Abbreviations: TMA (tetramethylammonium), PTMA (phenyl tetramethylammonium), 
DMPP (1,1-dimethyl-4-phenylpiperazinium).
amine cytisine becomes progressively less active when one, then two extra methyls are added 
(Barlow & Mcloed 1969), while there is no significant conformational perturbation. Conversely, as we 
will see in section 2.3.5.2, nicotine increases in potency following methylation of nornicotine to 
nicotine. The N-methylated ferruginines behave disparately (Spivak e ta l 1983).
The group which may function as a hydrogen bond acceptor appears in many guises, yet 
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Figure 2.2: Structural representations of nicotinic cholinergic antagonists. In the top panel (a) 
are drawn the complex structures recognised as competitive antagonists as mentioned in the text. 
The large polypeptide chain conformation of aBgt derived from crystal data, is represented in ribbon 
form. The lower panel (b) shows some non-competitive antagonists thought to bind mainly in the 
channel.
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(PHT) it becomes an amine, but in a few cases it appears as either a phenolic or alcoholic OH. The 
existence of these latter auxiliary groups in active compounds indicates that a permanent dipole is 
not critical.
Pharmacological specificity
The pharmacological profiles of the two neuronal nAChR populations of concern to this project 
are the subject of many reviews, for instance, Wonnacott 1987a: Wonnacott 1990: Clarke 1993. The 
agonists ACh, (-)nicotine, (-)cytisine, lobeline, DMPP and carbamylcholine are particularly potent at 
inhibiting [3H]-(-)-nicotine binding being active at nanomolar concentrations with the rank order: 
cytisine> (-)nicotine> ACh> DMPP= lobeline> carbamylcholine (see table 7.2 of Wonnacott 1990). 
(+)Anatoxin-a is the most potent agonist at this protein. All of these molecules discriminate between 
the sites labelled by [3H]-(-)-nicotine and [125l]ocBgt, having greatest affinity for the former. However 
the pharmacological specificity exhibited by the [3H]-(-)-nicotine labelled receptor is not common to 
all agonists as (+)nicotine, DMPP, anabasine and carbamylcholine are almost equipotent at both 
sites. Nicotinic agonists are only physiologically active when at micromolar concentrations, a 
discrepancy which results from the prolonged incubation periods associated with the binding assay 
converting the binding site into a high affinity, desensitised configuration (Schwartz et al 1982). That 
[3H]-(-)-nicotine identifies a distinct population of neuronal nAChR is evidenced by the failure of aBgt 
to inhibit [3H]-(-)-nicotine binding. [3H]cytisine binds to nicotinic sites in rat brain membrane 
homogenates with a KD<1nM (Pabreza e ta l 1991) which, along with its slow dissociation rate, low 
non-specific binding and high stability, make it a very useful alternative probe to [3H]-(-)-nicotine. 
Similarly, other radiolabelled agonists, [3H]acetylcholine (Schwartz et al 1982) and N- 
[3H]methylcarbamylcholine, have the same binding characteristics with affinities for the same 
neuronal nAChR of 3-12nM.
2.1.2 Cholinergic antagonists 
Examples and features
While compounds that lack the full complement of structural characteristics of agonists 
behave as partial agonists, so the addition of larger groups confers antagonist properties to these 
molecules. Retention of certain agonist features without the associated agonist activity is a property 
of the competitive antagonists such as methyllycaconitine (MLA), dihydro-p-erythroidine (DHpE) and 
d-tubocurarine (d-TC) - figure 2.2a. All these molecules possess a cationic headgroup and a number 
of candidate sites for the formation of hydrogen bonds with the receptor. The larger bulk of the 
antagonists distinguishes them from agonists, a feature most probably responsible for the activity 
deficit. aBgt, being a polypeptide, is exceptional in terms of size though this bulk does not preclude it 
binding with high affinity to the receptor with which it interacts via possibly hydrophobic residues 
(see section 1.4.4). Being larger structures the nicotinic competitive antagonists are most probably 
more conformationally labile than the small, semi-rigid agonists, a feature which may also 
discourage receptor activation.
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Non-competitive inhibitors (NCIs) are structurally more closely related to the agonists and are 
comprised largely of ring systems which lend rigidity to many of the molecules (Figure 2.2b). They 
too possess a centre of positive charge which comes in various guises but most commonly as an 
amine function. This positive charge is presumed to be the main interaction site with polar amino 
acid residues in the narrowest part of the ion channel (see section 1.4.4.1 & 1.4.4.2), a site which 
poses obvious size restrictions. There is generally a notable lack of any hydrogen bond accepting 
moiety.
Pharmacological specificity
Romano and Goldstein (1980) were the first to report the inability of most classical nicotinic 
antagonists to effectively inhibit ligand binding to neuronal proteins labelled by [3H]-(-)-nicotine. This 
has since also proved to be the case for the [125l]aBgt labelled site (see table 7.2 of Wonnacott 
1990). The few notable exceptions to this are DHpE (see Reavill et al 1988), d-TC (Marks et al 
1986), MLA (MacAllen et al 1988) and neosurugatoxin (see Rapier et al 1985).
DHpE is an effective neuromuscular blocking agent, but is equally potent in autonomic ganglia and 
CNS (Wonnacott 1987b). Tritiated DHpE shows saturable, specific binding to two sites in rat brain 
(Kd=4 and 21 nM). The high affinity site resembles the [3H]-(-)-nicotine labelled receptor in its 
pharmacology, the other being the [125l]aBgt site. d-TC, a curare alkaloid used in poison arrow tips, 
used as a tritiated derivative also labels two brain sites showing some correlation with [3H]-(-)- 
nicotine and [125l]aBgt sites - however it is a relatively weak antagonist in brain (Larson & Nordberg 
1985). d-TC unusually shows a preference for [125l]ocBgt labelled sites (Marks et al 1986). This 
selectivity is also demonstrated, though more extremely, with MLA. Isolated from delphinium seeds, 
MLA is thus an important, highly selective competitive antagonist of neuronal [125l]ocBgt labelled 
sites, and as such is presently the subject of intensive structure-activity studies in this laboratory. 
Neosurugatoxin, an extract of the Japanese ivory shell, is a highly selective ganglionic blocker (see 
Wonnacott 1987b), which in the CNS competes for [3H]-(-)-nicotine binding sites, but does not inhibit 
binding to [125l]cxBgt or [3H]QNB sites.
It is increasingly recognised that many of these drugs block nicotinic transmission by interacting with 
the ion channel of the nicotinic receptor, and there is much evidence from electrophysiological, 
pharmacological and molecular biological sources to indicate this (see Sargent 1993).
The ten carbon atom containing (C10) antagonist decamethonium and its shorter analogue 
hexamethonium (C6) were used in early classification of nicotinic receptors as they distinguished the 
muscle receptor (termed the 'C10 receptor') from that found in neurons (the 'C6 receptor'). These 
classical antagonists although able to block functional receptors which demonstrate a clear nicotinic 
profile are, like mecamylamine, MK801 and others, ineffective competitors of [3H]-(-)-nicotine and 
[125l]cxBgt binding. This observation is attributed to their non-competitive mechanism of action at a 
site remote from that of the competitive antagonists described above.
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2.2 Experimental procedures
2.2.1 Tissue preparation 
Preparation of rat P2 membrane fraction
Male Wistar rats, (200-250g, maintained in a 12h:12h light:dark cycle, with free access to food 
and water), were killed by cervical dislocation. Whole brains were removed following decapitation, 
and were either used immediately or rapidly frozen at -70°C before use. This latter treatment has no 
significant effect on the number of detectable high affinity nicotine binding sites (Benwell & Balfour
1985).
The method essentially follows the protocol devised in this laboratory (MacAllen e ta l 1988). Whole 
brains (minus the cerebellum) were homogenised in a glass homogeniser (10%(w/v)) in 0.32M 
sucrose (4°C, pH 7.4), containing protease inhibitors (1mM EDTA, 0.1 mM PMSF and 0.01%(w/v) 
NaN3), by repeated (x10) up and down strokes at approximately 300 rpm. The resulting homogenate 
was centrifuged at 1000xg for 10min (Sorval RC-5B) at 4°C. Supernatant (S^ was decanted and 
retained on ice, and the pellet (PJ was resuspended in 0.32M sucrose, (5ml/g original wet weight), 
and recentrifuged as above.
Supernatants were combined and centrifuged at 12000xg for 30min at 4°C. The pellet (P2) was 
washed twice by resuspension in 50mM potassium phosphate buffer (40mM K2HP04, 10mM 
KH2P04 and anti-proteases: 5mM EDTA, 0.1 mM PMSF and 0.02%(w/v) NaN3, pH 7.4), giving a final 
volume of 2.5ml/g original wet weight, and centrifugation as before (12,000xg, 30min, 4°C), before 
final resuspension in 50mM phosphate buffer. TRIS-HEPES buffer, (118mM NaCI, 4.8mM KCI, 
2.5mM CaCI2,20mM HEPES, 200mM Tris, and protease inhibitors: 0.1 mM PMSF, 0.01%(w/v) NaN3, 
pH 7.4), was used for resuspension for [3H]-(-)-nicotine assays, as this buffer reduces the level of 
non-specific binding (Romm e ta l 1990). Samples (5ml) were stored at -20°C until required. Figure
2.3 describes the procedure.
Preparation of rat muscle extract (RME).
Male Wistar rats, (200-250g, kept as described in section 2.2.1), were killed by cervical 
dislocation. Their hind limbs were skinned, muscle tissue stripped from the bone and the tissue used 
immediately or rapidly frozen for storage.
Extract was prepared according to the method described by Rozental and co-workers (1989) for frog 
muscle. Muscle tissue from six rats (approximately 100g) was pooled and homogenised (40%(w/v)) 
in 2.5mM sodium phosphate buffer (90mM NaCI, 3mM KCI including protease inhibitors (1mM 
EDTA, 2mM benzamide, 0.1 mM benzethonium chloride, 0.1 mM PMSF, 0.01%(w/v) NaN3, pH 7.2)), 












Centrifugation 12000xg, 30min, 4°C
Supernatant
Figure 2.3: Scheme representing 
the preparation of P2 membranes 
from whole rat brains (minus cerebellum) 











Homogenate was centrifuged at 20,000xg for 60min, supernatant decanted and the pellet 
resuspended in the same buffer (1.5 ml/g wet weight), by re-homogenising in the Waring blender as 
before. Triton X100 was added (final concentration 2%(v/v)) before stirring for 3h at 4°C. 
Centrifugation at 100,000xg for 60min yielded the rat muscle extract (RME) as supernatant, which 
was decanted and stored at 4°C. The procedure is summarised in figure 2.4.
Muscle tissue
Homogenisation 
























Protein content of samples was measured essentially according to the method of Lowry and 
co-workers (1951). Standard curves were constructed using bovine serum albumen (BSA) in a 
concentration range of 50-500 jug/ml.
Figure 2.4: Flow diagram demonstrating 
the preparation of rat muscle extract 
(RME) as described in the text (2.2.1).
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Sample duplicates (2 0 0 jllI)  of BSA standards, P2 membranes or rat muscle extract, were diluted with 
distilled water between the range 1:40 to 1:1000. Equal volumes of 1%(w/v) CuS04.5H20  and 
2%(w/v) sodium tartrate were diluted 1:100 with 0.1 M NaOH containing 2%(w/v) Na2C 03 to make 
alkaline cupric tartrate, 1ml of which was added to each sample. Following incubation at 20°C for 
10min, 0.1ml Folins-Ciocalteaus reagent (100jxl; freshly diluted 1:1 with distilled water), was added 
with immediate mixing, and the colour left to develop for 40min. Water controls were treated 
similarly. Absorbancies at 690 nm were measured on a Titertek Multiscan Spectrophotometer using 
96 well plates and relative protein concentrations determined from standard curves.
Triton X100 and TRIS-HEPES buffer perturb the colour reaction, therefore samples with these 
constituents were modified to maintain constant Triton X100 and buffer concentrations relative to 
each sample.
2.2.3 lodination of abungarotoxin (aBgt)
aBgt was labelled to high specific activity with [125l]Na. All procedures were carried out at 
room temperature. [125l]Na (20pJ; 100mCi/ml, stored at ambient temperature), and aBgt (20pl; 
0.5mg/ml), were mixed with reaction buffer (10pJ, 0.05M potassium phosphate, pH 7.5). The reaction 
was initiated by the addition of Chloramine T (10 jliI, 0 .5 % (w /v ) ) ,  and allowed to continue for 1min 
with continuous stirring, after which time sodium metabisulphite (750jil, 0.016%(w/v)), and 
potassium iodide (200 pJ, 1%(w/v)), were added to terminate the reaction.
The reaction mixture was immediately chromatographed on a Sephadex G25 column (25x1 cm), 
equilibrated in 0.01 M potassium phosphate (pH 7.5) containing 1%(w/v) BSA, and eluted with the 
same buffer. Fractions (1ml) were collected and samples (5pl) counted using an LKB 1280 
Ultragamma counter (efficiency 70%) for 10s. Peak fractions of the radio-iodinated protein were 
pooled, and the specific activity of the [125l]aBgt calculated assuming 100% recovery of protein and 
radiolabel. The protein was stored at 4°C and used for up to 21 days following iodination. Typical 
values for the specific activity of the radiolabelled toxin were >700Ci/mmol.
2.2.4 Generic binding protocol
Procedures for determining levels of radioligand bound to rat brain P2 membranes and rat 
muscle extract were determined for three independent types of assay and involved the application of 
constant conditions. These conditions are outlined below for the three radioligands used and were 
applied in protein dependence (section 2.2.5), saturation binding (section 2.2.6) and competition 
binding (section 2.2.7) assays, except [3H]QNB with which only competition assays were performed. 
Physostigmine (10pM) was included in assays involving acetylcholine (ACh).
2.2.4.1 [3H]-(-)-nicotine
Binding of [3H]-(-)-nicotine was based on the methods of Romano and Goldstein (1980) and 
Marks and Collins (1982), using ligand stored in mercaptoacetic acid (Romano & Goldstein 1980). 
All assays were carried out as triplicate determinations at 20°C using TRIS-HEPES buffer (Romm et
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al 1990) and 250|il P2 samples (diluted to 2mg protein/ml). Levels of specific binding were 
determined by measuring the difference between total binding (i.e. 10(il [3H]-(-)-nicotine at a final 
concentration of 10nM in the assay) and non-specific binding (i.e. 10|il [3H]-(-)-nicotine (10nM) in the 
presence of 1mM (lOpil) unlabelled (-)nicotine). Reactants were thoroughly mixed and incubated for 
60min.
Separation of bound from free ligand was carried out at 4°C. Initially, samples were chilled to 4°C 
(60min), before addition of 2ml ice-cold phosphate buffered saline (PBS: 10mM potassium 
phosphate, 0.15mM NaCI and 0.01%(w/v) NaN3, pH7.4), and rapid filtration, under vacuum, through 
double thickness Gelmann A/E glass fibre filters, (pre-soaked in 0.3% polyethyleneimine (diluted in 
PBS) for at least 3h), using a Brandell cell harvester. Sample tubes were rinsed with 2x3ml PBS - 
filtration and washing was achieved within 20s. Filters were counted in 5ml Optiphase scintillant 
using a Packard scintillation spectrophotometer (counting efficiency 30%).
2.2.4.2 [125l]abungarotoxin (aBgt)
P2 membranes - A similar protocol was employed to that described above (section 2.2.4.1) involving 
triplicate determinations. Assay reactants were mixed at 20°C using 50mM potassium phosphate 
buffer and 500jil P2 samples (1 mg protein/ml). Total binding (20 jliI; [125l]aBgt at a final concentration 
of 1 nM) and non-specific binding ([125l]aBgt (1nM) in the presence of excess (20|nl; 1|liM) unlabelled 
aBgt) levels were assessed to determine specific effects. Following thorough mixing, reactants were 
incubated at 37°C for 2h.
Ligand bound to P2 membranes was precipitated from unbound at 20°C by centrifugation (MSE 
microfuge, 2min @10,000xg). Supernatant was disgarded and membrane pellets washed two times 
by resuspension in PBS (1ml, 4°C) and recentrifugation. P2 pellets were counted directly on a LKB 
ultragamma counter.
Rat muscle extract - Assays to determine total and non-specific binding were setup as for the P2 
preparation using homogenisation buffer. Protein separation of free ligand from that bound to muscle 
extract (RME) was achieved by rapid filtration through Whatman GFC filters (pre-soaked in 0.3% 
polyethyleneimine overnight at 4°C), using a benchtop millipore vacuum manifold. Samples were 
rapidly washed with 3x3ml PBS (4°C) containing 0.1%(w/v) BSA. Filters were counted using an LKB 
ultragamma counter.
2.2.4.3 [3H]Quinuclidinylbenzilate
In this study [3H]QNB binding was occasionally performed to ascertain whether novel 
synthetic ligands displayed any muscarinic activity. [3H]QNB, a potent muscarinic cholinergic 
antagonist, has been extensively used as an effective probe in CNS AChR characterisation using 
various brain preparations. In whole brain [3H]QNB exhibits a KD of 0.04nM and reveals the number 
of muscarinic sites labelled by this ligand as 20- and 4-fold larger than [3H]-(-)-nicotine and [125l]aBgt 
sites, respectively, on the same tissue (Marks & Collins 1982). The distribution of central muscarinic
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receptors is distinct from that of both [3H]-(-)-nicotine and [125l]aBgt. [3H]QNB binding to rat brain 
exhibits a characteristically cholinergic pharmacology with the most effective competitor being 
atropine (K~2.8nM).
Triplicates were setup to determine total (10pJ; 0.2nM [3H]QNB) and non-specific (0.2nM [3H]QNB in 
the presence of 10nM atropine) binding to P2 membranes (250|il; 2mg/ml in PBS). Reactants were 
mixed and incubated at 20°C for 60min. Separation of bound and free ligand was performed by 
filtration at 4°C, as described for [3H]-(-)-nicotine (section 2.2.4.1). Filters were counted for tritium 
using a Packard scintillation spectrophotometer.
2.2.5 Protein dependence of binding
The linearity of [3H]-(-)-nicotine and [125l]cxBgt binding with increasing tissue concentrations 
was investigated in rat brain P2 preparations and rat muscle extracts (RME). Protein content was 
varied by dilution of stock P2 in TRIS-HEPES buffer ([3H]-(-)-nicotine) or phosphate buffer ([125l]cx 
Bgt). RME was diluted in homogenisation buffer. Specific binding, defined as the difference between 
total and non-specific binding, was determined for [3H]-(-)-nicotine and [125l]aBgt as described in 
sections 2.2.4.1 and 2.2.4.2 respectively.
Possible effects due to the presence of Triton X100 on the binding of [125l]ocBgt to RME were 
investigated by maintaining a constant protein concentration (1 mg/ml) while varying Triton levels 
between 0% and 2 %(v/v).
2.2.6 Saturation binding
The saturability of [3H]-(-)-nicotine binding to P2 membranes, and [125l]ocBgt binding to P2 and 
RME, was established over a concentration range of 1-40nM for [3H]-(-)-nicotine, 1-20nM for [125l]a  
Bgt binding at P2, and 1-1 OnM for [125l]aBgt at RME. Total binding and non-specific binding, 
determined in the presence of the respective unlabelled ligand (see sections 2.2.4.1 and 2.2.4.2J, 
established specific binding levels which were used to calculate KD and Bmax values - see section 
2.2.8.
2.2.7 Competition binding
PH]-(-)-nicotine - All drugs were assayed up to mM concentration using, in most cases, 10-fold 
serial dilutions prepared from frozen stocks on the day of assay. Drug (10pJ), was pre-incubated 
with P2 membranes (2mg /ml TRIS-HEPES) for 10 min at 20°C prior to addition of [3H]-(-)-nicotine 
(10nM) - total and non-specific levels of binding were determined as described in section 2.2.4.1.
P 5// a B g t - Drug (20 |il), prepared as described for [3H]-(-)-nicotine binding above, was pre- 
incubated with P2 membranes (1 mg/ml 50mM phosphate buffer), or RME (1 mg/ml in homogenisation 
buffer) for 10min at 20°C prior to addition of [125l]aBgt (1 nM) and subsequent incubation at 37°C - 
full details of this assay are described in section 2.2.4.2.
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PHJQNB - Each of the ligands (10pJ - prepared as described for [3H]-(-)-nicotine) was preincubated 
with P2 (2mg /ml 50mM phosphate buffer) for 10min. Following the addition of [3H]QNB (0.2nM) the 
mixture was incubated at room temperature for 1h and samples processed as detailed in section 
2.2.4.3.
2.2.8 Data analysis
First order linear regression of Scatchard plots (i.e. bound/free radiolabel verses bound label) 
was used to determine values for KD (dissociation constant for the equilibrium binding of the 
radiolabel) and Bmax (the maximum number of binding sites). Hill plots (log (bound/Bmax-bound) 
verses log free ligand ) of the same data were used to derive Hill numbers (r|H) also by linear 
regression. Data from radiolabel protein dependence and saturation assays were fitted to a 
rectangular hyperbola (y=(Bmax-x)/(KD+x)) using Bmax and KD estimates from Scatchard analysis - 
where x=protein concentration or radioligand concentration.
Semilogarithmic plots of dose-response curves for competition assays were used to derive IC50 
values (the concentration of drug that inhibits specific binding by 50%) by linear transformation. 
These values were used to determine K; values by the method of Cheng and Prusoff (1973) - 
K—ICgo/fl +([radiolabel]/KD)), assuming KD values of 10nM (for the [3H]-(-)-nicotine labelled rat brain 
site), 1nM (for the [125l]ocBgt labelled site of both rat brain and muscle) and 0.2nM (for the [3H]QNB 
labelled muscarinic receptor of rat brain). All assays were performed using radiolabel at its 
calculated KD. Means (±SEM) of the experimental data were plotted. The mean KD values from at 
least three experiments were used to curve fit the data according to the sigmoid function 
y=a-((a-b)-(1/1+(KD/x)TlH - where a=value of minimum inhibition(%), b=value of maximum 
inhibition(%) and x=[radiolabel],
2.2.9 Materials
(-)-[N-methyl-3H]Nicotine (80 Ci/mmol: stored at 4°C in 4-fold molar excess of mercaptoacetic 
acid), [125l]Na and [benzylic-4,4'-3H]Quinuclidinyl benzilate (40 Ci/mmol: stored at 4°C) were 
purchased from NEN Dupont (Stevenage, Herts). aBungarotoxin, (-)nicotine base, ACh.HCI, (- 
)lobeline, cytisine, physostigmine and atropine sulphate were supplied by the Sigma Chemical Co. 
(Poole, Dorset). (+)Nicotine hydrogen tartrate came from BDH (Poole, Dorset). DMPP.I was 
obtained from Aldrich (Gillingham, Dorset), and AMP.HCI (dissolved in 70% ethanol) and AMP.Mel 
(prepared as a 50mM solution in DMSO) were gifts from Dr I. Stolerman. (+)Anatoxin-a.HCI was 
initially provided by Dr E.X. Albuquerque, as was N,1 '-dimethylanatoxinol (Me-AnTx-mol). 
Subsequent preparations of anatoxin.HCI, (as the (+) enantiomer and the racemate (±)), were 
supplied by Drs P.A. Brough & T. Gallagher, who also supplied homoanatoxin (HomoAnTx), 
propylanatoxin (PropylAnTx), isopropylanatoxin (IsopropylAnTx), HeteroAnTx, EpoxyAnTx and 
HydroxyAnTx. The hydrochloride salts of the AnTx analogues were dissolved in aqueous ethanol 
(AnTx, 19%; HomoAnTx 50%; PropylAnTx, 95%; IsopropylAnTx, 50%; Hetero-, Epoxy- and 
Hydroxy-AnTx, 100%). Methyllycaconitine (citrate salt) was a gift from Prof. M. Benn. Unless 
otherwise stated, all drugs used in binding assays (and electrophysiological studies - see section
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3.2.3.22) were made as 10mM stock solutions in distilled water, adjusted to pH7.4, and stored in 
aliquots at -20°C. Serial dilutions of drugs for competition assays were made in assay buffer. Control 




2.3.1 Protein content of tissue preparations
Total protein levels in P2 preparations and rat muscle extract were determined using the 
Lowry reaction (see section 2.2.2) with BSA 
standards. The linearity of the colour reaction 
with increasing concentrations of tissue was 
examined from which protein concentrations 
were derived as summarised in table 2 .1.
Approximately 40% of the total protein in the rat 
muscle P2 pellet was recovered by 
solubilisation with Triton X100.
2.3.2 [3H]-(-)-nicotine binding to P2 
membranes
The effect of altering the protein level of the P2 membrane preparation in the reaction medium 
on [3H]-(-)-nicotine binding is demonstrated in figure 2.5. Total binding initially increased linearly, but 
saturated at P2 concentrations above 3mg/ml - data were best described by a rectangular hyperbola. 
Non-specific binding levels showed a shallow linear increase with protein concentration. Specific 
[3H]-(-)-nicotine binding, (the difference between total and non-specific levels), essentially mirrored 
the total binding profile, being linear to ~3mg/ml before saturating at around 3000cpm in the example 
shown. A protein concentration of 2mg/ml accounted for between 50-70% of the specific binding, 
depending on individual P2 preparations, and consequently was selected as the working protein 
concentration in all subsequent [3H]-(-)-nicotine binding assays.
Saturation assays, performed to assess the effect of increasing [3H]-(-)-nicotine concentration on 
specific binding to P2 membranes at a protein concentration of 2 mg/ml, are demonstrated in figure 
2.5b. Specific binding was almost completely saturable at 20nM, and Scatchard analysis (inset) gave 
a straight line indicative of a single binding site. Linear transformation of Scatchard data from three 
independent P2 membrane preparations gave a KD of 13nM and a Bmax of 65fmol/mg (Table 2.2).
A Hill plot (Figure 2.5c) of the specific binding data from figure 2.5b, produced a Hill coefficient (r|H) 
of 1.1. Mean data from four independent rat brain P2 preparations are summarised in table 2.2.
2.3.3 lodination of abungarotoxin (aBgt)
Commercially purified aBgt was labelled with 125l to a specific activity of 740±28 Ci/mmol with 
>90% incorporation of the total 125l used in the reaction. Values (±SEM) represent 3 independent 
iodinations, an example of which is given in figure 2 .6 .
Table 2.1: Protein contents of various tissues. Data 
are for at least 3 independent determinations.
[P rote in ] mg/g 
w e tw t.(±  SEM)
P2 (brain) 0.35 ±  0.05 
0.73 ±  0.09 
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Figure 2.5. Protein dependence and saturability of [3H]-(-)-nicotine binding to rat brain P2 
membranes. [3H]-(-)-nicotine (10nM) was incubated for 1h with increasing levels of P2 protein in the 
presence and absence of 1mM unlabelled (-)nicotine, as described in 2.2.5. Bound radiolabel was 
recovered by rapid filtration at 4°C. Data from a representative experiment (a) show levels of total 
[3H]-(-)-nicotine bound (V) and non-specific binding (□ ) which were used to determine the levels of 
specific [3H]-(-)-nicotine binding ( • ) .  Points represent the means of triplicate determinations. The 
same tissue preparation (at 2mg protein/ml) was incubated with various concentrations of [3H]-(-)- 
nicotine (1-40nM), and the degree of specific binding ( • )  determined (b) - see section 2.2.6. 
Scatchard analysis (inset) revealed an apparent KD=9.6nM and Bmax=66frnol [3H]-(-)-nicotine/mg 
protein (r2=0.94). A Hill plot (c) of the specific binding levels from the saturation assay, using the Bmax 
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Figure 2.6. lodination of abungarotoxin. Commercially purified abungarotoxin (aBgt) was radio 
labelled to high specific activity with 125lodine as described in section 2.2.3. Activated aBgt was 
mixed with 125lodine for 1min and following termination of the reaction the products were 
chromatographed on a Sephadex G25 column (25 x 1 cm). Fractions (25 in total) were collected and 
their activity counted: activity associated with the large [125l]aBgt peptide was eluted first (large
peak), and unbound label was eluted @ fraction 13 (*). The example here achieved 96% 
incorporation of the radiolabel resulting in [125l]aBgt with a specific activity of 765Ci/mmol.
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KD {nM) Smax (fmol/mg) n h
P2 {[3HM-}-mcotine) 13.2 ± 3 .7 65 ±1 2 1.08 ±0 .1 3
P2 ( p i ]  aB g t) 1.3 ±0 .7 84 ±2 4 1.05 ±0 .1 5
RME ( p i ]  aB g t) 0.9 ± 0.3 11 ± 3 0.98 ±0 .0 8
Table 2.2. Parameters for [3H]-(-)-nicotine and [125l]cxBgt binding to rat brain and muscle nAChR. P2 membranes 
of whole rat brain, and rat skeletal muscle extracts (RME), were prepared as described in section 2.2.1. The saturability 
of [3H]-(-)-nicotine and [125l]ocBgt binding to P2 membranes, and [125l]ocBgt binding to RME, was assessed and 
parameters determined from Scatchard analysis of at least three independent tissue preparations. Experiments were 
performed in triplicate. Values for the apparent KD(nM) and Bmax(frnol/rng), ±SEM, were derived by linear 
transformation of the data for the radioligands at their respective binding sites. Hill coefficients (r|H) were determined by 
linear regression of Hill plots. The Bmax for [125l]aBgt binding sites in whole brain was higher than expected (20 
fmol/mg: Schmidt et al 1980), though values between 100-500 fmol/mg are obtained for 'low-affinity' nicotine sites 
(Wonnacott 1986).
2.3.4 [125l]ocBgt binding to rat brain P2 membranes and muscle extract (RME)
Whole rat brain P2 membranes
Radiolabelled aBgt binding to increasing protein levels of P2 membranes was assessed using 
a centrifugation method for separating bound and unbound radiolabel (see section 2.2.4.2). 
Equilibrium binding data was generally less reproducible compared with [3H]-(-)-nicotine, though a 
similar hyperbolic saturation binding profile was observed with increasing levels of P2 membranes 
(Figure 2.7a). Non-specific binding levels remained relatively constant and equilibrium was achieved 
with a protein concentration of about 3mg/ml - around 70% of the total radiolabel signal was 
detected at a protein concentration of 1 mg/ml and this became the concentration used in 
subsequent saturation and competition assays. Equilibrium binding of [125l]aBgt to P2 preparations 
(1 mg/ml) was assessed up to a toxin concentration of 20nM (Figure 2.7b). Specific binding 
approached saturation at 5nM [125l]aBgt, and generated a linear Scatchard plot (inset) with a mean 
Kd of 1.3nM and Bmax of 84fmol/mg (Table 2.2). An average Hill coefficient (rjH) of 1.05 was derived 
from Hill plots (Figure 2.7c) for 3 independent tissue preparations. There appeared to be roughly 
equal numbers of [3H]-(-)-nicotine and [125l]aBgt binding sites in the whole rat brain preparations 
studied.
Rat skeletal muscle extract (RME)
Protein in rat muscle was extracted with Triton X100 due to heavy contamination of the 
preparation with connective tissue. Quantitative detergent extraction has been documented as 
inactivating a significant proportion of [3H]-(-)-ACh binding sites (Schneider et al 1985), so steps 
were taken to assess whether muscle aBgtBPs were similarly affected using a filtration method. The 
variance in binding levels as protein, and consequently Triton X100, levels were increased to 









4 60 2 8 10  12  14
P2 protein content ( m g / m l )
Figure 2.7. Protein dependence and saturability of [125l]abungarotoxin binding to rat brain P2 
membranes. [125l]aBgt (1 nM) was incubated for 2h with increasing levels of P2 protein in the 
presence and absence of 1p,M unlabelled aBgt, as described in section 2.2.5. Bound radiolabel was 
recovered by centrifugation. Data from a representative experiment (a) show levels of total [125l]aBgt 
bound (V) and non-specific binding (□ ) which were used to determine the levels of specific [125l]a  
Bgt binding ( • ) .  Points represent the means of triplicate determinations. The same tissue 
preparation (at 1mg protein/ml) was incubated with various concentrations of [125l]aBgt (1-20nM), 
and the degree of specific binding ( • )  determined (b) - see section 2.2.6. Scatchard analysis (inset) 
revealed an apparent KD=0.76nM and Bmax=77frnol [125l]aBgt/mg protein (r2=0.96). A Hill plot (c) of 
the specific binding levels from the saturation assay, using the Bmax from (b), gave a Hill coefficient 
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Figure 2.8. Protein dependence and 
saturability of [125l]abungarotoxin 
binding to rat muscle extract (RME), 
and the effect of detergent. [125l]aBgt 
(1nM) was incubated for 2h with 
increasing levels of RME protein in the 
presence and absence of 1 jllM 
unlabelled aBgt, as described in section
2.2.5. Bound radiolabel was recovered by 
rapid filtration. Data from a representative 
experiment (a) show levels of total [125l]a 
Bgt bound (V) and non-specific binding 
(□ ) which were used to determine the 
levels of specific [125l]aBgt binding ( • ) .  
Points represent the means of triplicate 
determinations. A similar experiment to 
(a) in which [125l]aBgt (1 nM) was 
incubated with RME protein (1 mg/ml), in 
the presence and absence of 1 jllM aBgt, 
included increasing levels of Triton X100 
(0 -2 .0%(v/v)) (b) - see section 2 .2 .2 . 
Total)V), non-specific(O) and specific(# 
) binding levels were established, as 
above, from triplicate determinations.
The same tissue preparation (at 1mg 
protein/ml) as that used in (a), was 
incubated with various concentrations of 
[125l]aBgt (1-1 OnM), and the degree of 
specific binding ( • )  determined (c) - see 
section 2.2.6. Scatchard analysis (inset) 
revealed an apparent KD=0.55nM and 
Bmax=11.2frnol [125l]aBgt/mg protein 
(r2=0.95). A Hill plot (d) of the specific 
binding levels from the saturation assay, 
using the Bmax from (c), gave a Hill 
coefficient nH=0.99. Mean data are 
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generally higher than in brain preparations, with specific binding saturating above 3mg/ml. When 
protein levels were maintained at 1 mg/ml, specific binding levels appeared to be relatively 
unaffected up to 2%(v/v) Triton X100 (Figure 2.8b). Consequently a working protein concentration of 
1 mg/ml (0.1%(v/v) Triton X100) was used for all subsequent assays.
The saturability of [125l]ocBgt binding to RME at 1mg protein/ml, is represented in figure 2.8c. Results 
were very reproducible, with specific binding saturating almost fully at levels greater than 3nM of 
radiolabelled toxin. Linear regression of the Scatchard plots revealed a receptor site with a very 
similar apparent KD (0.9nM) to that found in whole brain P2 membranes, though 8 times fewer sites 
were present (Table 2.2). A Hill plot (Figure 2.8d) of specific binding data produced an average 
coefficient of 0.98. Mean data for all parameters from 3 independent tissue preparations are 
summarised in table 2.2.
2.3.5 Competition binding - agonists
A series of agonists were assessed for their biological potency at two distinct nicotinic 
cholinergic receptor sites, as measured by their ability to inhibit the binding of [3H]-(-)-nicotine and 
[125l]aBgt to receptor proteins in whole rat brain, and in certain instances [125l]aBgt labelled rat 
muscle sites. The agonists, and putative agonists, have been rationalised into structurally related 
groups to facilitate more direct correlations between affinity and structure. The group termed 
'classical agonists' (section 2.3.5.1) share little structural homology but have served to gauge the 
correlation between the sites identified in this project and similar sites reported in the literature.
2.3.5.1 Classical agonists
Effects due to the direct competition of the classical ganglionic agonists; (-)cytisine, (-)lobeline 
and (-)nicotine, at brain [3H]-(-)-nicotine and [125l]ocBgt labelled sites were examined in preincubation 
assays for comparison with the published pharmacological characteristics of these sites. Inhibition 
binding curves (Figure 2.9) were used to calculate the IC50 values represented in table 2.3. The 
endogenous ligand (ACh) was least potent of the agonists assayed at the [3H]-(-)-nicotine site with a 
Kj of 0.17jiM, being well within the values cited in the literature (Wonnacott 1987a) - this ligand is 
some 60-fold less potent an inhibitor of [125l]aBgt binding with a Kj of 11 jllM. Physostigmine was 
impotent at both neuronal receptor types up to concentrations of 100p,M (data not shown). The (-) 
enantiomer of nicotine was 8 times more potent than ACh at the [3H]-(-)-nicotine site, (K~22nM). 
Greatest potency among this group was displayed by (-)cytisine (K~14nM) but was only marginally 
more effective than (-)nicotine, whereas lobeline was less potent with a Kj of 81 nM. The potency 
rank order demonstrated by these ligands at the [3H]-(-)-nicotine site of cytisine>(-) 
nicotine>lobeline>ACh upholds the trend observed in the literature, which has a consensus ranking 
of: cytisine>(-)nicotine>lobeline=ACh. At the [125l]aBgt site the potency order of (-) 
nicotine>cytisine>lobeline>ACh was observed with Kj values of 1.0, 2.6, 6.4 and 11jiM respectively. 
However, there was a decrease in potency of between 50-200-fold for these ligands, with greatest 
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Figure 2.9. Competition binding 
assays of cholinergic agonists at (a) 
[3H]-(-)-nicotine and (b) [125l]a
bungarotoxin binding sites in rat brain 
membranes. Serial dilutions of (-) 
cytisine(#), (-)lobeline(O), (-)nicotine(V) 
and acetylcholine^) were assessed in 
preincubation assays for their ability to 
inhibit the binding of radiolabel, as 
described in section 2.2.7. Points 
represent the mean from at least three 
independent experiments, with bars 
indicating SEM. Linear transformation of 
the data determined values for 50% 
inhibition of radiolabel binding (IC50), 
which were used to calculate an inhibition 
constant, Kj, (Table 2.3) according to the 
method of Cheng and Prusoff - radiolabel 
was used at its calculated KD (Table 2.2). 
Mean data were fitted to a sigmoid 













1.7 ± 2.9 x 10'7 
2.2 ± 1 .8 x 1  O'8 
1.4 ± 2.0 x 10'8 
8.1 ± 1 .2 x 1 0 ’8
0.91 ±0 .19  
1.04 ±0 .13  
1.16 ±  0.17 
0.93 ±0.11
1.1 ± 0 .4  x 10'5 
1.0 ± 2.7 x 10‘6 
2.6 ± 2 . 5 x 1  O'6 
6.4 ± 1.2 x 10'6
1.4 ±0 .0 3  
0.84 ±0 .1 4  
0.67 ±0 .1 2  
0.79 ±0 .09
Table 2.3. Inhibition of [3H]-(-)-nicotine and [125l]ocBgt binding to rat brain by cholinergic agonists. The ability of 
various agonists to inhibit the binding of [3H]-(-)-nicotine and [125l]cxBgt to preparations of P2 membranes was 
determined in competition assays (Figure 2.9). [3H]-(-)-nicotine and [125l]aBgt were used at their KD values (10nM and 
1nM respectively) in all assays, which were performed in triplicate. Concentrations of agonist required to inhibit 
radioligand binding by 50% (IC50) were estimated by linear transformations of dose-response curves. Inhibition 
constants (Kj), calculated from IC50 values using the method of Cheng and Prusoff, and Hill coefficients (rjH), are the 
means (±SEM) of at least three independent determinations.
preference for the tritiated agonist site is typical of nicotinic agonists (Wonnacott 1990: Wonnacott et 
a/1991).
Inhibition curves for ligands binding to [3H]-(-)-nicotine and [125l]aBgt labelled sites generated Hill 
coefficients of near unity, an observation that is consistent with literature reports. The quantitative 
significance of these values is unclear.
2.3.5.2 Nicotine
The active form of nicotine appears to be the univalent nicotinium ion, as methylation of the 
pyrrolidine nitrogen, in nicotine monomethiodide, retains a significant degree of activity in 
competition assays at sites identified by [3H]-(-)-nicotine (Figure 2.10). The 40-fold shift in activity on 
methylation (Table 2.4) is largely attributable to the increased bulk at the cationic head (see section 
2 .1.1), which may reflect the volume of the binding cavity around this crucial pharmacophore point.
Nicotine was found to be nearly 2 orders of magnitude less effective in the (+) stereoisomer at the 
[3H]-(-)-nicotine brain site (Table 2.4), exemplifying the obvious stereospecificity of this nAChR 
population for this ligand. Indeed the (+) isomer may bind exclusively to the low affinity site for 
nicotine (see section 2.4). Previous studies have found (+)nicotine to be generally 20-70 times 
weaker in inhibiting binding than (-)nicotine (Wonnacott 1987a). This nicotine stereoselectivity is 
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Figure 2.10. Competition binding assays of nicotine analogues at [3H]-(-)-nicotine binding 
sites in rat brain membranes. Serial dilutions of (-)nicotine(A), (-)nicotine monomethiodide(A), 
(+)nicotine tartrate(o) and (+)nicotine toluoyltartrate(#) were assessed in preincubation assays for 
their ability to inhibit the binding of radiolabel, as described in section 2.2.7. Points represent the 
means from at least three independent experiments, with bars indicating SEM. Linear transformation 
of the data determined values for 50% inhibition of radiolabel binding (IC50), which were used to 
calculate Kj values (Table 2.4) according to the method of Cheng and Prusoff - radiolabel was used 
at its calculated KD (Table 2.2). Mean data were fitted to a sigmoid function (see section 2.2.8).
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lilll
lllll pHJ-f-J-nicotine n  H
Relative
potency
(-)Nicotine (1) 2.2 ± 1.8x1 O'8 1.04 ±0 .1 3 1
(-)Nicotine monomethiodide (2) 8.7 ± 0 .9 x 1  O'7 0.89 ±  0.09 40
(+)Nicotine (3) 3.3 ±1.1 x 10'6 1.14 ±0 .1 0 150
(+}Nicotine-di-toluoyltartrate 1.8 ± 2.5 x 10'6 0.97 ±0 .09 82
mm
Table 2.4. Inhibition of [3H]-(-)-nicotine binding to rat brain by nicotine and analogues. The ability of the 
stereoisomers and an N-methylated analogue of nicotine to inhibit the binding of [3H]-(-)-nicotine to preparations of P2 
membranes was determined in competition assays (Figure 2.10). [3H]-(-)-nicotine was used at 10nM (KD) in all assays, 
which were performed in triplicate. Concentrations of agonist required to inhibit radioligand binding by 50% (IC50) were 
estimated by linear transformations of dose-response curves. Inhibition constants (Kj), calculated from IC50 values using 
the method of Cheng and Prusoff (see section 2.2.8), and Hill coefficients (r|H), are the means (±SEM) of at least three 
independent determinations.
2.3.5.3 Piperazine based compounds
As their names suggest, this group of ligands all have a piperazine ring as the structural core - 
see figure 2.11 for structures. In this study the affinities of these 'piperazines' were assessed at the 
rat brain sites labelled by [3H]-(-)-nicotine (Figure 2.11a) and [125l]aBgt (Figure 2.11b), and 
additionally, for comparison with Torpedo data, against [125l]aBgt receptors of rat muscle (Figure 
2.11c) - see also Garcha eta! 1993. Binding affinity data are summarised in table 2.5.
Ki brain sites (M} K} RME s ite  m




1.1 ± 0.5 x 10'7 
2.5 ± 0 .7 x 1  O'7 
3.0 ± 0 .3 x 1 0 -5
0.92 ±  0.05 
0.85 ±  0.08 
1.14 ±0 .09
3.8 ± 1 .4 x 1 0*6




2.9 ± 1.4 x 10'6 
7.0 ± 5 .0 x 1 0 -6 
1.2 ± 0.1 x 10"3
1.07 ±0 .12  
0.98 ±  0.09 
0.82 ±  0.05
Table 2.5. Inhibition of [3H]-(-)-nicotine and [125l]aBgt binding to rat brain, and [125l]aBgt binding to rat muscle 
extract, by compounds based on the piperazine ring structure. The ability of piperazines to inhibit the binding of 
[3H]-(-)-nicotine and [125l]cxBgt to preparations of P2 membranes, and [125l]aBgt to rat muscle extract (RME), was 
determined in competition assays (Figure 2.11). [3H]-(-)-nicotine and [125l]cxBgt were used at their KD values (10nM and 
1nM respectively) in both brain and muscle assays, which were performed in triplicate. Concentrations of ligands 
required to inhibit radioligand binding by 50% (IC50) were calculated by linear transformation of dose-response curves. 
Inhibition constants (Kj), calculated from IC50 values using the method of Cheng and Prusoff (see section 2.2.8), and 
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Figure 2.11. Competition binding assays 
of piperazine analogues at (a) [3H]-(-)- 
nicotine and (b) [125l]abungarotoxin 
binding sites in rat brain membranes, 
and also at (c) [125l]abungarotoxin sites 
in rat muscle extract. Serial dilutions of 
DMPP(#), AMP.Mel(Y) and AMP.HCI(O) 
were assessed in preincubation assays for 
their ability to inhibit the binding of 
radiolabel, as described in section 2.2.7. 
Points represent the means from at least 
three independent experiments, with bars 
indicating SEM. Linear transformation of the 
data determined values for 50% inhibition 
of radiolabel (IC50), which were used to 
calculate an inhibition constant, Kj, (Table 
2.5) according to the method of Cheng and 
Prusoff - radiolabel was used at its 
calculated KD (Table 2.2). Mean data were 
fitted to a sigmoid function (see section 
2.2 .8).
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1,1 -dimethyl-4-phenylpiperazinium (DMPP) was able to inhibit 50% of [3H]-(-)-nicotine binding to rat 
brain sites at a concentration of 0.2jiM (K-O.IillM), making it the least potent of the classical 
nicotinic agonists (cytisine>(-)nicotine>lobeline>ACh>DMPP), 10-fold less effective than cytisine and 
almost equipotent with ACh. DMPP is almost invariably the least potent of these five agonists at rat 
brain P2 receptor sites (Wonnacott 1987a). Affinity for the neuronal [125l]ocBgt site is 40-fold lower 
than for [3H]-(-)-nicotine, though in some studies there is little discrimination (Marks et al 1986). At 
the homologous rat muscle nAChR labelled by [125l]aBgt, DMPP potency was comparable to that 
observed at the brain protein (Kj=2.9|iM (muscle) cf. 3.8jiM (brain)).
The DMPP analogue, 1-methy!-4-acetylpiperazinium methiodide (AMP.Mel) displays agonist 
potency at the frog neuromuscular junction (Spivak efa/1986). In this study, AMP.Mel inhibited [125l] 
aBgt binding to the rat muscle site with a Kj of 7|iM, nearly 3 times more effective than at the 
equivalent brain site (Kj=19jxM). AMP.Mel is nearly two orders of magnitude more potent at inhibiting 
[3H]-(-)-nicotine binding to the same brain tissue preparation. The methiodide was between 2 and 5 
times less potent than DMPP at each of the sites assayed.
The hydrochloride salt of AMP proved to be considerably less potent, being in excess of two orders 
of magnitude less so relative to the methiodide, at both the brain and muscle nAChR populations. Kj 
values were greater than 1mM at [125l]aBgt binding sites in brain and muscle, with a value of 30p.M 
at [3H]-(-)-nicotine sites (Table 2.5). Hill coefficients were near unity for all the compounds.
2.3.5.4 Anatoxins
This family of ligands is structurally based on the semi-rigid azabicyclononene skeleton of 
anatoxin-a (AnTx: see figure 2.12 for structures). Figure 2.12 represents inhibition binding curves for 
the parent compound, (+)anatoxin-a, and a series of rationally designed alkyl modified sidechain 
analogues, synthesised to probe configurations relevant to the nAChR pharmacophore (Thomas et 
al 1994). All were very effective inhibitors of brain receptors (Figure 2.12a and b), but fail to have any 
significant effect at muscarinic sites (Figure 2.12c). Figure 2.13 comprises more conformationally 
constrained analogues, which were considerably less potent. These potential ligands were 
synthesised by Paul Brough (Brough et al 1992: Thomas et al 1994), with the exception of the 
tertiary alcohol (N-methyl anatoxin-10-methyl alcohol (Me-AnTx-mol)), which was synthesised 
previously (Sardina et al 1989: Howard et al 1990), and was used for comparative purposes in this 
study. All analogues were assayed as racemic mixtures with the exception of (+)Me-AnTx-mol.
(+)Anatoxin-a ((+)AnTx) inhibited the binding of [3H]-(-)-nicotine to rat brain membranes with a Kj of 
8.2nM (Figure 2.12a: Table 2.6), a value which corroborates previous findings with this toxin 
(MacAllen et al 1988: Wonnacott et al 1991), making (+)AnTx the most potent agonist at neuronal 
nAChRs. (+)AnTx was approximately 60-fold less potent at [125l]aBgt labelled binding sites. Inhibition 
by (±)AnTx at the same sites generated Kj values of 19nM and 0.9|nM respectively. The roughly two­
fold difference in potency between (+) and (-) forms are in line with those observed at peripheral 
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Figure 2.12. Competition binding assays 
of potent anatoxin (AnTx) analogues at 
(a) [3H]-(-)-nicotine, (b) [125l]cc
bungarotoxin and (c) [3H]QNB binding 
sites in rat brain membranes. Serial 
dilutions of (+)AnTxp), (±)AnTx(0), ( 
±)HomoAnTxp), (±)PropylAnTx(T), (± 
)lsopropylAnTx(V) and atropine (□ ) were 
assessed in preincubation assays for their 
ability to inhibit the binding of radiolabel, as 
described in section 2.2.7. Points represent 
the means from at least three independent 
experiments, with bars indicating SEM. 
Linear transformation of the data 
determined values for 50% inhibition of 
radiolabel (IC50), which were used to 
calculate K, values (Table 2.6), according to 
the method of Cheng and Prusoff - 
radiolabel was used at its calculated KD 
(Table 2.2). Mean data were fitted to a 
sigmoid function (see section 2 .2 .8 ).
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Figure 2.13. Competition binding assays of conformationally constrained anatoxin (AnTx) 
analogues at (a) [3H]-(-)-nicotine and (b) [125l]abungarotoxin binding sites in rat brain 
membranes. Serial dilutions of (±)HeteroAnTx(a), (±)EpoxyAnTx(H), (±)HydroxyAnTx(A) and 
(+)Me-AnTx-mol(A) were assessed in preincubation assays for their ability to inhibit the binding of 
radiolabel, as described in section 2.2.7. Points represent the means from at least three independent 
experiments, with bars indicating SEM. Linear transformation of the data determined values for 50% 
inhibition of radiolabel binding (IC50), which were used to calculate K, values (see Table 2.6) 
according to the method of Cheng and Prusoff - radiolabel was used at its calculated KD (Table 2.2). 
Mean data were fitted to a sigmoid function (see section 2.2.8).
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between (+) and (-) racemates at hippocampal and cerebellar [3H]-(-)-nicotine labelled sites 
respectively (Zhang & Nordberg 1993).
Addition of methine or methylene units to the acetyl side chain of the AnTx skeleton to produce the 
compounds homoanatoxin (HomoAnTx), propylanatoxin (PropylAnTx) and isopropylanatoxin 
(IsopropylAnTx), did not appear to diminish binding potency at either radiolabelled brain site (Figure 
2.12: Table 2.6).
Ugand pHH-l-nicotine 'H H Bgt ^  H
(+)Anatoxin-a (AnTx) (1) 8.2 ± 2 .3 x 1  O’9 1.32 ±0 .15 5.3 ± 2 .6 x 1  O'7 1.41 ±0 .15
(±)AnTx 1.9 ± 0.3 x 10'8 1.07 ±0 .03 9.0 ± 0 .5 x 1 0 -7 1.43 ±0.11
(±)HomoAnTx (2) 5.5 ± 0 .5 x 1  O'9 0.93 ±0 .05 3.4 ±0 .8 x1 0 -7 1.51 ±0 .0 9
(+)PropylAnTx (3) 2.4 ±1.1 x 10'8 0.97 ±  0.06 4.4 ± 0 .7 x 1  O'8 1.19 ±0 .08
(±)lsopropylAnTx (4) 7.5 ± 3.0 x10'9 1.03 ±0 .07 1.2 ± 0 .3 x10 -7 1.56 ±0 .12
(±)HeteroAnTx {5} 5.0 ±1 .2x1  O'5 1.26 ±0 .13 >10’4 -
(±)EpoxyAnTx (6) >10'4 - >10*4 -
(±)HydroxyAnTx (7) 6.8 ± 1 .5 x 1  O'5 1.95 ±0 .2 >10-3 -
(±)Me-AnTx-mol (8) >10‘4 - nd -
Table 2.6. Inhibition of [3H]-(-)-nicotine and [125l]aBgt binding to rat brain by anatoxin and a series of 
analogues. The ability of anatoxins to inhibit the binding of [3H]-(-)-nicotine and [125l]aBgt to preparations of P2 
membranes was determined in competition assays (Figures 2.12 & 2.13). [3H]-(-)-nicotine and [125l]aBgt were used at 
their KD values (10nM and 1nM respectively) in all assays, which were performed in triplicate. Concentrations of toxins 
required to inhibit radioligand binding by 50% (IC50) were calculated by linear transformation of dose-response curves. 
Inhibition constants (Kj), calculated from IC50 values using the method of Cheng and Prusoff (see section 2.2.8), and 











HomoAnTx, PropylAnTx and IsopropylAnTx competed for [3H]-(-)-nicotine binding sites with Kj 
values of 5.5, 24 and 7.5 nM respectively. Corresponding values at [125l]aBgt sites were 0.3, 0.04 
and 0.1 jiM  respectively. Estimates for HomoAnTx mirror those of previous determinations 
(Wonnacott et al 1992), and PropylAnTx appears to be more selective for the [125l]aBgt labelled 
receptor protein, the difference in affinity being less than two-fold between the two sites. No affinity 
for these compounds was displayed by muscarinic AChRs (Figure 2.12c).
Of the more conformationally constrained analogues poor affinity was observed at both of the 
neuronal nAChR sites (Figure 2.13: Table 2.6). N-methylation of the alcohol derivative abolished 
activity, as reported by Wonnacott and co-workers (1991). A lack of material precluded investigation 
above 100jiM concentrations of some ligands.
2.3.6 Summary
Competition binding potencies (relative to acetylcholine) of all agonists assayed in this study 
are summarised in figures 2.14 and 2.15, representing [3H]-(-)-nicotine- and [125l]ocBgt-labelled rat 
brain sites respectively - potencies were calculated using the Kj values from data tables in this 
chapter. The relative potencies of certain competitive antagonists are also included although the 
data has not been formally presented in this section - (IC50 values (M) for [3H]-(-)-nicotine-labelled 
brain site: MLA (2.2x1 O’6), DHpE (1.7x1 O'6) and d-TC (4.9x1 O'5), and the [125l]aBgt-labelled brain 
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Figure 2.14. Relative potencies of all compounds assayed in competition studies at the [3H]- 
(-)-nicotine binding site. Potencies of all drugs (agonists and antagonists) inhibiting [3H]-(-)-nicotine 
binding to rat brain P2 membranes are represented relative to the endogenous ligand acetylcholine 
(ACh, Kj=0.17|LiM). Potency values were determined from Kj values (±SEM) calculated from data in 


















1111 r 11 m  11111
o  o  oo o o o O
O  O  O  00 x f
ro cm * -
Fold po ten cy  ( c f  ACh)
Figure 2.15. Relative potencies of all compounds assayed in competition studies at the [125l] 
aBgt binding site. Potencies of all drugs inhibiting [125l]aBgt binding to rat brain P2 membranes are 
represented relative to the endogenous ligand acetylcholine (ACh, K -H pM ). Potency values were 
determined from Kj values (±SEM) calculated from data in sections 2.3.5. Bars deflecting to the right 
indicate lower potency, whereas those to the left are more potent than ACh.
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2.4 Discussion
Two principal radioligands selective for distinct neuronal nACh receptor subtypes were used 
in this study. Although all nAChR recognise nicotine by definition, only those that bind nicotine with 
nanomolar affinity are labelled by the radiolabelled agonist. The single site labelled by [3H]-(-)- 
nicotine in brain appears to represent the presence of a4 and 02 subunits (Flores et al 1992). [125l]a  
Bgt also binds with high affinity to another class of receptor(s) which are believed to contain a7 
and/or a 8 subunits. In certain cases in this study, comparisons have been made between the [125l]a  
Bgt-sensitive sites of rodent central and peripheral nervous system in order to gage the effects due 
to the presence of a7/oc8- or a1-containing receptors, alongside the effects due to a4-containing 
receptors.
[3H]nicotine displays saturable high affinity binding to brain tissue (Figure 2.5) exhibiting a 
dissociation constant (KD) of 13nM (Table 2.2) - in mammalian brain in general the range is between 
1 and 10nM (Wonnacott et al 1990), reported disparities being attributable to many factors such as 
assay method, tissue preparation and ligand purity. The rodent brain sites identified by [125l]aBgt 
also showed high affinity for this iodinated toxin (KD=1nM: Table 2.2), though again the literature 
reports some variation among KD values, though all exhibit nanomolar affinity (Schmidt e ta l 1980). 
In contrast to the affinity for aBgt in muscle and electric organ (KD=1nM), neuronal receptors bind a  
Bgt in a reversible fashion. Scatchard analysis and Hill plots of the saturation binding data (Figures
2.5, 2.7 and 2.8) indicate binding to a single class of receptor for both ligands. However, although 
a7-containing aBgtBPs predominate in brain (Schoepfer et al 1990: Anand e ta l 1993), other minor 
components are also present and may represent a7a8- or a 8-containing receptors.
Pharmacological specificity
Binding of well established classical nicotinic agonists to the nAChR sites labelled in this study 
was initially undertaken in order to provide a standard against which to compare results obtained for 
novel ligands not previously assessed for their activity at the nicotinic receptor. Acetylcholine, (-) 
nicotine, cytisine and lobeline are particularly potent at inhibiting [3H]-(-)-nicotine binding to rat brain 
P2 membranes (Table 2.3). The potency rank order of cytisine>(-)nicotine>lobeline>ACh closely 
agrees with previous studies (see Wonnacott 1987a). All of these agonists discriminate the [125l]aBgt 
brain binding site, showing markedly reduced affinity (roughly 100-fold) relative to the [3H]-(-)- 
nicotine labelled receptor site. (+)Nicotine exhibits greater than 100-fold lower potency than the (-) 
enantiomer at [3H]-(-)-nicotine sites (Table 2.4), demonstrating the extreme stereoselectivity of the 
receptor for this ligand (Romano & Goldstein 1980), a trait not common to the [125l]aBgt binding site 
(Marks et al 1986: Wonnacott et al 1986).
A general feature of the binding of these ligands to the two populations of brain receptor is their 
higher affinity relative to the concentrations that are required to activate the functional physiological 
equivalents. This deficit is reconciled by the understanding that in the equilibrium binding assay, 
prolonged incubation with ligand converts the binding site into a high affinity, desensitised state 
(Schwartz et al 1982). Although desensitisation is also seen with the functional receptor, whereby
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the channel becomes unresponsive in the continued presence of the agonist following its initial 
confrontation with the receptor, the pharmacological response is more a measure of the affinity of 
the initial resting state of the receptor for the ligand. The desensitised state represented in the 
binding assays is therefore quite different, its induction and conversion to alternative modes most 
probably being via a complex series of intermediate states (Hucho 1986). Support for this 
conversion of the agonist binding site is apparent from kinetic analysis of binding (Lippiello et al 
1987) and functional desensitisation (Higgins & Berg 1988) by nicotine. Now discounted theories 
suggested that desensitisation occurred via a site remote from the ligand binding site (Conti- 
Tronconi & Raftery 1982). The desensitised state predominant in the radioligand binding assays 
may be a consequence of induced fit of ihe ligand in the agonist site, a phenomenon which would 
be influenced by structural properties of the ligand beyond those essential to the pharmacophore 
which is recognised by and causes activation of the receptor. Evidence from an investigation 
undertaken as a part of this project, though not presented, exploring the hydrophobicity of ligands 
revealed that in general the more hydrophobic a ligand the greater was its potency, and furthermore 
that active ligands at the [125l]ocBgt labelled neuronal receptor were roughly 20% more hydrophobic 
than those active at the [3H]-(-)-nicotine site. The data set for this study was derived from in excess 
of 120 ligands comprising the basic pharmacophore features and ranging widely in size and 
electrostatic character. Each had been assessed for activity at both the [3H]-(-)-nicotine and [125l]a  
Bgt labelled neuronal site in radioligand binding assays. Hydrophobicity indicators, generated using 
the CLOGP program, were representative of whole molecules thus were unable to distinguish 
specific effects due to, for example, the introduction of hydrophobic moieties around sensitive 
aspects of the pharmacophore model. This evidence may indicate that beyond the recognition event 
between receptor and ligand, increased hydrophobic character may be important in promoting 
transition of the receptor to a desensitised state, consistent with an induced fit model of a 
hydrophobic molecule in a hydrophobic binding pocket. Many hydrophobic aromatic amino acid 
residues have been implicated to participate in the formation of the binding site (see section 1.4). 
Thus it may be that the stability of the desensitised state presented in the binding assay is dictated 
by the extent of the hydrophobic interaction between ligand and these receptor residues, more 
hydrophobic molecules inducing a tighter fit and thus demonstrating higher affinity for the receptor. 
This situation would demonstrate how the features of the pharmacophore which are required for 
initial recognition events may be less relevant in the desensitised mode of the nicotinic receptor. It 
might then be a useful exercise to quantitate the hydrophobic parameters of individual functional 
groups of nicotinic ligands to ascertain around which area of the pharmacophore hydrophobicity 
plays the most important role.
Thus, although both [3H]-(-)-nicotine and [125l]aBgt binding sites in brain demonstrate a nicotinic 
pharmacology the inhibition of the binding of these radioligands by nicotinic agents is dissimilar. 
Furthermore, aBgt is unable to inhibit [3H]-(-)-nicotine binding (data not shown), findings consistent 
with the distinctness of the nAChR proteins labelled by these ligands, and which correlate with the 
variation in relative densities and non-overlapping distributions of these two sites (Romano & 
Goldstein 1980: Schwartz e ta l 1982: Clarke eta! 1985).
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Classical ganglionic antagonists hexamethonium and mecamylamine, and MK801, were totally 
ineffective competitors of [3H]-(-)-nicotine and [125l]aBgt binding (data not shown). However, other 
ganglionic antagonists, DHpE and d-TC exhibited antagonistic effects at the [3H]-(-)-nicotine site 
(with Kj values of 2|iM and 50|iM respectively), and are reported to be equally effective at the [125l]a  
Bgt site (see Wonnacott 1990). These results are in line with those of previous studies (Marks et al 
1986: McAllen eta! 1988), and exemplify the non-competitive nature of small antagonists, which act 
by blocking the channel site (see section 1.4.4.1 & 1.4.4.2.), and the competitive properties common 
to larger antagonists which share features of the nicotinic pharmacophore (see section 2.1.2) and 
bind directly to a site shared by agonists. The only other antagonist used in this study to verify the 
fidelity of these two distinct receptor sites was MLA which showed quite significant selectivity (more 
than 3 orders of magnitude greater affinity) for the [125l]aBgt-sensitive site (K(~4nM). This specificity 
goes beyond that of [125l]cxBgtBPs in general (having lower affinity for muscle sites), as reconstitution 
of neuronal nAChR subunits in Xenopus oocytes reveals possible a7  specificity for this complex 
molecule (see section 3.3.3.1).
The univalent nicotinium ion is the active form of nicotine. Quaternisation of the pyrrolidine nitrogen 
in nicotine monomethiodide demonstrates this as potency is largely retained (Table 2.4), the 40-fold 
decrease in affinity more probably a consequence of the increased steric bulk. Notably, the 
secondary amine derivative of nicotine, nornicotine, is also weaker (9-fold) than (-)nicotine but the 
stereoisomers, unlike nicotine, are equipotent when displacing [3H]-(-)-nicotine (Copeland et al 
1991). This effect is not a consequence of changing the physical properties of the cationic site, as 
the basicity of the pyrrolidine nitrogen in nicotine and nornicotine is similar so should have little effect 
on the proportions of mono-cation for each ligand. However, lipophilicity is altered by the presence 
or absence of methyls around this nitrogen. Since the binding affinity of (+)nicotine is considerably 
less than (-), and since nicotine monomethiodide and nornicotine stereoisomers are slightly less 
potent, although the latter are equipotent with each other, it is evident that the N-methyl group exerts 
a profound effect on binding to the nAChR. This effect is reflected in the affinities exhibited by many 
other nicotinic ligands. For instance N-methylation of piperazine derivatives (see section 2.3.5.3) and 
cytisine increases potency, yet the same modification to anatoxin-a and its derivatives (see section 
2.3.5.4J and ferruginines serves to reduce the potency of these ligands at the nicotinic receptor. 
Thus, simple extrapolations regarding the effects of N-methylation are not possible.
In the case of nicotine it would appear that the addition or removal of an N-methyl group destabilises 
the conformation and that consequent effects on hydrophilicity and basicity are of less importance. 
For instance the proton attached to the pyrrolidine nitrogen of the protonated form of nicotine may be 
directed towards the complementary cationic binding site (i.e. the bulky methyl is out of the way). In 
(-)nicotine this structure may be represented where N-methyl and pyridine ring are in the trans 
configuration (see section 4.3.2). Binding of (+)nicotine would require that in order for the proton to 
assume the same directionality, the pyridine ring would be forced into an energetically less 
favourable cis configuration relative to the N-methyl. The stereoselectivity of nicotine may therefore
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be a consequence of steric repulsion between pyridine ring and N-methyl decreasing stability of the 
ligand-receptor complex. Alternatively, if the trans configuration were retained in (+)nicotine then the 
methyl would be oriented towards the cationic site which may not be favourable. In nornicotine these 
steric interactions due to the N-methyl group would not apply, hence the observed lack of 
stereoselectivity. If this is the case, then (+)nicotine monomethiodide should also demonstrate 
equipotency with the (-) stereoisomer.
DMPP was roughly equipotent with ACh at the [3H]-(-)-nicotine labelled site yet did not appear to 
favour this site over that labelled by aBgt to the same extent as that of other nicotinic agonists 
(Table 2.5). This reflects the observations of Marks and co-workers (1986), who found DMPP to be 
almost equipotent at these two rodent brain sites. Remarkably, DMPP showed similar affinity for the 
a 1-containing skeletal muscle receptor of the rat as for the brain site. Given the limited sequence 
homology that exists between a1 and a7/a8 genes, and the presence of p, 7, 8 subunits in the 
muscle protein homologue, and presence of only non-a subunits in the neuronal receptors, the 
conservation of potency between ocBgtBP subtypes is perhaps significant. This may reflect either a 
well conserved feature in the aBgt-sensitive a  subunit which forms the binding site, or a minimal 
contribution to the binding site from neighbouring subunits, suggesting a less subunit interface 
oriented binding site in the aBgtBPs.
The novel nicotinic ligand AMP.Mel inhibited the binding of nicotinic radioligands to sites in rodent 
muscle and brain. Previously this salt was examined in preparations of Torpedo electric organ 
(Spivak et al 1989a) and at frog neuromuscular junction (Spivak et al 1986). The present study 
extends this profile (Garcha et al 1993). Replacement of the benzene ring of DMPP with an acetyl 
group in AMP.Mel produces a ligand of comparable potency (Table 2.5). Whereas AMP.Mel 
exhibited potencies at [125l]ocBgt sites similar to those of Torpedo (Spivak et al 1989a), removal of an 
N-methyl group in the hydrochloride salt (AMP.HCI) reduced potency by some two orders of 
magnitude at each of the brain and muscle binding sites examined (Table 2.5). Similarly, the 
hydrochloride salt of the structurally related isoarecolone has been shown to be 25-fold less potent 
than the corresponding methiodide at [3H]-(-)-nicotine binding sites of rat brain (Reavill et al 1987), 
contrary to the effects of N-methylation of cytisine and anatoxin-a. It has been proposed that simple 
tertiary amines are weak agonists because the requirement for steric bulk perpendicular to the plane 
defined by the carbonyl carbon and its substituents is not fulfilled (Spivak et al 1989a). The N,N- 
dimethylpiperazinium structure is common to both DMPP and AMP.Mel and these two ligands are 
almost equipotent at each site. However, the hydrochloride salt of AMP does not share the potency 
of the methiodide despite existing as a monovalent ion. Thus it seems that although the univalent 
piperazinium ion is common to potent ligands, the presence of a methyl around this cationic head is 
also important, perhaps due to increased lipophilicity or stability differences. The hydrogen bond 
accepting moiety is substitutable and therefore is of secondary importance, represented by 
delocalised pi electrons. The benzene ring associated with DMPP may occupy a hydrophobic pocket 
in the receptor, residues for the provision of this there is certainly no shortage of. Many of the more 
potent nicotinic agonists are semi-rigid and the bulk of their volume is asymmetrically displaced.
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Piperazines are essentially substituted cyclohexanes with a rotatable bond between the tertiary 
nitrogen and substituent carbon, and thus are relatively flexible in their number of conformations and 
are, perhaps crucially, fairly planar (see section 4.3.3). The quaternary nitrogen is evidently crucial in 
bestowing potency via the introduction of the out of plane bulk, and possible alterations to the 
lipophilic character. Notably, the carbamyl analogue of AMP.Mel is 17-fold less potent in evoking 
twitch responses in the frog muscle (Spivak et al 1989a), a factor ascribed mainly to the greater 
hydrophilicity of the carbamyl, which disfavours the partitioning of this agonist from the aqueous 
phase to the receptor phase. This may be a general rule for ligands with groups which can donate 
hydrogen bonds to water.
Although AnTx has a rigid azabicyclononene ring system, the rotatable bond of the acetyl sidechain 
means the enone moiety can adopt two important low energy conformations where the carbonyl 
bond is either cis or trans (see section 4.3.4). Which of these two conformations represents the 
bioactive form is controversial (see section 4.1.2). According to the Beers-Reich model of the 
nicotinic pharmacophore the cis conformation of AnTx best complies with the distance between 
cationic group and carbonyl oxygen, but the angle by which these two groups are disposed is best 
fulfilled by trans AnTx. Given the universally potent nature of (+)AnTx at neuronal nAChR (Thomas 
eta! 1993), determining the bioactive conformation may have significant implications for an extended 
model of the nicotinic pharmacophore.
Previous studies with AnTx and a series of 18 rationally designed analogues (see table 4.7 and 
Swanson et al 1991: Wonnacott et al 1991) re-evaluated the nicotinic pharmacophore and chemical 
hypotheses concerning agonist interaction with nAChRs. The analogues comprised rational changes 
to the acetyl moiety and secondary amine function, and mainly evaluated the importance of 
hydrogen bonding strength, planarity, steric bulk and side chain configuration - structural 
modifications of these analogues and respective Ks values at [3H]-(-)-nicotine and [125l]ocBgt sites are 
given in table 4.7. In this previous study, (+)AnTx was the most potent competitor of binding to [3H]- 
(-)-nicotine and [125l]aBgt labelled neuronal sites, a feature repeated in this current study. 
Modification of the AnTx structure reduced potency. N-methylation reduced potency by at least two 
orders of magnitude (Table 4.7) consistent with the same effect among piperazine based 
compounds, but contrary to effects on ferruginine and cytisine (Swanson & Albuquerque 1992). The 
potential of AnTx as a starting point for structure-activity relationships was clearly illustrated among 
the amido analogues, two of which (AnTxNOMe and AnTxisox) demonstrated a 1000-fold 
preference for the [3H]-(-)-nicotine site, and another (AnTxMe2N) was relatively more potent at aBgt 
sites (Table 4.7).
With some of the lessons from this previous study in mind a series of constrained analogues were 
synthesised (Paul Brough & Timothy Gallagher, Univ. Bristol). The objective behind these rational 
modifications was to determine the bioactive configuration of the carbonyl of the acetyl sidechain by 
restricting its conformational freedom - the racemic compounds synthesised are shown with table
2.6. In the so-called HeteroAnTx and HydroxyAnTx the hydrogen bond accepting group was locked
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in the cis configuration, in the former through the addition of a pyrazole ring system and in the latter 
by a hydrogen bond with an adjacent hydroxyl (Brough et al 1992). EpoxyAnTx was designed to 
effectively distort the carbonyl group away from cis via charge repulsion due to the introduction of an 
epoxide - it is unlikely that this structure exists as either cis or trans as a result. Additionally, the N- 
methylated tertiary alcohol, Me-AnTx-mol (structure 8 in table 2.6), a synthetic analogue from the 
previous AnTx study mentioned above (Swanson et al 1991), was also included. Unfortunately, 
these constrained analogues were largely ineffective at both nicotinic (Table 2.6) and muscarinic 
(data not shown) sites. The cis constrained analogues (HeteroAnTx and HydroxyAnTx) were 
possibly slightly more effective than the epoxide, but given the extent to which the AnTx structure 
has been modified in volume and charge this observation cannot be ascribed to configuration of the 
hydrogen bond accepting moiety alone. Therefore, although not a positive result, these observations 
could be informative in that they reflect effects due to changes in charge distribution, loss of flexibility 
and steric restraints about the hydrogen bond accepting group, as well as conformation alterations. It 
should be noted that for this initial characterisation racemic compounds were employed yet the 
nicotinic potency of AnTx resides predominantly in the (+) enantiomer (Table 2.6: Spivak et al 1983): 
thus the assays may underestimate nicotinic potency by a factor of two.
Having taken on board the message that significant structural changes around and to the hydrogen 
bond accepting group are detrimental to activity, alternative alkyl-modified sidechain analogues of 
AnTx were deemed to be a less disruptive and less complicated approach. Previously extension of 
the acetyl sidechain, in HomoAnTx, has been shown not to affect potency (Wonnacott et al 1992). 
Further extension of this sidechain was undertaken by addition of one or more methine of methylene 
units producing PropylAnTx and IsopropylAnTx (see structures with table 2.6). It was assumed these 
alterations would be tolerated to a certain extent by the receptor binding site and perhaps that the 
extra hydrocarbon bulk, especially of IsopropylAnTx, would influence the configuration of the 
carbonyl group.
In competition binding assays AnTx and the three alkyl modified sidechain analogues inhibited [3H]- 
(-)-nicotine binding with K; values between 5nM and 24nM as racemic mixtures (Table 2.6): the rank 
order of potency at this site was HomoAnTx>lsopropylAnTx>AnTx>PropylAnTx. K( values for these 
analogues at the [125l]aBgt binding site were between 40nM and 900nM with the rank order 
PropyAnTx>lsopropylAnTx>HomoAnTx>AnTx. Thus the parent compound was not the most potent 
of the series, and there appeared to be some evidence of subtype specificity with PropylAnTx in 
favour of the [125l]ocBgt labelled neuronal site. HomoAnTx retained its potency relative to a previous 
study investigating the same sites (Wonnacott et al 1992); K|=7.5nM ([3H]-(-)-nicotine) and 1.1 (iM 
([125l]aBgt). In contrast, none of these novel AnTx analogues was effective at the muscarinic 
acetylcholine receptor, as defined by [3H]-quinuclidinyl benzilate competition binding (Figure 2.12).
HomoAnTx and IsopropylAnTx gave comparable K; values (0.34|iM and 0.12|iM respectively) at the 
[125l]aBgt sensitive brain site. Activation of the a7 nAChR in Xenopus oocytes by these two 
analogues (see section 3.3.3.4) was also comparable, taking into account the different receptor
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states, with EC50 values of 0.72(j.M and 0.66|nM, giving EC50/Kj ratios of 2 and 5 respectively. These 
potencies compare well with our published data for enantiomerically pure (+)AnTx at the a 7 nAChR 
(Amar et al 1993) which yielded an EC50 value of 0.58jiM and an EC50/K| ratio of 1.5. In the same 
study (Amar et al 1993) we obtained EC50/Kj ratios between 0.8 and 8.4 for six other agonists, so 
these novel AnTx analogues seem to fall within the same range.
Interestingly, PropylAnTx appears to be more selective for the [125l]aBgt site, having a Kj value 
(44nM) less than twice that at the nicotine site - AnTx, HomoAnTx and IsopropylAnTx exhibit ratios 
for the two sites of 46, 62 and 16 respectively, as is more common for nicotinic ligands. A previous 
series of AnTx analogues (Wonnacott et al 1991), typically gave K( ratios for [3H]-(-)-nicotine:[125l]a  
Bgt sites of between 30 and 100. The apparent selectivity of PropylAnTx for the [125l]ocBgt site is an 
interesting feature. Unfortunately a shortage of material precluded investigations with this ligand at 
the functional a7  nAChR.
These structure-activity studies based on the potent naturally occurring agonist AnTx have defined 
two new potent nicotinic ligands at neuronal nAChR that retain or exceed the potency of the parent 
compound. The agonist properties of AnTx are also retained by HomoAnTx, PropylAnTx and 
IsopropylAnTx at the a7 receptor (see section 3.3.3.4). Comparison of results from competition 
binding assays acknowledge that the ligand binding site of the receptor is able to accommodate the 
increasing hydrophobic bulk of the extended side chain of these analogues. Indeed, PropylAnTx 
may show some a7 subtype selectivity requiring a very exact hydrophobic subsite for the sidechain 
to interact with, a subsite which is too remote to be reached even by either the IsopropylAnTx or 
HomoAnTx sidechain. The existence of this hydrophobic subsite could be probed using even longer 
extensions of the side chain, or its toleration of charged groups be examined by substitution at the 
extremity of the sidechain. The apparent specificity shown by PropylAnTx argues against the 
orientation of the sidechain away from the binding surface and into an aqueous environment for the 
aBgt-sensitive receptor, for if this were the case then there would probably be little if any difference 
in [3H]-(-)-nicotine:[125l]aBgt potency ratios for this ligand. If this is so then there could exist important 
differences in the local environment of the binding site of the two receptor subtypes studied in this 
project. The many hydrophobic aromatic residues identified in this region could be candidates for 
this as mentioned previously. Receptor mutants in which these hydrophobic residues are substituted 
would be useful in exploring whether PropylAnTx in particular suffers any decrease in potency as a 
result.
It has been shown that the acetyl sidechain of AnTx can be extended considerably with little loss of 
potency (Huby e ta l 1991: Thomas et al 1994:). As such these novel analogues represent potential 
affinity ligand candidates which could be coupled to CNBr-activated sepharose and used to affinity 
purify nAChR of rat brain, cultured cell lines (e.g. M10, BC3H1, PC12), Xenopus oocytes etc. At 
present there is a paucity of affinity ligands for nAChR. These small analogues have the added 
advantage that elution using other nicotinic ligands would not denature the receptors, as happens 
with immunoisolated proteins (Whiting & Lindstrom 1987). Considering that the subunit composition
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of neuronal nAChR is largely unknown, these ligands could prove to be excellent starting structures, 
especially PropylAnTx if it is confirmed to be a7 selective. Conroy and co-workers (1992) have 
reported association of the a5 subunit with a4 and (32 subunits which were considered to comprise 
the high affinity agonist binding sites (Whiting et al 1987a: Flores et al 1992). This sort of 
complication, as well as the unresolved issue of the subunit composition of neuronal aBgtBPs, could 
be investigated using an AnTx analogue purification procedure.
At present these synthetic AnTx analogues probably have greater potential as tritiated radioligands. 
Their high affinity may enable the detection of a3-containing nAChR that are not detectable using 
the currently available tritiated nicotinic agonists. Also, being secondary amines, passage across the 
blood brain barrier is possible and would facilitate examination of the pharmacokinetics of CNS 
delivery following systemic injection. Centrally acting nicotinic agents could have an important 
therapeutic future in the symptomatic treatment of Alzheimer's disease (Kellar & Wonnacott 1990). 
Distribution patterns of a tritiated AnTx analogue could also be compared to those of other tritiated 
nicotinic ligands.
A hybrid of anatoxin-a and nornicotine, known as pyridohomotropane (PHT), is comparable in 
potency to anatoxin-a in its ability to compete with [3H]-(-)-nicotine at rat brain nicotinic receptor sites 
(Kane & Abood 1988). Methylation of the pyrrolidine ring nitrogen of PHT to generate a structure 
equivalent to nicotine reduced potency considerably. This structure is potentially a more precise tool 
with which to extend the pharmacophore model and map of the receptor binding cavity, since the 
position and orientation of its hydrogen bond acceptor and pyrrolidine nitrogen are more strictly 
defined.
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3.1.1 Oocytes as tools to probe receptor function
Since the early 1970s a powerful tool has been exploited and developed which has made 
easier the assessment of the products of molecular biology. The technique essentially involves the 
injection of exogenous nucleic acid into the oocyte of the African clawed toad, Xenopus laevis, 
whose biosynthetic machinery provides the surrogate translation system for the production of the 
related protein.
The oocyte's suitability for this role stemmed from its extensive use in elucidating gene expression 
mechanisms and the mechanism by which cell division is regulated. Xenopus laevis is unique 
among other laboratory anurans in that a new reproductive cycle can be initiated through the 
administration of certain hormones and, moreover, oogenesis in this Xenopinae subfamily is a 
continuous, asynchronous process with ovaries containing oocytes at all stages of development 
throughout the adult life.
The first demonstration of this system's ability to manufacture exogenous protein involved the 
synthesis of rabbit haemoglobin after microinjection of reticulocyte 9s mRNA (Gurdon et al 1971). 
Although the cell-free system of reticulate lysate had been successfully used to this point, it was 
estimated that the efficiency of the oocyte system was about 30 times that of the lysate over the 
same incubation period. Furthermore, the culture of oocytes over long periods of time increased this 
efficiency to over 1000-fold. The advantages of the oocyte were quickly realised, though for more 
routine assays the cell-free extracts remain the simplest and most economical translation systems 
available. Advantages of the oocyte lie in their ability to carry out post-translational modifications of 
the foreign protein, such as precursor processing, glycosylation and phosphorylation. These cells 
are also able to direct proteins to the correct cell membrane and export secretory proteins. 
Additionally, synthesised macromolecules acquire their native activity even if this requires co­
assembly of many subunits, as has now very convincingly been demonstrated for the proteins which 
represent neuronal receptor subunits.
It is only relatively recently that there has been increased interest in the routine use of oocytes in 
assessing the viability of cloned proteins. The reasons for this result largely from the huge advances 
achieved in the micromanipulation and analysis of genetic material, coupled with the urgent need for 
a robust gene expression system in which to assess these products. Particularly attractive as a tool 
for the investigation of structure-function relationships of membrane proteins, the oocyte was the 
obvious choice for the cloned voltage and ligand-gated ion channels, and neurotransmitter receptors 
that began to appear in the early 1980s. Xenopus oocytes were used in the expression of AChRs for 
the first time by Sumikawa and co-workers (1981) who injected heterologous mRNA isolated from 
Torpedo electric organ. The subsequent synthesis and assembly of the multisubunit nAChR was 
detected immunologically and by [125l]aBgt binding, which identified four polypeptides with molecular 
weights very similar to those found in the native Torpedo receptor (Lindstrom et al 1979). Notably, 
the cell-free system was incapable of faithfully synthesising intact receptor molecules. Later studies
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implementing the same technique confirmed this receptor to be membrane-bound, and when 
challenged with ACh, the voltage-clamped oocytes were observed to gate ions with a permeability 
which resembled that of nicotinic cholinergic receptors in other cells (Barnard et al 1982). These 
currents were also blocked by d-tubocurarine and aBgt.
Fully grown, mature oocytes at stage VI of their anatomical development, consist of two halves 
referred to as animal and vegetal hemispheres. The whole cell is contained within the plasma 
membrane which, in the follicular form, is surrounded by four layers (Figure 3.1): the fibrous vitelline 
membrane; a monolayer of follicle cells (which form many membranal contacts with the oocyte); a 
connective tissue layer (theca) containing capillaries, nerve fibres and fibroblasts; and a layer of 
ovarian epithelial cells, a continuation of the ovary wall (Dascal 1987). The follicle cell layer contains 
endogenous receptors for catecholamines, gonadotrophins and purinergic agonists, as well as GTP- 
binding proteins (Kusano et al 1982: Dascal et al 1985: Snutch 1988). Follicular oocytes (those 
dissected from the ovarian envelope) also possess an endogenous response to ACh, of a 
muscarinic nature (Kusano et al 1977), which can be blocked by atropine (see section 3.3.1) or lost 
through collagenase treatment. Denuded oocytes, (those stripped of everything but vitelline and 
plasma membranes using collagenases and other proteolytic enzymes), retain the ability to generate 
endogenous voltage gated Na+, K+ and Ca++ currents (Dascal 1987) but these are small relative to 








Figure 3.1: Anatomy of the follicular 
oocyte. Schematic diagram of the Xenopus 
oocyte and surrounding tissues as dissected 
from the ovarian envelope of the toad. In this 
follicular form the oocyte is enveloped by 
several cellular and non-cellular layers which 
must be removed as they harbour 
endogenous receptors which may complicate 
interpretation of electrophysiological 
recordings following the injection of 
exogenous nucleic acid.
Because oocytes are actually germ line cells in the meiotic prophase of cell division, they contain 
considerable quantities of various enzymes and storage yolk protein and are very active in RNA and 
protein synthesis, though not in DNA synthesis (Gurdon & Wickens 1983). However, although 
mature Xenopus oocytes contain much maternal cytoplasmic mRNA (~70ng), the presence of 
inhibitory binding proteins largely prevents their translation. It is this inablility to process native 
mRNA, coupled with the high translational capacity of this self-sustaining cell, which have led to its 
exploitation as an effective message-dependent translation system for exogenous mRNA and cDNA. 
Additional attributes such as their robust nature and large size (<1.3mm diameter) also make them 
amenable to a series of electrophysiological manipulations.
3.1.2 Dual electrode voltage clamp electrophysiology
Most electrophysiological methods are applicable to oocytes. In the simplest arrangement, the 
membrane can be penetrated with a single microelectrode and the membrane potential measured. 
Impalement with two microelectrodes (Figure 3.2) permits current- or voltage-clamp recording
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methods, the latter being the most popular. Patch-clamp methods are applied to oocytes in the study 
of single channels. The whole cell voltage-clamp technique was employed in this study, a procedure 
which measures the ion flux across the whole of the lipid membrane as electric current, whilst the 
potential difference (voltage) across the membrane is held under experimental control (Figure 3.2). 
In the case of LGIC currents, once leakage has been accounted for, the ion flux is only observed on 
application of agonist molecules to the oocyte which is maintained in physiological buffer. The 
principles of this technique were first described by Cole in 1949, and extended through studies on 
squid giant axon (Hodgkin & Huxley 1952).
Figure 3.2: Dual electrode voltage-clamp electrophysiology. Recording of the electrical current across the oocyte 
membrane induced by the bath application of agonists to cells expressing exogenous nACh receptors. A voltage 
recording electrode (V) inserted in the membrane is used to 'clamp' the membrane potential to the desired value 
while a second electrode (I) injects the required current into the cell in order to maintain this potential difference. 
Current injected as a result of the opening of ion channels in the presence of agonist molecules can be recorded - a 
downward deflection of the activity spike represents the movement of ions into the cell.
3.1.3 The resting oocyte membrane
Microelectrode impalement reveals that the membrane of a healthy oocyte is electrically 
negative inside relative to the outside by some tens of millivolts. This resting potential (RP) can vary 
widely among oocytes of different frogs and among frogs from different batches and sources. 
However, this does not mean that a healthy oocyte may have a RP anywhere between -20 to -90mV 
(see table 2 of Colman 1986). Several factors may contribute to this discrepancy such as maturity of 
the cell, the method of its dissection, and others. The membrane of the oocyte possesses an active 
Na-K pump which is largely responsible for the unequal distributions of ions either side of the semi- 
permeable membrane. Thus, treatments which affect this pump affect the RP - immediately following 
manual or chemical defolliculation cells tend to hyperpolarise, but 'repolarise' to less negative values 
2h to 48h later (typically -45 to -65mV). These phenomena may be explained by the 'uncovering' of 
pump sites or their activation due to the increase in [Na]in that accompanies defolliculation. Thus, the 
observed RP value (E) is maintained largely by the Na-K pump which creates a chemical imbalance 




Many different ionic populations contribute to the potential difference (principally Na+, Ca++, K+ and 
Cl ) and include those associated with proteins and other organic anions which are trapped inside 
the cell due to the selective permeability of the membrane.
The appearance of active nicotinic receptors in the membrane permits the inward flow of ions (Na+, 
K+ and Ca++) perturbing the equilibrium. The electric charge that results from the opening of 
thousands of such channels, driven by the P.D. across the membrane, is detected using 
electrophysiological methods - Ohm's law states that the current is proportional to the P.D.:
I = V /R  (2)
When inactive the closed receptors behave as electrical resistors (R). Therefore, the agonist- 
induced current is proportional to the receptor conductance, G(=1/R), so when the P.D. is held 
constant (clamped) the current observed results directly from the properties of the predominant 
receptor population, i.e. ion selectivity, activation and desensitisation properties, gating mechanisms 
etc. In the whole cell clamp setup, especially with cells as large as oocytes, the membrane 
capacitance (C, due to ionic charge stored therein) is so large that electronic effects due to it are 
negligible.
3.1.4 Exploitation of oocytes in the project
In the present study oocytes have been employed as a functional index for the a l  homomeric 
receptor derived from nAChR of avian brain. Given that there is now a well established background 
for the use of oocytes in the study of functional neuronal nAChR formed upon injection of certain 
combinations of cloned subunits from native receptors (rev. Sargent 1993) this system seemed an 
obvious choice for our first steps into electrophysiological recording. The paucity of aBgt-sensitive 
functional cholinergic responses in other, biochemical preparations, has required that some 
confirmation and pharmacological characterisation of a functional homomeric receptor sensitive to a  
Bgt be undertaken. Additionally, the acquisition of a7 has permitted the study of structure-function 
relationships with agonist molecules in attempts to identify features of the functional pharmacophore 
of the neuronal nicotinic receptor.
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3.2 Experimental procedures
3.2.1 Xenopus oocyte preparation 
Animals
Mature Xenopus laevis females were kept in groups of up to six animals for at least 3 months 
in a 12h light:dark cycle at 18°C with access to diced heart or liver on alternate days. On the day of 
use, animals were killed by decapitation following submersion in iced water for 1h. All ovarian sacs 
were removed following abdominal incisions. Ovaries were washed in Isolation medium (NaCI 
108mM, KOI 2mM, EDTA 0.1 mM, HEPES 1mM, pH7.9) where individual lobes were cut away and 
opened out to expose the oocytes. All procedures were carried out at room temperature under 
steriie conditions.
Oocyte isolation
Oocytes were washed thoroughly in Isolation medium to remove contaminating proteases 
from ruptured eggs. Dissection was performed under a binocular microscope in Isolation medium. 
Individual oocytes were removed from their ovarian envelope using fine watchmakers forceps 
(Dumont no.5), and transferred to Modified Barth's Solution (MBS; NaCI 88mM, KCI 1mM, HEPES 
10mM, MgS04 0.82mM, Ca(N03)2.4H20  0.33mM, CaCI2 0.91 mM, NaHC03 2.4mM, pH7.5). Oocytes 
used were at stage V or VI of development, characterised by a distinctive boundary between animal 
and vegetal poles, and were the largest at ~1mm in diameter. Oocytes dissected in this way were 
generally washed at least twice in MBS and left overnight at 20°C to identify damaged eggs which 
were apparent as ruptured cells by the following morning. Roughly three times the number of cells to 
be injected were routinely isolated in order to compensate for such loses and to provide sufficient 
controls.
3.2.2 Nucleic acid injection
A subclone of a7  cDNA, from which 700 base pairs of 3' untranslated sequence had been 
deleted, was spliced into the Xenopus oocyte expression plasmid bluescript (Bertrand et al 1990) to 
yield the plasmid flip a7A. The plasmid was generously donated by Marc Ballivet. The subcloning 
procedure of this plasmid is explained in section 3.2.5: each generation of clones was equally 
effective in the Xenopus oocyte expression system when compared to the original flip oc7A plasmid. 
The Simian Virus 40 (SV40) early promoter controls expression of the a7 gene. Samples of the a7 
cDNA were stored at -20°C and thawed on the day of use before dilution in sterile water to a 
concentration of 250 ng/pi
Injection needles were pulled on a 763 programmable micropipette puller (Campden Instruments, 
Loughborough) using 10jllI borosilicate capillaries. Tip diameters were typically < 1 0 jm  Needles 
were sealed with mineral oil and cDNA (total volume ~2jil) was drawn slowly into the needle using a 
Drummond syringe (10|il) secured to a micromanipulator. Approximately 10nl (c. 108 copies of DNA) 
were injected into the oocyte nucleus under binocular magnification.
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Incubation
Injected oocytes were transferred to 24 well titre plates, 2-3 oocytes per well containing 2.5ml 
Incubation medium (containing penicillin-streptomycin 50mgs/ml, gentomycin sulphate 30mgs/ml, 
and pyruvic acid 2.5mM, in MBS), and incubated at 20°C under sterile conditions - expression levels 
are very temperature sensitive. Functional receptors (as judged by ACh-induced responses) 
appeared in the oocyte membrane about two days after injection of cDNA. Incubation medium was 
replaced every 2-3 days.
3.2.3 Whole cell electrophysiology of injected oocytes
3.2.3.1 Perfusion chamber
Two types of chamber were used for the application of cholinergic drugs during 
electrophysiological recording of a7 responses, the essential difference being in the volume of 
perfusion medium in the bath surrounding the oocyte. The initial perfusion chamber (demonstrated in 
figure 3.3a) comprised a solid perspex block with a conical chamber which was fed with medium 
from above and evacuated through a capillary at the bottom. The egg rested on a perforated plastic 
mesh in the bath (volume ~300jil), through which medium freely flowed (enlargement of figure 3.3a) 
at a rate of approximately 5ml/min - this flow rate maintained mechanical stability of the oocytes and 
recording electrodes. Whole cell recordings of a7  responses to nicotine for this chamber are 
represented in figure 3.7. The importance of a smaller volume bath was realised in a second 
chamber suggested and constructed by Daniel Bertrand. In this setup, bath volume was reduced to 
50|jJ by using a plastic trough in which the oocyte was partially secured in a small recess (Figure 
3.3b). Rapid solution exchange was achieved through the close proximity of perfusion inlet and 
outlet to the oocyte. A desensitisation plateau, not discernible with the previous chamber, was 
apparent in the oc7 response (Figure 3.7). This improved setup was employed for subsequent 
recordings.
In both of the above cases superfusion was based on gravity flow. Perfusion medium, (degassed 
MBS containing 0.5|nM atropine to block the endogenous muscarinic AChR of the oocyte), was 
placed above the recording chamber and, as with drug reservoirs, was connected to the chamber 
via a continuous siliconised rubber tube (1.8mm diameter). Switching between reservoirs of the 
various drug and perfusion solutions was achieved using a manually operated pinch-valve system. 
The dead space between reservoir and chamber was kept to a minimum and no mixing between 
solutions was possible. The outlet from the chamber was a polyethylene tube leading to a trap.
3.2.3.2 Dual electrode voltage-clamp electrophysiology
Current, Voltage and Reference electrodes were pulled on a 763 programmable micropipette 
puller (Campden Instruments) using GC150TF-10 borosilicate glass capillaries (Clark 
Electromedical Instruments) and filled with 3M KCI. Electrical connection to the recording equipment 
was established through silver chloride wire insulated with Teflon. Typical tip resistances were 1-5M 
£1, i.e. small enough to inject current effectively and minimise damage to the oocyte.
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Figure 3.3: Oocyte perfusion chambers used in the application of cholinergic drugs during 
electrophysiological recording of a7 responses. Initially, experiments were performed using a 
relatively large volume chamber (300pJ) in which the oocyte was supported on a perforated plastic 
mesh (a). Several such perforations allowed free flow of perfusion medium around the cell at a rate 
of ~5mls/min. In this configuration the response profile of the a 7 homomeric receptor to cholinergic 
ligands was as demonstrated in figure 3.7a. Later experiments employed a chamber of 1/6,h the 
volume of (a) consisting of a plastic trough mounted in a petri dish (b). In this arrangement the 
oocyte rested in a small recess in the plastic with medium perfusing horizontally rather than vertically 
as in (a).
The smaller volume chamber 
(suggested by Daniel Bertrand) 
was required to disclose the 
desensitisation plateau of the 
a 7 response (Figure 3.7b). In 
both chambers, buffer (MBS 
containing atropine) and all 
drugs were applied through a 
gravity fed perfusion system 
and removal was aided by a 
peristaltic pump (a) and tap 
vacuum (b). Perfusion medium 
was connected to earth through 
an agar bridge. (Arrows indicate 
the direction of flow of the bath 








Ligand induced currents were measured using conventional two electrode voltage-clamp. The 
resting potential of the cell was measured using a recording (Voltage) electrode connected to the 
input of a VF120 amplifier (Biologic, Herts.). A second (Reference) electrode was connected to a 
subtractor amplifier where the value of the Reference was subtracted from that of the Voltage. This 
value was fed into a CA100 clamping amplifier which was used to set the desired clamping potential. 
The output of this amplifier became the input to a VF180 microelectrode amplifier which was used to 
inject the required current into the cell to attain the desired clamping potential through a third 
(Current) electrode. The output of the CA100 clamping amplifier was passed through a filter, a 
second amplifier and an attenuator, before being displayed using a pen recorder and oscilloscope. 
The same output was also captured and stored on a DTR1200 analogue-to-digital DAT recorder 
(Biologic).
For data acquisition, recordings were selected from the DAT tape and fed to an IBM AT compatible 
computer. Here they were digitised using a data translation (DT2801A) A/D converter activated 
through the program AQ (Amar et al 1991), before being directly stored on the hard disc. The 
resulting 12-bit binary files were then analysed using the program PAT2L (Amar et al 1991) and 
manipulated using the graphics package SIGMAPLOT version 4.1.
3.2.3.2.1 Current-voltage (l/V) relationships
The l/V characteristics of a ligand induced current were determined by holding the membrane 
potential at a constant voltage and perfusing ligand to evoke a current response. The holding voltage 
was then stepped to new values and the drug applied at each step. A minimum wash period of 5min 
was allowed between each 3s drug pulse (see section 3.2.3.2.2). The l/V curve was obtained by 
plotting the amplitude of the ligand-evoked currents as a function of the holding voltage.
3.2.3.2.2 Drugs and their application
Stocks solutions (made up as described in section 2.2.9) were stored in aliquots at -20°C and 
thawed immediately prior to use when they were diluted as required in MBS containing 0.5p,M 
atropine. All solutions were retained on ice prior to use in the perfusion system. Control samples of 
aqueous ethanol and DMSO were used to confirm that these solvents had no direct effect.
Generally drug was perfused through the chamber in which the egg was being monitored for 3s. At 
lower concentrations of agonist, perfusion times were sometimes extended to 5s in order that slower 
onset responses might be observed. The a7 receptor is fully activatable approximately 3min after a 
3s desensitising concentration of drug so to ensure complete recovery the test oocyte was washed 
with MBS for a minimum period of 5min under such conditions.
Inhibition studies with acobratoxin (aCbt - a close analogue of aBgt) and Methyllycaconitine (MLA) 
required that the antagonist be incubated with the egg in the chamber for a period of up to 45min for 
aBgt or 15min for MLA, before perfusion of the activating ligand. In order that antagonist would not 
be washed off during agonist perfusion, the same concentration of the antagonist was included in
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the agonist solution. Again, stimulations were of 3s duration, immediately after which the time for full 
or partial recovery of the a l  response was recorded following application of the same agonist.
3.2.4 Data analysis
a l  dose response curves were constructed for the various ligands by normalising currents to 
the largest induced current for a particular ligand on a specific oocyte. The peak heights of all the 
activation spikes for a particular ligand were measured directly from the program PAT2L (Amar et al
1991) and converted into nA currents, the values of which were used to generate the response 
curves at the various ligand concentrations. Curves were iteratively fitted to, and values for the EC50 
(half maximal activation of the receptor) and Hill coefficient (rjH) were calculated, according to the 
non-linear Hill equation:
Y=1/(1 +(EC50/X)t,h) (3)
where X= agonist concentration and Y=% of maximum response. Current responses to 25|liM (-)- 
nicotine were used to standardise oocyte responses.
3.2.5 Molecular biology
3.2.5.1 Transformation of bacterial cells
Escherichia coli bacterial cells (stored in glycerol at -20°C) were cultured overnight at 37°C in 
Luria Broth (LB: NaCI 10g, yeast extract 5g and tryptone 10g in 11 sterile water, pH7.5). Enriched LB 
was inoculated with this culture and cells grown with vigorous shaking for 3h before being chilled on 
ice (10min). Cells were harvested by centrifugation (4000g, 5min, 4°C) - surplus bacterial cells were 
stored in a 15% glycerol solution at -20°C - and permeabilised by resuspension in an ice-cold, 
sterile solution (pH8) of 50mM CaCI2 (0.5vol of original culture, 30min, 4°C). This procedure was 
repeated and the suspension retained on ice for at least 1h.
The bluescript plasmid incorporating the a7 cDNA (in sterile water) was mixed (~300ng/ml) with this 
solution of permeabilised cells (4°C, 30min). The reaction mixture was then placed in a 42°C water 
bath for 3min after which time 1 ml of LB was added. Cells were then maintained at 37°C for 45min 
with occasional gentle mixing.
Successful transformants were selected by their resistance to ampicilin, the gene for which is 
included in the bluescript plasmid. Cells treated as above were spread on selective media (LB 
containing 1.5%(w/v) agarose and 100|ig/ml ampicilin) until absorbed into the agar, inverted and 
maintained at 37°C (12-16h). Plates were stored at 4°C. Competent cells, distinguishable by their 
red colour, were carefully removed from plates into ampicilin-containing LB (one colony per 3ml LB) 
and these colonies incubated overnight in a 37°C shaker.
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3.2.5.2 Transformant nucleic acid viability 
Cell lysis using alkali
Successful a7  gene transformants were lysed and subjected to nucleic acid digestion with 
restriction enzymes. Competent cells were harvested by centrifugation (4000g, 10min, 4°C) of 1 ml 
samples from a selection of colonies. Pelleted cells were washed in 1 5 0 jllI ice-cold GTE (Glucose 
50mM, TRIS 25mM (pH8), EDTA 10mM), and kept on ice for ~10min before lysis with 300pJ of a 
mixture of SDS (1 %(w/v)) and NaOH (0.2M). The mixed solution was kept on ice for 10min. Addition 
of 200fil of ice-cold 5M KAc (pH4.5 in 3M acetic acid) and thorough inversion precipitated the larger 
cell remnants (4°C, 10min).
Isolation of plasmid nucleic acid
Cellular DNA and bacterial debris was spun down at high speed (20,000rpm, 4°C, 20min) 
leaving the lighter plasmid DNA in the supernatant. Extraction of the latter was achieved using 
isopropanol (0.6 vols) which was gently mixed with the supernatant (15min, 4°C). Plasmid DNA was 
recovered from the solvent layer by precipitation with absolute ethanol (2 vols, 4°C), spun down 
(12000g, 30min, 20°C) and the pellet washed with 70% ethanol before eventually being dried 
(vacuum dessicator) and resuspended in ~50jil TE (Tris 10mM, EDTA 1mM, pH8) containing 
RNAse (1 mg/ml).
Restriction enzyme digestion
The a7 sequence is flanked by a BamH1 and Hindlll site in the bluescript plasmid. Digestion 
with these enzymes should yield two fragments of lengths 1830 and -5000 bp corresponding to a7 
and bluescript respectively. These enzymes require specific buffers in order to be maximally 
effective so digestion was two-step, requiring ethanol precipitation in between. For each of the 
colonies under scrutiny, 5 jil of the corresponding DNA (in TE+RNAse) was mixed with either 
BamH1 or Hindlll (1jjJ (1 unit) stored at -20°C), the appropriate buffer (2pJ, commercial preparation) 
and made up to 20pJ with sterile water. The reaction was incubated at 37°C for 1h.
The reaction was stopped by the addition of 0.5M EDTA (pH7.5) to a final concentration of 10mM. 
Fragmented DNA was precipitated by the addition of 3M NaAc (1.1 vol) and cold absolute ethanol 
(2.5vols), followed by cooling to -20°C for 30min. Precipitate was centrifuged (14,000rpm, 20min, 4 
°C), and the pellet washed in 70% ethanol. Following recentrifugation the DNA was dried and cut 
with the second enzyme using the appropriate buffer, as before.
Digestion analysis on agarose gel
The double-digested DNA pellet was resuspended in 10pJ Gel Loading Buffer (GLB; glycerol 
30%(v/v), xylene cyanol 0.25%(v/v), bromophenol blue 0.25%(v/v)) and run on a 1% agarose gel 
along with ^Hindlll markers, at a P.D. of ~5V/cm for 30min. Gel running buffer, TBE (TRIS 89mM, 
borate 89mM, EDTA 2mM), included ethidium bromide (0.5jig/ml).
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3.2.5.3 Increasing nucleic acid yield (Maxi-prep)
Essentially this involved scaling up the quantities in the method previously described (section 
3.2.5.2). Transformants were chosen from the colonies identified in the 'mini-prep.1 whose digestion 
products of the bluescript plasmid were of the correct size. Samples (500|il) were grown-up 
overnight at 37°C in sterile LB (800ml), containing ampicillin (100|ig/ml). Cells were harvested by 
centrifugation (4000g, 15min, 4°C) and the pellet resuspended in GTE (10ml/500ml original culture). 
Cells were lysed by the addition of lysis buffer (2 vols: NaOH 0.2M, SDS 1%(w/v)) with frequent, 
gentle inversion on ice for ~15min, prior to the addition of KAc (0.5vol: 5M). This solution was 
thoroughly mixed and retained on ice for 10min. The pellet produced on centrifugation (Beckman 
SW27 20,000rpm, 10min, 4°C) was discarded and the plasmid DNA in the supernatant precipitated 
in ice-cold isopropanol (0.6vols, 15min, 4°C). Recentrifugation (10,000rpm, 30min, 4°C) following 
ethanol extraction produced the DNA pellet which was vacuum dried before being resuspended in 
sterile water (8ml/500ml original culture). RNA material was digested by addition of RNAse (5p,g/ml) 
and incubation at 37°C for 20min.
Caesium chloride purification of plasmid DNA
Centrifugation to equilibrium was performed in gradient of CsCI (1g/ml of DNA solution) 
including ethidium bromide (600|ng/ml). The thoroughly mixed CsCI/DNA solution was sealed into 
5ml ultracentrifuge tubes (Beckman 50 rotor). Centrifugation was carried out in a fixed angle rotor at 
55,000rpm at 20°C for 18h.
The plasmid DNA containing the a7 gene appeared as the lower band and was removed under UV 
light using a hypodermic syringe. DNA was pooled from all tubes. Ethidium bromide was extracted in 
isoamyl alcohol (1 vol) following thorough mixing and centrifugation (1500g, 3min, 20°C). The 
aqueous phase containing plasmid DNA was removed and the extraction repeated until the pink 
colour disappeared. CsCI salt was removed following precipitation of DNA (-20°C in ethanol (4vols)) 
leaving CsCI in solution. Centrifugation (12,000rpm, 30min, 4°C) pelleted the DNA, which was 
vacuum dried, resuspended in sterile water and transferred to an eppendorf for reprecipitation in 
NaAc (0.1 vol, 3M) and ice-cold absolute ethanol (2 vol). Recentrifugation (12,000rpm, 10min, 4°C) 
pelleted the DNA which was dried, washed and precipitated as before to remove any remaining 
CsCI. The final pellet was washed with 70% ethanol, vacuum dried and resuspended in ~200|il 
sterile water.
Digestion products
As previously, in order to determine whether the plasmid DNA contained the a7 gene, 
samples (serially diluted) were subjected to restriction enzyme digestion with BamH1 and Hindlll 
consecutively - see section 3.2.5.2.
3.2.6 Spectrophotometric assessment of nucleic acid purity
DNA purity and concentration was determined spectrophotometrically. The optical density at 
260nm and 280nm was measured for dilutions of the plasmid DNA solution following standardisation
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with sterile water - a complete sweep was made between >240-320. The OD260/OD280 ratio was 
used to determine the purity of the DNA product. Pure preparations of DNA have a ratio of 1.8, 
contaminants will significantly reduce this value. An OD of 1 at >260 corresponds to approximately 
50jiig/ml for double-stranded DNA.
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3.3 Results
3.3.1 Endogenous cholinergic receptors in the oocyte membrane
Healthy oocytes prepared as described in section 3.2.1 recorded resting membrane potentials 
of between -30mV to -80mV on microelectrode impalement - potentials did not seem to be 
substantially affected by nuclear injection of exogenous nucleic acid. Responses resulting from the 
activation of endogenous muscarinic receptors by ACh on denuded oocytes (Figure 3.4a) were 
generally small (<100nA), and characterised by slow activation to a prolonged maximum response. 
The response persisted for the period of agonist application and deminished to basal levels upon 
removal of the stimulus. This reflects the observations of Kusano and co-workers (1977) who first 
reported cholinergic responses in the oocyte. Studies since then have revealed more complex 
response patterns associated with this G-protein coupled receptor, involving multiple depolarisation 
and/or hyperpolarisation phases (rev. Dascal 1987). Inclusion of 0.5jiM atropine in the perfusion 
buffer abolished all responses to cholinergic ligands (Figure 3.4b), confirming the muscarinic nature 
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Figure 3.4: Endogenous muscarinic response of the oocyte. Representative trace demonstrating the inward current 
evoked on application of 10pM ACh (60s) to a denuded oocyte (a). The uninjected cell (stage V) was tested the day 
after dissection using dual electrode voltage clamp (see section 3.2.3.2). Inclusion of 0.5piM atropine in the perfusion 
buffer abolished all endogenous responses to cholinergic drugs on the same cell (b). Not all cells were assessed for 
muscarinic activity, though currents were detectable in the majority (8/13 cases) taken from various oocyte batches (3).
3.3.2 Characteristics of the reconstituted homomeric receptor
Digestion of the bluescript vector with BamH1 and Hindlll was used to identify the presence of 
a l  cDNA transformants. Fragments corresponding to a l  (-1800) and bluescript (-5000) were 
detected on agarose gels. Figure 3.5a shows the digestion products from various bacterial colonies - 
A/Hindlll markers verified the presence of the a l  fragment in the majority of cases. In the case 
shown here the colony in lane six was used to perform a maxiprep, the digestion products of which 
are shown as serial dilutions in figure 3.5b. DNA yield was generally high (>10mg/ml) and showed 
little contamination (A260/A280>1.8) following spectrophotometric assessment (Figure 3.5c).
Figure 3.5: Transformation of bacterial 
cells with vector containing «7 cDNA. (a)
DNA fragments produced following digestion 
of the isolated vector from transformed cells 
with BamH1 and Hindlll restriction enzymes 
- the 9 central lanes (flanked by X markers) 
each represent a separate bacterial colony 
prepared as described in section 3.2.5. 
Serial dilutions of the maxiprep products 
revealed the strong presence of the a 7 gene 
(b) - in this case the yield was >10mg/ml and 
the 260nm:280nm ratio was 1.89 (c). 
Aliquots of the a l  cDNA were stored in 








Following nuclear injection of a 7 cDNA into Xenopus oocytes, responses to (-)nicotine could be 
recorded from >50% of eggs after 2 days. Large currents, typically 0.2-2.0fiA, were recorded on 
application of saturating doses (high micromolar concentrations) of (-)nicotine to cells held at -70mV 
(Figure 3.6a). This holding potential was sufficiently far removed from the reversal potential to 
observe consistent, robust currents evoked by agonist stimulation, and ensured the physiological 
stability of the oocyte during prolonged periods of examination. Consequently -70mV became the 
standard holding potential of subsequent recordings. Cells injected with sterile water alone were 
insensitive to all ligands.
Receptor activation at low doses of (-)nicotine was slow with little or no desensitisation for agonist 
applications up to 10s duration (Figure 3.6b). At higher concentrations of (-)nicotine, activation rates 
were faster and displayed rapid desensitisation within the 3s application time, in keeping with 
published results for the same reconstituted homomer (Couturier et al 1990a). The importance of 
rapid application and removal of agonist is demonstrated in figure 3.7. An initial perfusion chamber 
with a volume of ~ 3 0 0 jllI (see section 3.2.3.1 and figure 3.3a) detected the two exponential 
components to the desensitisation phase of the a7 homomeric receptor (Figure 3.7a). Replacement 
of this chamber with one of smaller volume (~ 5 0 jllI), in addition identified a plateau representing 
incomplete desensitisation of the receptor population (Figure 3.7b), which generally occurred at 
levels below 10% of the peak response, and was further reduced at saturating agonist 
concentrations (Figure 3.7c). Basal current levels were recovered on removal of the agonist from the 
bath. The desensitisation plateau was observed for all agonists studied. Initial data was obtained 
with the larger chamber but subsequent experiments were performed with the smaller when its 
advantages had been realised.
3.3.3 Pharmacological properties of the reconstituted a 7  protein complex
3.3.3.1 Antagonism of nicotine-induced responses
Currents evoked by (-)nicotine (40|iM) were completely abolished following incubation 
(30min) of a7  injected oocytes with 10nM acobratoxin (aCbt: Figure 3.8a) a toxin closely related to 
abungarotoxin. Oocytes from 3 further animals were similarly sensitive to this toxin. The pseudo- 
irreversible nature of the inhibition was demonstrated by the inability of (-)nicotine, and other 
cholinergic agonists (not shown), to stimulate the receptor up to 45min after washing. 
Methyllycaconitine (MLA: 1nM) was also able to completely block nicotine-evoked currents (Figure 
3.8b), following a 15min oocyte incubation period. Inhibition was reversible with full recovery of the 
response after ~30min washout. An inhibition-response curve for MLA was constructed (Figure 3.8c) 
by immediately measuring the extent to which the nicotine (25jxM, 3s) induced response was 
depleted following incubation (15min) with increasing concentrations of MLA. Oocytes were washed 
(>30min) following inhibition, prior to the application of consecutive standardising (-)nicotine pulses 
(40p,M, 3s), another wash (10min), and subsequent incubation (15min) with a higher concentration 
MLA. Agonist application (3s, containing the same concentration of MLA as in the bath) was 
immediately after the incubation period. Peak heights were used to plot an inhibition curve of the 25|i 
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Figure 3.6: Cholinergic activation of the a7 receptor expressed in Xenopus oocytes.
Superimposed traces of inward currents elicited by 3s pulses of increasing concentrations of (-) 
nicotine are indicated (a). Oocytes, injected with ~2.5ng of a7 cDNA four days previously, were 
rested for 10min between each agonist pulse to allow full recovery from desensitisation, VH=-70mV. 
Little or no desensitisation was observed in response to low concentrations (3p.M) of (-)nicotine 





Figure 3.7: Desensitisation of the a7 response. Inward currents were recorded from oocytes perfused with 25jiM 
(-)nicotine (3s), in a chamber (Figure 3.3a) of ~300|il volume (a). Agonist evoked currents constituted rapid activation 
and desensitisation phases, occurring within the 3s application time. A subsequent perfusion chamber (Figure 3.3b), 
50pJ volume, revealed a desensitisation plateau (b,*) which persisted until agonist (25piM (-)nicotine) was removed. The 
position of the plateau from basal level, relative to the current peak height, was reduced on application of saturating 
agonist doses (c).
3.3.3.2 Classical agonists
Several agonists were investigated for their ability to activate nicotinic currents in the oocyte 
resulting from the presence of the a l  homomer. In each case a range of agonist concentrations 
were tested on a single oocyte and dose-response curves of peak currents, normalised to (-)nicotine 
(25piM), were averaged from several such experiments on different batches of oocyte (Figure 3.9: 
Table 2.1). (-)Nicotine elicited half-maximal stimulation (EC50) of the expressed a l  receptor at a 
concentration of 24fxM. Nicotine stereoselectivity was not as pronounced in this functional system as 
in competition binding, in that the (+) enantiomer was only two times less potent (EC50=45jiM) than 
the (-) form. Experiments using (+) and (-) enantiomers on the same oocytes verified this.
(-)Cytisine was more than 4-fold more potent than (-)nicotine (EC50=5.6|iM), whereas ACh 
(EC50=320|liM) was the least potent of these agonists, giving a potency rank order of (-)cytisine>(- 
)nicotine>(+)nicotine>ACh at the a l  receptor. Normalisation of responses to 25jiM (-)nicotine 
revealed that maximal responses resulting from application of cytisine were smaller than those of
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Figure 3.8: a7 channels are 
functionally blocked by acobratoxin 
(aCbt) and methyllycaconitine 
(MLA). Responses of oc7 injected 
oocytes to 40|nM (-)nicotine were 
completely abolished after incubation 
(30min) with 10nM aCbt (a). No 
recovery was seen up to 45min after 
washing. Incubation (15min) of an 
independent oocyte with 1 nM MLA also 
blocked currents evoked by 40|u.M (-) 
nicotine (b).
Roughly 60% recovery was observed after 15min washing, with full recovery after 30min. Inhibition of 
responses to 25|iM (-)nicotine by various concentrations of MLA were assessed for several (n=6) oocytes from 
different batches. Data points (±SEM), representing the inhibition curve (c), were curve-fitted using the non­
linear Hill equation (see section 3.2.4), producing an IC5Q value of 1.8 ±  2.2 x 10'12M (nH=0.51). VH=-70mV for 
all experiments.
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Figure 3.9: Dose response profiles for classical agonists activating the a7 receptor. Superimposed inward 
currents recorded from individual oocytes exposed to 3s pulses of increasing concentrations of agonist (a): (-) 
cytisine (▼), (+)nicotine(0) and ACh(V) - see figure 3.6a for (-)nicotine(#) - >5min washing intervals between 
consecutive pulses were sufficient for full recovery from desensitisation, VH=-70mV. Dose response curves (b) 
were calculated by normalisation of responses to the maximum peak height for data from at least three oocytes. 
Curves were subsequently normalised against (-)nicotine (25piM) applied to the same oocyte. (A more 
quantitative determination of agonist efficacies was later determined - see section 3.3.4). Symbols represent 
mean data points with SEM indicated by vertical bars. Lines represent the theoretical dose response curves 
fitted to the data points using the non-linear Hill equation (see section 3.2.4). EC50 values derived from the 
analysis are recorded in table 2.1.
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(-)nicotine 2.4 ± 0 .7 x 1  O'5 4 1.4 ±0.1 1 24 100
(+)nicotine 4.5 ± 1.0 x 10'5 3 2.5 ± 0.7 0.53 0.9* 95.2 ±1.2
cytisine 5.6 ± 1.3 x 10"6 7 1.9 ±0.2 4.3 2.2 58 ± 6.2
acetylcholine 3.2 ± 1.5 x 10‘4 5 1.8 ±0.3 0.08 29 91.5 ±6.8
DMPP 6.4 ± 2 .7 x 1  O'5 7 2.0 ± 0.2 0.37 16.8 20.9 ± 3.9
AMP.Mel 1.7 ± 0.3 x 10'4 5 1.3 ±0.1 0.14 9.0 65.2 ±5.1
AMP.HCI >10'3 2 - - - -
(+)anatoxin (AnTx) 5.8 ± 0 .9 x 1  O'7 5 2.6 ±0 .3 41 1.1 111.2 ± 2.6
(±)HomoAnTx 7.2 ± 5.5 x 10‘7 3 0.83 ±0.1 33 2.1 102 ±3.4
(±)lsopropylAnTx 6.6 ± 0 .2 x 1  O'7 3 7.2 ± 0.3 36 5.5 95.4 ± 6.4
Table 2.1. Pharmacology of the reconstituted a 7  homomeric receptor in Xenopus  oocytes. EC50 values for 
various agonists activating the receptor were calculated using several oocytes (#) from independent animals more than 
2 days after nuclear injection of a7  cDNA. Data were curve-fitted to the non-linear Hill equation (see section 3.2.4). 
Relative efficacies were determined following successive applications of the various agonists to the same oocyte (see 
section 3.3.4). EC50/Kj ratios were calculated using Kj values from section 2.3.5, except *(Wonnacott 1986), at the [125l] 
aBgt binding site.
nicotine and ACh - this discrepancy in efficacy was further investigated (see section 3.3.4). Hill 
slopes for all agonists were greater than one (Table 2.1), consistent with the binding of more than 
one agonist molecule for activation of the homomeric protein. (+)Nicotine produced a notably 
steeper activation curve (nH=2.5±0.7).
3.3.3.3 Piperazine based compounds as agonists
The dose-response curve for DMPP (Figure 3.10), gave an EC50 of 64piM (Table 2.1), a 
potency intermediate to nicotine and ACh. Acetylated piperazines were less potent than DMPP, 
especially the monomethylated AMP.HCI which failed to elicit any response of the reconstituted 
protein up to 1mM concentration. The dimethylated analogue, AMP.Mel, produced an EC50 of 170jll 
M, giving a potency rank order for these compounds in line with the competition binding data, 
namely: DMPP>AMP.Mel»AMP.HCI. Limited availability and poor solubility of AMP.Mel precluded 
investigation above 1mM, therefore the curve fit may be underestimated. Significant differences were 
observed in the extent to which these ligands were able to activate a7 relative to nicotine, most 
noticeably DMPP, which was considerably less efficacious than nicotine - see also section 3.3.4. Hill 
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Figure 3.10: Activation of a7 nAChR by piperazine based compounds. Superimposed inward 
currents recorded from individual oocytes exposed to 3s pulses of increasing concentrations of 
agonist (a): DMPP(B) and AMP.MelfD) - >5min washing intervals between consecutive pulses 
were sufficient for full recovery from desensitisation, VH=-70mV. Dose response curves (b) were 
calculated by normalisation of responses to the maximum peak height for data from at least three 
oocytes. Curves were subsequently normalised against (-)nicotine (25|iM) applied to the same 
oocyte. Symbols represent mean data points with SEM indicated by vertical bars. Lines represent 
the theoretical dose response curves fitted to the data points using the non-linear Hill equation (see 
section 3.2.4). EC50 values derived from the analysis are shown in table 2 .1.
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3.3.3.4 Anatoxin-a related compounds
(+)Anatoxin-a (AnTx) was clearly the most potent of the agonists tested at the a 7 receptor 
with an EC50 value of 0.58jliM (Table 2.1), some 550-fold more potent than ACh. Racemic 
preparations of the alkyl-modified side chain variants homoanatoxin-a (HomoAnTx) and 
Isopropylanatoxin-a (IsopropylAnTx) were equipotent agonists of the receptor (Figure 3.11), with 
EC50 values of 0.72 and 0.66jiM, respectively. This reflects the competition binding data. (± 
)lsopropylAnTx, like (+)AnTx, consistently produced very rapid and full (relative to nicotine) 
activation of a7, with Hill coefficients in excess of 2 (Figure 3.11: Table 2.1). Higher concentrations ( 
>3|iM) of IsopropylAnTx produced smaller currents resulting in a bell-shaped dose-response curve 
(Figure 3.11b). HomoAnTx, although equally efficacious (see section 3.3.4) produced a shallower 
dose response curve (nH=0.7).
The overall potency rank order of all agonists at the functional homomeric a7 receptor was; 
AnTx=HomoAnTx=lsopropylAnTx»cytisine>(-)nicotine>(+)nicotine>DMPP>AMP.Mel>ACh»AMP.HCI.
3.3.4 Apparent efficacies of the a7  agonists
Normalisation of piperazine dose-response data with respect to (-)nicotine (Figure 3.10), 
revealed the inability of DMPP to activate the a7 receptor to the same extent as (-)nicotine, despite 
their comparable potency (Table 2.1). Similarly poor activation of a7  channels was also noted for 
this drug by Bertrand and co-workers (1992). Lower efficacy was also evident for the structurally 
related compound AMP.Mel, though to a lesser extent. Similar observations were made with cytisine 
(Figure 3.9). In an attempt to establish the apparent efficacies of all agonists, relative to nicotine, a 
maximally effective dose of each agonist was applied consecutively to the same oocyte (Figure 
3.12) - data for anatoxin-a analogues were obtained independently but also normalised to nicotine. 
These experiments corroborated the relative efficacies of agonists indicated by the mean dose- 
response curves. Agonists which showed reduced efficacy were cytisine (50% of (-)nicotine 
response), DMPP (20%) and AMP.Mel (60%). Limited availability and low solubility of AMP.Mel 
precluded investigations above 1mM, so 60% could be an underestimate (Amar eta! 1993).
All other agonists, namely: AnTx, HomoAnTx, IsopropylAnTx, (+)nicotine and ACh, were able to 
activate the a7 receptor to comparable extents (Figure 3.12). Efficacy comparisons were also 
carried out at EC50 concentrations of the agonists. These experiments confirmed that AMP.Mel is at 
least three times more efficacious than DMPP, and verified the reduced efficacy of (-)cytisine.
3.3.5 Electrophysiological properties of the a 7  receptor
The relationship between holding potential (V) and the extent of the agonist evoked current 
(I),was determined as described in section 3.2.3.2.1. Each of the agonists was applied at its 
approximate EC50 concentration as the membrane potential was stepped between -120mV and 
+40mV, in 10-20mV increments (Figure 3.13). The a7 receptor demonstrated the same relationship 
for all agonists, namely a strong linear dependence of current responses with membrane potential 
between -120mV and about -40mV. Strong inward rectification of the receptor was observed at more 
depolarised potentials, persisting up to +30mV, with no apparent reversal of current.
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Figure 3.11: (+)Anatoxin-a and alkyl-modified side chain variants as agonists of the a7 
receptor. Superimposed inward currents recorded from individual oocytes exposed to 3s pulses of 
increasing concentrations of agonist (a): (+)AnTx(A), (±)HomoAnTx(A) and (±)lsopropylAnTx( ♦ )  - 
>5min washing intervals between consecutive pulses were sufficient for full recovery from 
desensitisation, VH=-70mV. Dose response curves (b) were calculated by normalisation of 
responses to the maximum peak height for data from at least three oocytes. Curves were 
subsequently normalised against (-)nicotine (25p.M) applied to the same oocyte. Symbols represent 
mean data points with SEM indicated by vertical bars. Lines represent the theoretical dose response 
curves fitted to the data points using the non-linear Hill equation (see section 3.2.4). EC50 values 
derived from the analysis are shown in table 2 .1 .
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Figure 3.12: Relative efficacies of agonists at their maximally effective concentrations. Seven agonists were tested sequentially on the same oocyte for their ability to activate the a7  
receptor. Agonists were applied at their maximally effective concentrations: (-)nicotine (250^M); (+)nicotine (300[iM); cytisine (IOOjiM); ACh (4mM); DMPP (1mM); AMP.Mel (1mM) and 
(+)AnTx (4p.M). An independent oocyte was similarly exposed to maximally effective concentrations of (-)nicotine (250jiM), (±)HomoAnTx (IOjliM) and (±)IsopropylAnTx (3^iM). Current 
responses were normalised with respect to currents evoked by 250p.M (-)nicotine. Oocytes were clamped at -70mV and >12 min intervals separated consecutive agonist applications. Bars ( 
□  classical agonists, E  piperazine and ■  anatoxin analogues) represent the mean (±SEM) from 5 (3 for the anatoxin analogues) individual oocytes. Representative current traces are shown 
above the mean values of the data.
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Figure 3.13: Current-voltage relationships of the a 7 receptor. Each of the nine agonists were 
examined by successive application (3s) at >5min intervals while the membrane holding potential 
was stepped between -120mV and +40mV, as represented by HomoAnTx activated currents (a). 
Current responses were normalised with respect to the maximum response. Representative curves 
demonstrate the voltage dependence of currents induced by classical agonists (b), piperaziniums (c) 
and anatoxin-a analogues (d). Agonist concentrations approximated to their EC50 concentrations: 
(b), (-)nicotine 25|iM(**#m); (+)nicotine 40pM ( -  O  -); (-)cytisine 5|iM(« - T *  -); ACh 200 |iM 
(—V —); (c), DMPP 60jliM(— ■  -); AMP.Mel IO O ^iM (-D -); (d), (+)AnTx 0 .5 | iM ( - A - ) ;  
(±)HomoAnTx 1|xM(- A -); (±)lsopropylAnTx 1jiM(«*^m). The strong linear IV relationship and 
rectification properties were evident with at least 4 independent oocytes for all agonists.
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3.4 Discussion
3.4.1 Pharmacological properties of the a 7  homomer
The chicken neuronal a7 subunit gene has been successfully expressed in Xenopus oocytes 
where it assembles as a functional homomeric ligand-gated cation channel which demonstrates a 
nicotinic pharmacology. Chicken a7 is clearly a member of the nicotinic ACh receptor gene family. 
Until very recently the a7 homomeric receptor was unique among the reconstituted neuronal 
receptor subtypes in its acute sensitivity to aBgt (Couturier et al 1990a). This observation has been 
corroborated in this study and is a property shared only by two other nicotinic AChRs, namely the a  
8 homomer (Gerzanich e ta l 1994) and the muscle nicotinic receptor (Li et al 1993). Thus the myth 
surrounding non-functional aBgt-sensitive neuronal nAChRs seems now to have been dispelled.
Results described in this study generally corroborate and extend the quantitative agonist profile of 
the chicken homomeric a7  receptor. EC50 values for (-)nicotine and ACh agree well with those 
described previously (Bertrand e ta l 1992). These are also typical of rat and human a7 homomer 
responses (Segeula et al 1992: Peng et al 1994) and the a7-like responses of Type IA currents of 
hippocampal neurons (Zorumski e ta l 1992: Alkondon & Albuquerque 1993). (+)nicotine was two-fold 
weaker than the naturally occurring enantiomer, an observation that reflects the stereoselectivity 
exhibited by the fast channels of hippocampal neurons (Alkondon & Albuquerque 1993) and aBgt- 
sensitive binding sites in Torpedo and brain (Wonnacott e ta l 1986), yet is in marked contrast to a  
Bgt-insensitive Type II hippocampal nAChR and brain binding sites which show a 100-fold 
preference for (-)nicotine (Rapier et al 1988). A difference in steepness between (-)- and (+)-nicotine 
dose-response curves was apparent (n=1.4 and 2.5) and also occurs among the anatoxins (see 
section 3.4.6).
Cytisine was more potent than (-)nicotine in the present study. Conversely, this rigid agonist was 
found to be slightly less potent than (-)nicotine in the previous chicken a7 study (Bertrand et al
1992), and also other functional a7  homomers from rat and human (Segeula et al 1992: Peng et al 
1994) and additionally fast channels in hippocampus (Alkondon & Albuquerque 1993). Interestingly, 
the relative potencies of (-)nicotine and cytisine for chicken a7 homomers as measured by their 
ability to inhibit the binding of 2nM aBgt (Anand et al 1993) are 0.55jllM and 0.08|iM respectively. 
The order is reversed for the immunopurified native brain a7  nAChRs (1.4|liM and 3.9jiM 
respectively). This near 50-fold difference in affinity exhibited by cytisine between these two a7- 
containing receptor sites was exceptional in this latter study and emphasises the acute sensitivity of 
this semi-rigid alkaloid with regard to the receptor constitution. A more obvious instance is apparent 
among the aBgt-insensitive heterologously expressed nAChRs in Xenopus oocytes which are most 
sensitive to cytisine when the (34 subunit is present, whereas |32-containing receptors are almost 
completely insensitive to cytisine (Luetje & Patrick 1991). This selectivity may reflect a situation 
whereby cytisine interacts with a more subunit interface oriented region of the binding site than most 
other agonists. Chimeras of (34.(32 expressed with a3 reveal two residues at positions 108 and 110 
in the N-terminal region of the (3 subunit which account for much of the relative cytisine sensitivity 
(Figl et al 1992). This region does not evidently contribute to the binding site (see section 1.4.3.1) so
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may be an important subunit contact region (Verall & Hall 1992), which if imprecise might alter the 
structural attributes of the N-terminal region and an interface binding site.
Anomalous post-translational modification of the a l  subunit seems unlikely to account for the slightly 
accentuated sensitivity to cytisine in the present study, as dose-response data were generated from 
7 separate oocytes from independent donors (Table 2.1). Besides, Torpedo nAChRs reconstituted in 
Xenopus oocytes are pharmacologically and functionally indistinguishable from native Torpedo 
receptors (Sakmann et al 1985), despite the altered glycosylation pattern of expressed subunits 
(Buller & White 1990a). Although fairly stable, chemical modification of the cytisine stock may also 
have been contributory, given the consistency of the data.
Cytisine was only -58% as effective as nicotine at stimulating the a7 homomer (Figure 3.12). This 
observation is also inconsistent with other a7 studies of different species (Bertrand et al 1992: 
Seguela et al 1992: Peng et al 1994). However, cytisine-stimulated rubidium efflux from a 
synaptosome preparation is only 20-30% as effective as (-)nicotine (Marks et al 1993). ACh-induced 
responses of p2-containing neuronal nAChR heterooligomers almost insensitive to cytisine (see 
above) are reduced upon coapplication with cytisine, an inhibition which is not voltage dependent 
but which is more likely to take place through direct competition with ACh at the agonist binding site 
(Papke & Heinemann 1993). Thus it seems for a3p2 and a4p2 receptors at least, cytisine is a true 
partial agonist in that it does not demonstrate local anaesthetic-like actions yet is intrinsically poor at 
opening the ion channel.
1,1 -Dimethyl-4-phenylpiperazinium iodide (DMPP) was a relatively potent agonist at a7  nAChR 
though was only 20% effective as (-)nicotine at activating the receptor. Bertrand and co-workers 
(1992) observed no significant currents (<3%) with DMPP even at concentrations up to 600p,M. 
Current responses were somewhat larger in the present study (on occasions mA currents were 
observed) which may have enabled the detection of DMPP-evoked responses. The recently cloned 
rat a7  subunit (Seguela efa/1992) also shows anomalous dose-dependency for DMPP (although it 
may be fully effective), raising the possibility of some channel blocking activity (Sine & Steinbach
1984), or occlusion by receptor desensitisation and slow solution changes associated with the large 
300|il perfusion chamber used. However, no obvious differences are evident upon inspection of the 
current traces of this agonist in its rate of activation or desensitisation (Figure 3.10). A striking 
difference in efficacy is shown with human a7 homomers (Peng e ta l 1994) and aBgt-sensitive rat 
hippocampal nAChR (Type IA: Alkondon & Albuquerque 1993), where DMPP demonstrates 
comparable potency, yet crucially is as efficacious as ACh. Most oocyte studies with a7  homomers 
have been performed at holding voltages around -60mV, a voltage at which secondary Ca++- 
dependent Cl- currents (see section 3.4.4) appear to be proportional to the activation 
(Vijayaraghavan et al 1992: Gerzanich et al 1994). No such poor relative efficacy of DMPP is 
indicated by any other neuronal nAChR, but as with cytisine, DMPP seems to be extremely sensitive 
to the constitution of the receptor as regards the (3 subunits (Luetje & Patrick 1991).
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An analogue of DMPP, dithiobis-DMAP (DT-DMAP), is both less potent and less efficacious than a 
comparable ACh analogue (DT-ACh) as an agonist of a3, a4, (32-containing nicotinic receptors in 
chick retina (Xie e ta l 1992). Although these compounds display equal potency in their oxidation of 
the reduced a 1 92-193 disulphide bond of the receptor, the oxidation products (which are also 
agonists) of DT-DMAP are also less potent and less efficacious than DT-ACh. Besides 
demonstrating that oxidation is independent of receptor activation this confirms that a close 
analogue of DMPP also has reduced efficacy at other neuronal receptors.
The related compound AMP.Mel was only slightly less potent than DMPP but was at least three 
times more efficacious and may be a fully effective agonist - determination of this was only precluded 
by a lack of material. Absence of a methyl group in AMP.HCI reduced the potency such that no 
detectable currents were observed up to mM concentrations. It seems, therefore, that the benzene 
ring of DMPP confers properties consistent with poor efficacy to this piperazine-based compound. 
AMP.Mel is a potent activator of the frog rectus abdominus muscle (Spivak e ta l 1989a) where it is 
some 17-fold more potent than carbamylcholine. In behavioural experiments, AMP.Mel has also 
been shown to function as an agonist in the rat CNS as evinced by its ability to induce nicotine-like 
discriminative stimulus effects (Garcha e ta l 1993). However, differences in the behavioural profile 
relative to (-)nicotine, and the piperadine-based isoarecolone, may be attributable to action on more 
than one class of receptor, or to partial agonist properties at a single receptor type. Interestingly, 
arecolone only effects -40% activation of the receptor (Alkondon & Albuquerque 1993) and is a 
weak agonist (EC50~640p.M).
(+)Anatoxin-a, ((+)AnTX), a highly selective nicotinic, not muscarinic, receptor toxin (Aronstam & 
Witkop 1981), was the most potent of the agonists tested at the reconstituted a7 nAChR, as is the 
case with other heterooligomeric neuronal nicotinic receptors (Thomas et al 1993). This conclusion 
is supported by studies with nAChRs of frog skeletal muscle and Torpedo electroplaque (Spivak et 
al 1980: Swanson eta l 1986), where this semi-rigid neurotoxin is between 12-110 times more potent 
than ACh and 2-8 times more potent than carbamylcholine - AnTx (EC50~4jllM) is 33-fold more 
potent than ACh and 64-fold more potent than carbamylcholine in eliciting fast activating Type IA 
currents of the rat hippocampus (Alkondon & Albuquerque 1993). The (-) enantiomer is an agonist of 
the muscle nAChR only in the fiM range (Swanson et al 1986).
Homoanatoxin-a (HomoAnTx) and Isopropylanatoxin-a (IsopropylAnTx), synthetic homologues of 
anatoxin-a differing only in the addition of one or two methylene units respectively to the acetyl side 
chain, were almost equipotent with the parent compound in their ability to activate the a7 receptor 
(Figure 3.11). This was despite their use as racemic compounds in which case the assays may 
underestimate nicotinic potency by a factor of two, given that anatoxin's potency resides 
predominantly, and probably exclusively, in the configuration represented by the (+) enantiomer 
(Spivak e ta l 1983). Although these are novel compounds to be assessed in the functional oocyte 
system, HomoAnTx has previously been demonstrated to elicit muscle contracture in frog muscle 
(Wonnacott et al 1992) where it has 4 times the potency of carbachol and only 1/10th the potency of
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the parent compound. The presence of the inactive (-)racemate was thought to play a large part in 
the potency discrepancy perhaps through channel blocking activity (Kofuji et al 1990), the NCI site 
showing no stereoselectivity for AnTx. No direct evidence of this is apparent upon visual inspection 
of a7  currents, and both HomoAnTx and IsopropylAnTx were found to be maximally effective. At 
high concentrations of IsopropylAnTx however, the dose-response curve became hooked (Figure 
3.11) suggestive of some rapid desensitisation or inactivation. It is therefore apparent that these 
alkyl-modified sidechain variants of anatoxin-a are at least able to retain the functional potency and 
efficacy associated with the parent compound active at the a7 nAChR. The agonist binding site for 
receptor activation can accommodate extension of the side chain which has implications for a model 
of the binding surface of AnTx and the orientation of residues in the binding pocket.
Nicotine (25|iM)-induced currents through the a7 homomer were strongly blocked by subnanomolar 
concentrations of MLA (Figure 3.8). Inhibition was reversible and a full dose-response curve for this 
toxin gave an EC50~2pM. Competitive and reversible inhibition of nicotinic responses by MLA is a 
finding common to most functional nicotinic receptors, though variation in potency is much evident, a  
Bgt-sensitive nAChRs of brain and ganglia (a3p2 and a4p2 reconstituted receptors), and muscle 
nAChR require |iM  concentrations of MLA for inhibition. Contrastingly, the aBgt-sensitive fast 
activating receptor in rat hippocampal neurons, and chick a7 in this study, define MLA as a unique 
probe for the discrimination between a7-containing and other nACh receptors. Functional 
characterisation of a7  receptors has relied on aBgt for its discrimination. Disadvantages such as 
poor accessibility and slow onset of inhibition of this large polypeptide should see supersedence by 
the equipotent (perhaps more potent) MLA which is more selective, having >1000-fold lower affinity 
for muscle nAChR. Perhaps surprisingly. MLA has similarly high potency at insect aBgt-sensitive 
nAChR. High sequence homology between the a7 gene product (Couturier et al 1990a) and the a  
L1 gene product (Marshall et al 1990) may underlie this unique sensitivity to MLA.
The spectrum of agonist sensitivities and efficacies recorded here for the chicken a7 homomeric 
nAChR reconstituted in Xenopus oocytes is quite specific and different from those displayed by other 
reconstituted neuronal nicotinic receptors (Couturier et al 1990b: Luetje & Patrick 1991). As regards 
comparison with the pharmacology of other a7-containing receptors, differences are apparent in 
potency and efficacy of some agonists both between species (chicken, rat and human) and for the 
native aBgt-sensitive receptors. This is exemplified by comparison of agonist rank orders of potency 
of the same agonists used in this study:
a7  chicken (this study) (+)AnTx>cytisine>(-)nicotine>(+)nicotine>DMPP>ACh
a7  chicken (Bertrand eta l 1992) cytisine=(-)nicotine>ACh»DMPP
a7  rat (Seguela eta l 1992) (-)nicotine)cytisine>DMPP>ACh
a7  human (Peng et al 1994)
a7-containing rat (Type IA)




Despite these indifferences the pharmacological and functional profile of the a7-containing nAChR 
is beginning to be defined.
3.4.2 Is the recombinant a 7  homomer representative of a physiological receptor?
That the pharmacological observations made in this study are of the purely homomeric a7 
receptor there is little doubt. In the initial instance when the subunit gene was cloned and expressed 
(Couturier et al 1990a) control for the possible interference of nAChR a-like subunits that might be 
endogenously produced in the oocytes (Buller & White 1990b: Hartman & Claudio 1990) was 
undertaken by injection of equimolar mixtures of p1,7  and 8 cDNAs or p2, p3 or p4 cDNAs. All such 
cells failed to respond to 100jiM ACh - conversely a p 7S and a4p2 combinations were responsive. 
Similarly, expression of the rat a7  gene co-injected with a3, a5, p2 or p4, did not lead to receptors 
pharmacologically distinct from a7 alone (Seguela et al 1992), and currents were proportional to the 
amount of a7  RNA or cDNA injected. More recently still, Anand and co-workers (1993) have used 
sucrose gradient sedimentation analysis to compare the chicken a7 protein expressed in Xenopus 
oocytes and native brain a7 nAChRs. The [125l]aBgt labelled receptors co-sediment at ~10S 
implying a common size and shape. Interestingly [35S]methionine labelling of the expressed a7 
reveals association with a broad array of protein complexes of which only the ones similar in size to 
native nAChRs bind [125l]aBgt. Furthermore, fractionation and SDS-PAGE of this latter band reveals 
it is only comprised of entities of the same size (~60kDa), thus unless endogenously expressed 
oocyte nAChR subunits have the same weight as a7 then these observations support the formation 
of a purely homomeric a7 nAChR in the oocyte membrane.
There is also little doubt that a7  homomers the size of native nAChRs exhibit the pentagonal 
symmetry common to other members of the neuronal nAChR gene family (Anand et al 1991: Cooper 
e ta l 1991). For instance the calculated protein molecular weight of the pentameric Torpedo a1py8 
nAChR monomer is 268kDa, compared to chicken a7 which is 272kDa (Anand et al 1993).
Two other cases of functional homomeric receptors forming following injection into Xenopus oocytes 
support the use of the a7 homomer as a valid pharmacological receptor. In the mammalian brain 
one of the two transcripts of the a4 subunit gene forms a functional nicotinic receptor, though 
responses in the presence of high concentrations (100|iM) of ACh are not as robust as a7  (Boulter 
et al 1987). The invertebrate nervous system, the nicotinic receptors of which are largely blocked by 
aBgt (David & Sattelle 1984), has also manifested a nicotinic subunit able to form functional 
homomeric channels in the form of the locust gene aL1 which contains cysteines at positions 201 
and 202, and shares 44% and 46% homology with the mouse a1 and rat a3  genes respectively 
(Marshall et al 1990). The magnitudes of the nicotine-induced depolarisations compare favourably 
with a7  and a p  combinations of mammalian neuronal subunits. Interestingly, the pharmacology of 
this locust homomeric nAChR closely resembles that of the in vivo insect receptor (Sattelle 1985) 
and an affinity purified receptor reconstituted in lipid bilayers (Hanke & Breer 1986), including block 
by both aBgt and nBgt. Thus this locust homomeric receptor may represent the nAChRs with similar 
pharmacology in invertebrate CNS. The formation of a functional channel following expression of a
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single subunit gene in Xenopus oocytes is also observed for the GABAa (Blair et al 1988) and 
glycine receptors (Schmeiden et al 1989), though their resemblance to the more usual 
heterooligomers in vivo is weak.
3.4.3 Desensitisation kinetics and channel block
The agonist-induced whole cell a7 currents undergo very fast and thorough desensitisation 
which can be described by two exponentials represented by an initial fast phase followed by a slow 
decay plateau which persists until the agonist is removed. Even in the nAChR-expressing oocyte, 
which is obviously a large cell when compared to cultured foetal neurons for example, the activation 
phase and fast decay component of the agonist-evoked whole cell current generally occurred in 
under 2s and became shorter still at saturating agonist concentrations. The whole cell currents 
associated with the a 7 expressing oocyte decline to a greater extent than in any other expressed 
neuronal nAChR (Couturier et al 1990b).
Using an improved perfusion system which better identified the slow decay phase, the ratio of 
current peak to plateau for the a7 homomer in this study was at least 16:1 at saturating agonist 
doses. Couturier and co-workers (1990a) obtained a ratio of 25:1 for (-)nicotine and ACh. These 
observations are reflected by the supposed a7-containing Type IA channels of hippocampal 
neurons (Alkondon & Albuquerque 1993), which exhibit a similar response profile to the chicken a7 
homomer, rat and human a7  (Seguela et al 1992: Peng et al 1994) and the human a8  homomer 
(Gerzanich et al 1994), desensitising more fully than either Type II currents (~oc4(32) or Type III 
currents (~a3p4) on the same neuron. The whole cell Type IA currents (~600pA at their peak) for 
these neurons are able to activate and undergo fast desensitisation in well under 0.5s. Indeed when 
the fast and slow desensitisation components are fitted to a double exponential Type IA currents 
exhibit decay rates of 27ms and 300ms respectively (Alkondon & Albuquerque 1993). A similar 
foetal hippocampal channel exhibits an 8ms fast component (Zorumski e ta l 1992), which has been 
resolved to 0.5ms for the single Type IA channel (Castro & Albuquerque 1993). Desensitising whole 
cell a7  nAChR currents in the present study have fast and slow components of 510±75ms (n=4) 
and 16.2±3.1s (n=4) respectively when maximally effective doses of (-)nicotine- and ACh-stimulated 
currents are fitted to a double exponential function using Sigmaplot 4.1. These values are 
comparable to values of 260ms and 13s respectively obtained for the same a7 homomer (Couturier 
et al 1990a). Consistent with either desensitisation or open channel block, the contribution of the fast 
decay component to the overall current was consistently seen to increase with increasing 
concentrations of agonist (Figure 3.7), concurrent with other studies - similarly at low concentrations 
the fast decay component reduced to the extent where desensitisation followed a single exponential.
Whether inactivation is a consequence of desensitisation because the receptor has greater access 
to the agonist, and/or open channel block is unclear. However, ACh, carbamylcholine and 
succinamide (Sine & Steinbach 1984: Ogden & Colquhoun 1985), (+)- and (-)-nicotine (Rozental et 
al 1989) and anatoxin (Kofuji et al 1990) all demonstrate open channel blockade of the nAChR. 
Presumably, depolarisation of the membrane would reduce the influence of open channel blockade,
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particularly for the positively charged nicotinic agonists. Single exponential decay time constants of 
whole cell Type IA currents in hippocampal neurons were not voltage sensitive for any of the 
agonists tested (which included (-)- and (+)-nicotine, ACh, cytisine, DMPP and AnTx) (Alkondon & 
Albuquerque 1993), suggesting that the rapid decay phase is not influenced by open channel 
blockade but is more probably a consequence of stabilisation of the desensitised state. In contrast, 
Type II currents (~a4|32) are clearly susceptible to open channel block. Interestingly, the a 7 channel 
in oocytes (Revah et al 1991) has a much longer open time (>10ms) than the Type IA current in 
hippocampal neurons (-0.1 ms: Castro & Albuquerque 1993). Desensitisation rates of the latter 
channel were found to be independent of ACh concentration and only weakly voltage dependent 
supporting the insignificant role of channel block to the much reduced burst-time of this possible a7- 
containing nAChR. The differences are more likely to be a consequence of structural anomalies 
between the native and expressed a7 receptor.
Biphasic decay of the fast a7  channels might be explained by the existence of the same nAChR 
subtype in different conductance states with different closing rates, one contributing to the fast and 
the other to the slow decay. Notably, the single channel conductance for a7  nAChR is reported to be 
45pS (Revah et al 1991) whereas Type IA channels have a conductance of 73pS (Castro & 
Albuquerque 1993). These two channels which are pharmacologically not dissimilar, may represent 
the same nAChR, the differences in observed conductances being a consequence of the nature of 
the preparation.
3.4.4 Current-voltage relationships, rectification and calcium permeability
Current responses to all the agonists assayed at the a7  receptor exhibited a linear 
dependence with membrane potential up to approximately -25mV (Figure 3.13). At more depolarised 
potentials (up to +40mV) agonist responses became dramatically voltage sensitive and rectified to 
the extent that reversal currents were not detectable with any ligand. This data shadows that for 
homomers of chicken, rat and human a7, and chicken a8  (Couturier et al 1990a: Seguela et al 
1992: Gerzanich e ta l 1994: Peng efa/1994). The oc7-like channel of hippocampal neurons have a 
slightly more positive reversal potential (7mV) and may (Alkondon & Albuquerque 1991: Zorumski et 
al 1992) or may not (Alkondon & Albuquerque 1993) show rectification. Most of the neuronal nAChR 
(with the exception of retinal ganglion cells (Lipton et al 1987)) reveal inward rectification of their 
macroscopic currents (Mathie et al 1990: Mulle & Changeux 1990: Zhang & Feltz 1990: Ifune & 
Steinbach 1992). Several mechanisms have been proposed for the observed inward rectification of 
neuronal channels which include Mg++ block of outward currents (in PC12 cells) and voltage- 
dependent gating kinetics of channels (Mathie et al 1990: Ifune & Steinbach 1992). The shape of the 
l-V curve for a7-like hippocampal channels is unaffected by intracellular Mg++ (Zorumski et al 1992), 
and Cs+, contrary to the claims of Hirando and co-workers (1987). Interestingly, nAChR rectification 
in cultured midbrain neurons is removed when atropine is applied suggesting that the muscarinic 
AChR masks the nicotinic component at positive membrane potentials (Bijak et al 1991), though 
nicotinic currents in the hippocampus are not likewise affected (Zorumski et al 1992).
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The absence of current reversal up to potentials of 40mV suggests a l  currents are carried by non- 
selective cations. The positive reversal potential of the Type IA current is compatible with the high 
calcium permeability found in human a l  (Peng et al 1994), chicken a l  and a8 (Gerzanich et al 
1994) and rat a l  (Segeula et al 1992) homomers in Xenopus oocytes, perhaps the highest among 
the known LGICs. A major proportion of the rat a l  currents result from the secondary activation of 
endogenous Ca++ dependent Ch channels which can represent up to 80% of the a l  current. 
Interestingly, the aBgt and MLA sensitive nAChR of chick ciliary ganglion mediate Ca++ influx 
without generating currents (Vijayaraghaven e ta l 1992). The a7-containing receptor therefore may 
possibly play an important role in neuronal physiology.
3.4.5 Nature of native neuronal nAChRs sensitive to [125l]abungarotoxin
Whether the a l  homomer expressed in Xenopus oocytes represents the native nAChR found 
in situ is unclear. aBgt affinity purification of aBgtBPs from mammalian brain yields fractions 
containing one to five bands on denaturing gels ranging from 48 to 72kDa in weight (Norman et al 
1982: Conti-Tronconi e ta l 1985: Kemp e ta l 1985: Whiting & Lindstrom 1987a). The affinity labels 
[3H]MBTA and [3H]BAC, (instrumental identifiers of binding site residues of the a  subunit), alkylate 
only the 55kDa protein presumed to be the a  subunit (Kemp et al 1985: Norman et al 1982). The 
components that sometimes copurify with this subunit may represent other subunits of the native a  
BgtBP heterooligomer, or may be proteolytic breakdown products or associated peptides which are 
not integral to the aBgtBP.
Although largely ineffective, aBgt can antagonise a few agonist-mediated nicotinic effects in the 
CNS, such as in the inferior colliculus (Farley et al 1983), and the cerebellum (de la Garza et al 
1987). It has not been until relatively recently that aBgt-sensitive, functional nAChR have been 
shown in the mammalian CNS by more direct approaches (see Zorumski et al 1992: Alkondon & 
Albuquerque 1993). Electrophysiological studies of these nicotinic receptors present on the neurons 
of rat hippocampus reveal the presence of multiple structural subtypes of the receptor, which differ in 
their sensitivity to not only aBgt, but also nBgt, MLA, DH(3E and mecamylamine (Alkondon & 
Albuquerque 1991: Zorumski et al 1992). Consideration of decay characteristics, rectification profiles 
and agonist sensitivities has revealed four discrete subtypes. As we have already seen, the currents 
associated with the Type IA channel probably represent a7-containing receptor(s), being blocked by 
10nM aBgt and are most prevalent appearing on -83% of neurons. These channels closely 
resemble those of a7-containing receptors in terms of pharmacology, desensitisation etc, and 
presently represent the best characterised potentially a7-containing native nAChR.
In the avian brain the picture is a little clearer. Schoepfer and co-workers (1990) demonstrated that 
over 90% of the immunoprecipitated aBgtBPs contain the a l  gene, whereas a8 is only represented 
in about 15% of cases. Values of 68% and 8% respectively are obtained for the presence of a l  and 
a8  in aBgt-sensitive nAChRs for a similar tissue preparation (Keyser et al 1992). A mixed a7a8 
AChR subtype occurred in 23% of the cases. Two aBgt-sensitive AChR subtypes have also been 
purified in the chick optic lobe (Gotti e ta l 1993). Polyclonal antibodies against synthetic peptides of
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chick a 7 and a8 subunits recognise a predominant subtype (a7-containing) representing 60% of a  
BgtBPs, and another subtype (a7a8-containing) present in 20% of the receptors. In addition to the 
a7  and/or a8  subunits (MW~57kDa), both subtypes are associated with other subunits 
(MW~52kDa). These two subtypes have the same affinity for antagonists, but a7a8  has higher 
affinity for agonists. Characterisation of these subunits was taken a step further with their 
reconstitution in lipid bilayer. Both are able to form cationic channels but the oc7oc8 receptor is less 
homogenous (channel conductance ranges between 10-50pS) than a7  which has conductance of 
45pS (Gotti e ta l 1993).
3.4.6 Extrapolating the significance of the Hill coefficients observed for the a 7  homomer in 
this study
Hill coefficients for most agonists interacting with a7  were typically greater than unity 
indicating the binding of more than one agonist molecule per homomer. Coefficients -1.5-2 are the 
norm for heterooligomeric nicotinic AChRs, which are expected to interact with two ligand molecules 
for activation before lapsing into a desensitised state when affinity for the agonist is enhanced. This 
generally turned out to be the case for the a7 receptor in this study (Table 2.1), exceptions being 
(+)nicotine and anatoxin and its analogues. The significance of this is unclear but anomalies are 
perhaps unsurprising given that the oc7 receptor in Xenopus oocytes is homomeric and therefore 
potentially provides five binding sites for activating ligands. HomoAnTx's Hill coefficient was less 
than one (0.83). Consistently low coefficients (0.83-0.91) are observed for Type II (~a4p2) currents 
in the hippocampus (Alkondon & Albuquerque 1993). Desensitisation and open channel blockade by 
the agonist was suggested to be the cause. Alternatively the binding of only one agonist molecule to 
a single a  subunit might be sufficient to activate the receptor, which could also feasibly be imposed 
by an nAChR population of a ^ 4 stoichiometry (Role 1992). This does not explain a Hill number of 
<1 for the a7 homomer though.
(+)Nicotine, (+)AnTx and (t)lsopropylAnTx exhibited Hill coefficients in excess of 2. This may be 
more consistent with the provision and occupation of >2 binding sites by agonists, possibly as many 
as 5 if a pentameric structure is supported. Increasing the concentration of ligand at the receptor 
may produce a commensurate increase in the number of sites occupied on each receptor (the extent 
of occupation might be ligand specific). This would create greater structural perturbations and mean 
that larger currents may be seen than if only 1 or 2 sites were occupied. Similarly, fast 
desensitisation might be more extensive which is possibly why IsopropylAnTx (r|H=7.2) produces a 
hooked dose-response curve - possibly all ligand binding sites are occupied on the receptor so 
currents are occluded by significant stabilisation of the desensitised state. This model would also 
argue against channel block as being the desensitisation mechanism, for higher affinity ligand 
binding sites would probably be fully occupied before the NCI site.
3.4.7 Sequence homology and the receptor structure
The chicken a 7 subunit gene used in this study shares 92% identity with the human a7  gene 
(Peng et al 1994). The human gene sequence is 94% identical to rat oc7 emphasising the high
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degree of conservation of the mature a7 subunit peptide across the different species. Greatest 
diversity is apparent in the large intracellular loop between M3 and M4. Transmembrane regions M1, 
M2 and M3 are identical for all three species, therefore if M2 lines the channel (see Karlin 1993) then 
these a l  homomers should share identical cation channel properties. As we have seen the chicken, 
rat and human a l  receptor, and also a8, all exhibit the same rapid activation/desensitisation profile, 
inward rectification and Ca++ permeability (this study: Couturier et al 1990a: Seguela et al 1992: 
Vijayaraghavan e ta l 1992: Gerzanich efa/1994: Peng eta l 1994).
Only limited sequence diversity (11 out of the 207 residues between chicken and human) occurs in 
the large N-terminal domain. The amino acids that do differ are not among those that participate in 
the binding site (Galzi et al 1990: Galzi et al 1991b) or sites for specific interactions between 
adjacent subunits (Verall & Hall 1992). Either these few residues are important in maintaining 
structural integrity of the regions adjacent to the binding site, or they are major participants in the 
transduction and/or allosteric mechanisms, or alternatively the large phosphorylatable intracellular 
loop is in some way responsible for modulating the receptor and manifesting the differences that are 
observed in pharmacologies between these a l  homomeric channels.
3.4.8 Functional role of abungarotoxin-sensitive nAChRs
Now that functional aBgt-sensitive nAChRs are recognised and pharmacological correlations 
can be observed between reconstituted and native receptors, inferences about the physiological role 
of this receptor can be made. The endogenous ligand for this/these nAChR subtype(s) is unlikely to 
be ACh as it is nicotine which, when acutely administered, regulates [125l]aBgtBPs (Marks et al
1985) and furthermore, anticholinesterase agents do not have the same effect. The fast 
desensitisation obviates ACh as the endogenous ligand as this precludes the need for ACh 
hydrolysis. Given that aBgtBPs are located predominantly in non-synaptic membranes in embryonic 
and adult neurons, it is unlikely that these possible a7-containing receptors contribute directly to 
synaptic transmission. A more plausible role for these aBgt-sensitive receptors would be a 
modulatory one, given the extensive calcium permeability of native (Vijayaraghavan et al 1992: 
Castro & Albuquerque 1995) and recombinant (Galzi et al 1992: Seguela et al 1993: Sands et al
1993) receptors, thus providing the potential for influencing a vast array of calcium related events in 
neurons. For instance, the nAChR of pseudodendrites that bind aBgt have been implicated to 
mediate neuronal morphology (Pugh & Berg 1994). Divalent cations are not thought to directly 
modulate aBgtBPs themselves (Sands et al 1993), as occurs with aBgt-insensitive neuronal 
nAChRs.
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4.1.1 Molecular modelling techniques and application
Molecular modelling is the term used to describe the theoretical aspects of chemistry which 
simulate the 3-dimensional structure and energetics of molecular systems. It encompasses 
techniques for the construction, manipulation and analysis of explicit atomic models which can be 
used to aid the understanding of the relationship between structure and physical/biological 
properties. It is a field that has recently seen increased development of commercial and academic 
molecular modelling packages as a result of the explosive growth in computer hardware.
In order that a new bioactive molecule may be rationally designed an assessment must be made of 
the structure-activity relationships of related molecules. Molecular features of molecules to be used 
for such purposes can be constructed through experiment or hypothetically. Interaction of small 
ligands with their particular macromolecular target is an important consideration in the formulation of 
hypotheses about the required features of an active molecule. For instance, ligand-receptor 
interaction involves specific intermolecular interactions based on geometry, size, shape, charge, 
polarity and so on. Such information may be available from experiment but equally may be derived 
from a catalogue of chemical structures and their biological potency, as is the case with the 
molecules studied in this project.
Before a computer graphic model of a molecular structure can be displayed and manipulated, and 
before structurally-dependent molecular properties can be calculated, the 3-dimensional co­
ordinates of all atoms comprising the molecule must be provided. Co-ordinates for some compounds 
can be found from x-ray crystallographic data and other databases. Generally though, the 3-D 
structures of compounds of interest are not readily available so it is necessary to sketch crude 
representations for such compounds using molecular graphics facilities. This structure must then be 
refined (or optimised) prior to it being used for predictive purposes. Optimisation is accomplished 
through adjustments to the atomic co-ordinates to minimise the potential energy of the molecular 
system through the use of molecular mechanics (MM - see section 4.1.1.2) or molecular orbital (MO) 
methods.
4.1.1.1 Molecular graphics
Graphics permit the visual display of 3-dimensional aspects of molecular systems generated 
through a model builder. One of the molecular graphics packages used in this study was INSIGHT 
(Biosym Technologies Inc., San Diego, USA) run on a MicroVax II computer and displayed through 
an Evans and Sutherland PS-300 vector graphic interface. The system displays structures from 
small ligands to large proteins with colour, a variety of surface representations, depth-cueing and 
stereo images. Additionally, it provides the facilities required for the construction, analysis and 
storage of molecular systems.
Another useful facility of INSIGHT is its ability to give an assessment of the 'goodness' of fit between 
the atomic co-ordinates of two similar molecular structures. The 'by eye' method provides a 
qualitative method of the fit by manual rotation and translation of one structure over another. A more
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quantitative method is provided when corresponding sets of atoms in the two structures are selected 
and a 'rigid body' movement performed such that the sum of the differences in the corresponding 
atom co-ordinates is a minimum - the root mean square (RMS) deviation calculated for the co­
ordinates of the superpositioned molecules quantitates the goodness of fit (see section 4.2.3)
The molecular modelling program HYPERCHEM (Autodesk Inc., San Diego, USA) was also used 
extensively for building and conformational searching and was run on a 486DX/2-50 personal 
computer. This relatively new modelling package, which operates through a Microsoft Windows 
environment, includes functions for drawing molecules and conversion into 3-D models, graphical 
manipulation of structures, changing display conditions and performing chemical calculations. The 
ability of the program to interface with other Microsoft applications such as EXCEL allows for flexible 
manipulation of calculations and data.
4.1.1.2 Molecular mechanics
Molecular mechanics, as the name implies, is a method by which the principles of mechanics 
are used to calculate the structure of a molecule. Molecular mechanics calculations treat the 
molecular system as a related set of spheres (atoms) that are associated by springs (bonds) whose 
interaction is governed by classical-mechanical potential functions (force-fields). In general, 
molecular mechanics force fields describe the potential energy of a molecular system using terms 
which simulate bond stretching, bond angles, torsion angles and Van der Waals interactions, i.e.:
^^total_ ^'^stretch"*'^^bend'^^torsion'*'^,^ VdW
Force constants are applied to each of these terms to describe their distortion. There exist many 
such functions which may contain any number of extra terms to describe phenomena such as 
distortion from planarity, the coupling of movements, electrostatics and non-bond interactions. The 
combination of the form of the potential energy function and the numerical value of the force 
constants are important to the success of any system for modelling. Force constants are derived 
mainly from experimental data and the values are constantly being updated and improved. The 
chemical structure is thus calculated by minimising the potential energy function for a particular 
molecular structure by using one, or maybe more, of a number of minimisation methods. Electronic 
descriptors (charge), used in the calculation of electrostatic interactions, are usually generated by 
semi-empirical MO methods (see section 4.2.2)
Structure predictions using molecular mechanics are less appropriate for systems which have a high 
degree of conformational flexibility. Semi-empirical or ab initio MO methods are preferable in such 
situations. A popular approach for large flexible molecules such as membrane proteins is molecular 
dynamics, though the drawback to this and the former two methods is the cost in computer time.
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4.1.1.3 Potential energy force-fields
Molecular mechanics calculations include a force-field which correlates the energy of 
molecular species and their internal co-ordinates. The force field contains adjustable parameters 
that are optimised to obtain the best fit of calculated and experimental values, and because of the 
intimate association between structure and energy a calculation will always involve parameters and 
force constants.
In this study the va09a force field of the program DISCOVER and MM+ force field of HYPERCHEM 
were used. Once all the correct parameters are defined it is possible to calculate the magnitude of 
the various interactions and their contributions to the total potential energy. The potential energy of a 
molecular system is described by an analytical function, the internal co-ordinates and the inter­
atomic distances. The Biosym va09a and HYPERCHEM MM+ function comprise terms for; bond 
stretching, bond dipoles, angle bending, bond stretch and angle bending cross terms, out-of-plane 
bending, torsion angle rotation, and Van der Waals interactions. The MM+ function is an extended 
version of Allinger's MM2 force field. MM+ uses the latest MM2 (1991) parameters and atom types 
with the 1977 functional form modified to incorporate non-bonded cut-offs, periodic boundary 
conditions, and the bond stretch term switched from cubic to quadratic form at long range.
4.1.1.4 Energy minimisation
Potential energy minimisation uses molecular mechanics to alter the molecular geometry 
within the constraints of the force field. The explicit aim is to minimise the energy of the system thus 
yielding a stable conformation. As the iterative calculations of the minimisation progress, searches 
are made for a molecular conformation in which the energy does not change with infinitesimal 
changes in geometry - i.e. the derivative of the energy with respect to the cartesian co-ordinates (the 
gradient) is close to zero. This is known as the 'stationary point' on the potential energy surface.
Minimisation calculations cannot cross or penetrate potential energy barriers so the minimum energy 
will represent the potential energy closest to the starting structure of the molecule. If the energy of 
the molecule increases with small changes in geometric parameters then the conformation is 
relatively stable, and has reached a minimum. However, if the energy decreases in one or more 
dimensions, but not all, then the conformation is a saddle point. A molecular system can have many 
minima, the lowest energy being the 'global minimum' and the other(s) being 'local minima'.
4.1.2 Exploration of the conformations of ligands studied in the project
Despite the wealth of natural and synthetic compounds which have been demonstrated to 
bind to and/or activate the nicotinic receptor, the functional features and geometrical requirements of 
the pharmacophore for this receptor remain unclear. Since the actual structure of the receptor is 
unknown, indirect methods have been developed to gain insight into the structure, binding 
mechanism and geometry of the binding site, an insight that can be aided to a large extent by the 
definition of geometric and chemical descriptors of active molecules. The pharmacophore model 
proposed by Beers and Reich (see section 1.5.1) has essentially stood the test of time and remains
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probably the most informative model for the nicotinic receptor. Development of this model has in part 
been compounded by the flexibility of many ligands, which has created difficulties in determining the 
exact nature of bioactive conformations, a task inexact enough even for rigid molecules. In an 
attempt to extrude more information with which to assimilate a more complete picture of the nicotinic 
pharmacophore, a conformational search was initiated for an extensive ensemble of agonists and 
related molecules. This search is outlined in this chapter.
Historical background
The conformations of acetylcholine and other cholinergic ligands have been studied 
experimentally and computationally by many workers. Many calculations have focused on the 
derivation of energy surfaces for discrete conformations of flexible molecules subjected to dihedral 
driver calculations. Early workers on both the nicotinic and muscarinic receptors have, for example, 
attempted to predict pharmacophore models based on experimental data for fixed conformations of 
agonists and antagonists bound to the receptor. Such models have proved insufficient to explain the 
full spectrum of pharmacological characteristics and have thus served to underlie the importance of 
deriving such models from flexible ligands and receptors. It is therefore apparent that the 
conformation of a bound ligand does not necessarily represent the conformation most pertinent to 
the initial receptor recognition event. Thus it has largely fallen to the predictive power of computer 
simulations of chemical structure, allied with methods such as QSAR (Quantitative Structure Activity 
Relationships), to generate theoretical molecular geometries which may represent bioactive 
conformations of pharmacologically active ligands. Comparison of the conformations of many such 
compounds should assist the building and development of the model of the pharmacophore for a 
particular receptor, a model which could provide the basis for predicting the interaction sites and 
geometrical constraints imposed in the receptor binding pocket itself.
Indeed the predictive power of computer simulation has been successful in the past on selective 
groups of nicotinic ligands. For example, the quantum mechanical calculations of the electronic 
properties of acetylcholine and nicotine (and muscarine) by Pullman and co-workers (1971), have 
demonstrated the excellent agreement that can be attained between theoretical and experimental 
data. Importantly, these workers also showed how the nitrogen of acetylcholine is almost neutral with 
the positive charge distributed among the three methyl groups forming a large positive area for 
interaction with the receptor. Pauling (1980) was able to determine which functional groups were 
necessary for pharmacological activity following calculations on anti-cholinergic compounds. He 
emphasised how the conformations represented in the crystal were not necessarily the global 
energy minimum for the structure.
The pharmacological activity and specificity of a molecule varies with its conformations and 
configurations, and since molecules are in a perpetual state of dynamic motion when in solution, the 
number of feasible geometrical varieties is almost limitless. The systematic computational study of 
the semi-rigid, and certain flexible, nicotinic receptor agonists detailed in this study, although by no 
means exhaustive, could assist in correlating the conformations of these molecules with their 
activity. Many of the ligands studied are conformationally restrained through the presence of cyclic
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systems which remove the degrees of freedom and restrict the available geometries. Although such 
restrictions may alter the chemical reactivity of functional groups through alterations to strain 
energies or steric environment, some of the impositions must evidently have a role or the ligand(s) 
would not be biologically effective. Anatoxin-a (AnTx: see figure 2.1) is one such important semi-rigid 
nicotinic agonist which possess both a five- and seven-membered ring system with an unsaturated 
component. We have established this ligand to be the most potent agonist at certain neuronal 
nicotinic receptors (Thomas e ta l 1993), a property which when taken in conjunction with its rigidity 
makes it an excellent candidate for the exploration of structure activity relationships facilitated 
through molecular modelling. Indeed because AnTx is such an obvious candidate for exploring the 
nicotinic pharmacophore it has become the focus of much attention over recent years, and indeed 
prompted our probing of the structure through the synthesis of active analogues. Currently, the likely 
identity of the bioactive conformer of AnTx is controversial (Witkop & Brossi 1984: Koskinen & 
Rapoport 1985: Hacksell & Mellin 1989: Thompson et al 1992), though both boat, els and chair, cis 
conformers of the azobicyclononene system meet the requirements of the Beers-Reich 
pharmacophore and may be likely candidates.
It is hoped that through the structural searches described in this chapter of some novel alkyl- 
modified side chain analogues of this molecule some light may be shed on this quandary, and that 
through collating geometrical information for a large number of active and inactive nicotinic agonists 




This chapter describes molecular mechanical calculations performed on a variety of mainly 
semi-rigid agonists of the nicotinic receptor. The study has been extended to include families of 
structurally related ligands for which descriptors of biological potency have been established and 
recorded earlier (see Chapters 2 and 3), or have been reported in the literature. The basic molecular 
structures and core structures of all the compounds examined are represented in the relevant 
ensuing results sections.
Crystallographic data retrieval
Crystal structure information for a small number of the nicotinic ligands was obtained from the 
Cambridge Crystallographic Data Bank at Daresbury - the program permits structural identification 
through compound names, formulae, connectivity tables, crystal parameters, reference identifiers 
and query structures. Conversion of the compound's crystal co-ordinates to a usable format and 
removal of associated ions was required prior to manipulation.
Molecule construction
For those structures for which no x-ray data were available, or were not used, manual 
construction was required. Molecular sketches were generated either through the fragment libraries 
in INSIGHT, or drawn and converted into 3-D representations using HYPERCHEM. The 
stereochemistry of the molecules was examined carefully to obtain the correct starting structures 
prior to minimisation: i.e. (+) or (-), boat or chair, cis or trans, axial or equatorial, syn or anti forms. 
Potential function types, (i.e. the nature of the atom present and the form in which it appears, such 
as whether an oxygen is part of an hydroxyl, carbonyl etc. grouping), were also carefully checked.
4.2.2 Charge assignment
Partial charge assignment is important among the nicotinic receptor agonists as the nitrogen 
atom of the principal pharmacophore feature is highly protonated at physiological pH, and partial 
charge effects can contribute significantly to the energy of a molecule. The presence of oxygen and 
nitrogen atoms with negative partial charge in the nicotinic agonists create a non-uniform charge 
distribution. Partial charge on an atom is proportional to some extent on its electronegativity, the 
most electronegative atoms (oxygen, nitrogen, fluorine etc.) having more negative charge and the 
most electropositive atoms having the most positive charge. Partial charges were assigned so as to 
maintain localised electroneutrality of the molecule, which can be achieved through the freely 
variable partial charge of the carbon atom.
Partial charge interactions are not considered for bonded atoms since the forcefield is already 
parameterised for such effects. They are of greatest significance to non-bonded atoms where 
electrostatic through-space effects are important. Charge values were generally allocated using the 
experience gained in the molecular modelling facility at Bath, but were also calculated using Dewar's 
& Thiel's (1977) MNDO (Modified Neglect of Differential Overlap) method available in the 
HYPERCHEM program.
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It should however be remembered that in reality charge is a smooth function of nuclei surrounded by 
electrons, thus in some ways the assignment of partial charges to atoms is somewhat artificial.
4.2.3 Energy minimisation
Following construction and partial charge assignment of the conformers, minimised energy 
conformations of every molecule were generated using one of the molecular mechanics force fields 
described in section 4.1.1.3. The minimising algorithm used in both the DISCOVER and 
HYPERCHEM program employed quasi Newton-Raphson molecular mechanics. This method 
calculates the gradient of the potential energy well occupied and also makes a numerical 
approximation of its curvature with respect to cartesian co-ordinates. This information dictates the 
direction and size of the iterative step making the equation increasingly accurate as convergence is 
reached. Unlike the full Newton-Raphson method, this algorithm calculates the second derivative 
matrix for one atom at a time. The minimiser in both packages was set to a maximum of 2000 
iterations, and the criteria for the convergence limit set for an atomic co-ordinate energy derivative 
less than 0.01kcal/mol/A.
It should be emphasised that all the calculations performed using both the DISCOVER and 
HYPERCHEM algorithm were on isolated molecules in vacuo.
Template forcing
A popular method for determining structural patterns of a particular receptor pharmacophore 
is to derive the possible conformations for similarly acting molecules and superimpose these 
structures to identify common features of active compounds. This approach is also useful for 
conformationally labile species in that comparison with more rigid analogues identifies the more 
pertinent conformations. Essentially the forcing method makes pair-wise comparisons of 
conformations, (the more rigid acting as a reference), and investigates the structural and geometric 
similarities or differences. Atoms incorporating important pharmacophore features were selected for 
superposition and initially a 'rigid body' comparison of the two molecules was performed - the RMS 
(root mean square) deviations between designated atoms in the two systems were minimised by an 
iterative non-linear least squares algorithm. Following this a minimising algorithm was used to locate 
the energetic balance between better superposition of the chosen atoms and the increasing potential 
energy of the flexible structure as it was forced toward this conformation (DISCOVER). This 
informative method of making structural comparisons was used only on a small number of the 
molecules examined.
4.2.4 Torsional energy barrier calculation
Ligands with rotatable bonds were subjected to dihedral driver calculations to explore other 
possible conformations relevant to the pharmacophore. Calculations, performed using 
HYPERCHEM and driven via a DDE (dynamic data exchange) link with EXCEL, involved applying 
an external torque about a specific dihedral angle during minimisation. Thus a specified torsion with 
a specified torsional forcing constant was imposed on a specific angle and held there while
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minimisation of the remainder of the molecule was carried out. The angle to which the torsion was 
forced was increased iteratively (20° increments) and each corresponding conformation optimised. 
The variation in minimised energy was plotted for each angle and used as a measure of the torsional 
energy barrier to rotation.
4.2.5 Monitoring conformational changes
Changes that occurred to the geometry of molecules as the result of modification and 
subsequent minimisation were monitored by following torsional angle changes for the rotatable 
bonds (e.g. the enone function of anatoxin-a), or for angles defined by ring atoms. However, given 
the omnipresence of the electropositive centre associated with the protonated nitrogen and the 
hydrogen bond accepting moiety in all active molecules, and their importance in the present 
pharmacophore models (see section 1.5), it was decided that monitoring changes in this so-called 
'Beers-Reich' distance would also be undertaken. Such measurements did not account for the Van 




4.3.1 Acetylcholine as a conformationally labile nicotinic agonist
Acetylcholine (ACh) shows considerable conformational flexibility and consequently a variety 
of crystal structures have been defined. The labile nature of the molecule results in significant 
differences in the conformations associated with bound and unbound states (Behling et al 1988). 
Sources which analyse the unbound molecule support a gauche conformation across the C5-C6 
bond (see inset of figure 4.1) with the approximate torsion angles:
0 1  N4-C5-C6-07 = 75° (1)
0 2  C5-C6-07-C8 = 180°.
Minimisation of the crystal structure using the va09a algorithm in DISCOVER was undertaken and 
the conformation generated had the energy components described in table 4.1. The corresponding
Beers-Reich distance (the measurement between carbonyl 
oxygen and quaternary ammonium ion) was only 4.35A for this 
structure. Given the propensity of ACh to adopt numerous 
conformations, this structure was template forced onto the 
corresponding carbonyl group and nitrogen ion of the semi­
rigid (+) c/'s, chair anatoxin (see 4.3.4), giving an RMS fit of 
0.261. Distances of 0.31 A and 0.33A respectively separated 
equivalent nitrogens and carbonyl carbons. This forced fit 
revealed a lower energy conformation than the original 
(E=78.263 kcal/mol) with an N-0 distance of 4.99A and the 
following torsion angles:
0 1  N4-C5-C6-07 = 294.6° (-65.4°) (2)
0 2  C5-C6-07-C8= 168.3°.
In order to monitor other possible conformations of ACh that may best represent the bioactive state, 
the torsion angle 01 and 02 , and additionally 03 , of the original crystal structure were subjected to 
dihedral driver calculations. These HYPERCHEM calculations rotated the angles independently in 
20° increments from the original co-ordinates. The energetic consequences to the conformation of 
the three rotated torsion angles are depicted in the figure 4.1. In general, rotation of the molecule 
around these points increased the energy of the system relative to the original structure - 
minimisation of the crystal structure using the HYPERCHEM algorithm generated a conformation 
with a potential energy 54.576 kcal/mol and N-0 distance of 5.01 A). However, four important minima 
can be identified with an average potential energy of 50.829±0.358 kcal/mol. Generally, these 
conformations reveal that the carbonyl group prefers to be perpendicular to the plane of the 
ammonium head group. There is repulsion between the two ionic headgroups when 02=-100°, 
generating the most unstable state with the coulomb and torsion energy at their highest. A more 
planar conformation is preferred around 0 3  due to the conjugated carbonyl, with deviation from this 
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Figure 4.1: Comparison of
acetylcholine conformations using 
computational chemistry. Intermediate 
conformations were explored by 
rotation of the indicated dihedral angles 
(01, 0 2  and 03), involving the 
numbered atoms, in 20° increments, 
with minimisation at each step (see 
section 4.2.4). Changes to (a) the total 
energy (kcal/mol) were monitored. 
Graphs represent calculations 
performed on the initial minimised 
crystal conformation.
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4.3.2 The conformers of the isoforms of nicotine
This bicyclic alkaloid, which through its activity lends its name to the nicotinic class of AChR,
has a lone pair of electrons on the pyridine ring nitrogen as the 
hydrogen bond acceptor in place of the carbonyl group. Some of 
the nAChRs show selectivity in favour of the (-) isomer which is 
generally 20-70 times more potent an inhibitor of [3H]nicotine 
binding to brain tissue than the (+) form (Wonnacott 1986), though 
little selectivity is evident for a7-containing receptors (see section 
2.3.5.1). The structure exists mainly in the protonated state at 
physiological pH (Barlow et al 1986). The pyrrolidine ring nitrogen 
represents the cationic head, the pyrrolidine ring system itself 
preferentially adopts a perpendicular arrangement relative io the 
pyridine ring, though there is little preference for a syn or anti arrangement with respect to Hx and Hy 
(Inset 3: Whidby et al 1979). Methyl and pyridine groups favour a trans arrangement about the 
pyrrolidine ring (Pullman et a /1971), thus reducing conformational freedom.
Four (-)nicotine conformations and their mirror images were used to investigate the stereospecificity 
of the interactions between nAChR and this molecule. The initial crystal structure of the (-)trans, syn 
form of nicotine was minimised and used to generate the other conformers. Energy components and 
N-N distance values of the (-) isomers are given (Table 4.2) following minimisation.
Table 4.2
(-) trans syn (■) trans antj_ J (-) cis syn (’ ) cis an ti
N-N Dist (A) 4.87 4.56 4.98 4.67
Energies (kcal/mol)
Phi 5.494 5.511 5.830 5.835
Bond 11.855 11.839 12.629 12.579
Theta 5.812 5.878 8.824 8.914
Non-bond 57.988 58.022 58.829 58.893
Coulomb 76.621 76.608 77.076 76.438
Total 128.063 128.054 132.263 131.641
Corresponding stereoisomers were essentially identical, the only difference being in the spatial 
arrangement of the atoms around the pharmacophore points. Preference for the trans arrangement, 
and the minor differences in the syn and anti forms, are corroborated by the models.
C R
(3)
★ dihedral angle atoms 
/  syn/anti hydrogens
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Rigid body comparisons with anatoxin were performed with the lowest energy trans form of the more 
active isomer (viz. (-) trans, anti) and the geometrically similar stereoisomer (viz. (+) trans, syn), 
both of which were deemed to show greatest structural correlation with the anatoxin 
pharmacophore. The syn/anti mode of the pyridine ring was chosen to achieve maximum 
correspondence to the pi bonding enone of anatoxin-a. Equivalent atoms in nicotine and anatoxin 
used for the fit are shown (inset 4) and the closest RMS fit was the (+) isomer with good overlap of 
the five-membered ring systems (inset 5).
'N *
(-)nicotine
★  superposition 
atoms
(4)
Nitrogens (secondary and pyridine) (■) 0.242
(+) 0.397 (5)
All atoms (-) 0.732
(+) 0.502
Trans and cis conformations of (-) and (+) isomers were subjected to dihedral driver calculations 
(HYPERCHEM) through the syn and anti positions, in 20° steps (Figure 4.2a). The approximately 
symmetrical energy profiles of these isoforms indicate a slight preference for the syn form, with 
movement of the ring systems away from orthogonality creating energetically less favourable 
conformations by some 6.7±0.6 kcal/mol. Beers-Reich distances (Figure 4.2b) were 4.66±0.02A for 
(-) and (+) isoforms in the absolute syn configuration (i.e. 0 °), with the most favourable distances 
(i.e. 4.8±0.3A) occurring between -2 0 ° to 160° for (-)nicotine (Figure 4.2b), though energy penalties 
are incurred. The reverse is true for the (+) isomer.
Nicotine monomethiodide - Minimised N-methylated (-)nicotine conformations (both trans and cis), 
constructed and analysed using HYPERCHEM, generated the total potential energy values and 
Beers-Reich distances represented in table 4.3.
Table 4.3
{-) trans syn (-) trans anti (- )c is s y n (-) c is an ti
N+/N- Dist(A) 4.54 4.48 4.54 4.50
Disposition 
of rings (°)
-25.08 162.34 -25.47 163.41
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Figure 4.2: Comparison of isomers of 
nicotine and nicotine mono-methiodide 
using computational chemistry.
Intermediate conformations of trans and cis 
forms of each structure were explored by 
rotation of the dihedral angle associated 
with the two ring systems as indicated on 
the core structure (★), in 2 0 ° increments, 
with minimisation at each step (see section 
4.2.4). Changes to (a) the total energy 
(kcal/mol), and (b) the Beers-Reich 
distance (A) were monitored. In this case 
0° implies a syn arrangement about the 
ring hydrogens indicated. Graphs represent 
calculations performed on the lowest 
energy conformers.
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A cis arrangement of the same methyl carbon as used for (-)nicotine was energetically favoured over 
trans, with essentially no preference for the syn or anti forms. When (-)trans, anti was compared to 
(+)AnTx as previously, the following RMS fit of crucial pharmacophore points was observed (inset 6):
Nitrogens (secondary and pyridine) (-) 0.261 (6)
All atoms (-) 0.754
This conformer best matched the conformation of (+)AnTx, though in order to attain the lowest RMS 
values a slight energy penalty was incurred. Rotation of the dihedral angle between the two ring 
systems from syn through anti to syn positions (Figure 4.2a) revealed a similar energy profile to 
nicotine, though the extra bulk of the methyl created pronounced clashes when the ring systems 
were moved away from orthogonal. This was more significant in the trans conformer (AEsyn. 
anti=~14kcal/mol). Nitrogen-nitrogen distances were on average about 0.1 A greater than those for (- 
(nicotine though were more pronounced (up to 0.3A) in the sweep between -180° to 0°, when the 
clash between methyls and pyridine ring force the nitrogens further apart as a result of electrostatic 
repulsion and the extra hydrophobic bulk (Figure 4.2b).
4.3.3 Conformers of substituted piperazine molecules
Piperazine is closely homologous to the cyclohexane ring which characteristically has multiple 
important minimum energy conformers which are accessed only by surmounting comparatively large 
energy barriers. The two basic low energy forms of this ring structure are the structurally rigid chair 
and the more flexible boat. In the former several of the C-C bonds are completely staggered, 
whereas the latter has C-C ring bonds which are eclipsed. Interconversion between the conformers 
requires around 10 kcal/mol making it possible at room temperature.
Simple substituted cyclohexanes will generally assume the chair conformation with substituents in 
equatorial and axial positions with respect to the ring plane - the equatorial position avoids the non­
bond repulsive forces experienced by the axial substituent, so is consequently more stable. As 
substituent size increases, and therefore becomes sterically more demanding, so the equatorial 
conformer is increasingly favoured.
The tetrahedrally hybridised and trigonal nitrogen atoms, and the saturated 6-membered ring system 
of piperazine make for a structure which approximates to cyclohexane. Both chair and boat 
conformations of the three substituted piperazines (viz. DMPP, AMP.HCI and AMP.Mel - see 
structures with 2.3.5.3), were modelled, though AMP.Mel was too energetically unstable to adopt 
any form of boat conformation due to the presence of the two methyls. Chair arrangements 
generated using HYPERCHEM were preferentially adopted by both DMPP and AMP.Mel (Table 4.4) 
which are dimethylated at the tetrahedral nitrogen. N-0 distance was monitored for these structures, 







































1 60  - 1 2 0  - 8 0 40 0 40 8 0  1 2 0  1 6 0
Dihedral angle
•  DMPP 
O  AMP.Mel 
▼ AMP.HCI (eq) 
V  AMP.HCI (ax)







N*^  X *
©
/  \R R
AMP
Figure 4.3: Comparison of piperazinium 
analogues using computational 
chemistry. Intermediate conformations of 
chair forms of each structure were explored 
by rotation of the dihedral angle indicated 
on the core structures (★) in 2 0 ° 
increments, with minimisation at each step 
(see section 4.2.4). Changes to (a) the total 
energy (kcal/mol), and (b) the Beers-Reich 
distance (A) were monitored. Graphs 
represent calculations performed on the 
lowest energy chair conformers, and 




E Chair (kcal/mol) N-0 (A) <t> | E  Boat (kcal/mol) N -0  (A) <s> n
DMPP 47.022 5.55 95.5 
59.307 4.96 1.47
58.356 5.34 104.78 
Too unstable to createAMP.Mel
The chair conformer of AMP.HCI, in which the methyl was in the axial position, was the lowest 
energy form of this structure though, notably, the chair, equatorial conformer was the most 
energetically unstable, even when compared to the boat (Table 4.5).
Table 4.5
Total E (kcal/mol) N-0 (A) d> f )
Chair (ax) 
Chair (eq)




43.689 4.97 2.05 
44.478 4.69 -4.53
The benzene ring of DMPP lies orthogonal to the plane of the piperazine ring, optimising the overlap 
of ring hydrogens with little preference for syn or anti conformations. Deviations from this 
arrangement (Figure 4.3a) introduces non-bond repulsive interactions which in general increase the 
energy of the system by 7.045±0.351 kcal/mol. In the lowest energy form of the boat conformer, 
which is less stable than the chair by some 11.334 kcal/mol, the main contributions to this instability 
seem to originate from mainly unfavourable torsion, but also non-bonded and electrostatic (coulomb) 
interactions (Table 4.6).
Table 4.6
E Chair (kcamot) E Boat (kcal/mol) A  E
Torsion (phi) -1.322 7.869 8.967
Non*bond 10.308 12.328 2.020
Coulomb 32.274 30.823 1.451
Because of the dispersed nature of the pi electron system associated with the benzene ring, which 
substitutes for the carbonyl pi system, the Beers-Reich distance has a certain amount of flexibility, 
though here it was taken to be the to the centre of the ring. As a result, distances from the cationic 
nitrogen to benzene carbon are consistently high (chair=5.54±0.09A (Figure 4.3b), boat=5.32± 
0.09A) which are outside the acceptable limits for this distance (4.8±0.3A), implying association with 
the complementary receptor point is possibly nearer C2 or C6 of the benzene ring, depending on the 
orientation.
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Conversely, the acetyl group of AMP.Mel prefers to be coplanar with the piperazine ring as evinced 
by the dihedral angle C-N-C=0 (Figure 4.3a and inset), being slightly more stable in the cis than 
trans configuration (AE=0.5kcal/mol). Deviations of up to 60° either side of cis increase the potential 
energy by a maximum of 11.068±0.997kcal/mol, the largest comparative differences being in the 
torsion energy (AE=12.037±0.776 kcal/mol). Beers-Reich distances are not satisfied between -160° 
and -50° (Figure 4.3b), though are in good agreement with the literature value for the two minima 
observed for cis and trans. Boat conformations of this dimethylated piperazinium were very unstable.
As mentioned above, AMP.HCI is also at its most stable in the chair form when the N-C(H3) bond is 
axial. Again two minima are observed when the carbonyl is in either the cis or trans arrangement 
(bond C-N-C=0), with the potential energy rising by some 11 kcal/mol in the orthogonal orientation 
relative to the ring position (Figure 4.3a). The chair, equatorial conformation incurs a 6.607 kcal/mol 
energy penalty in the cis configuration, largely due to steric clash of the methyl hydrogens with the 
C2 and C6 hydrogens which are forced to converge. In the boat configuration, there is little 
preference for the same methyl being axial or equatorial (AE=0.823 kcal/mol), but slightly larger 
energy penalties are incurred, relative to chair AMP.HCI, when the carbonyl is rotated out of 
planarity, due to the much closer proximity of the C=0 and CH3 of the acetyl side chain with the axial 
methyl of the tertiary nitrogen.
Significant differences (up to 1.55A) are observed in the Beers-Reich distances for boat, axial and 
boat, equatorial conformations of AMP.HCI (not shown). Distances are smaller in the equatorial form 
as the carbonyl is rotated into the -90° position over the ring where steric clash is less pronounced, 
when compared to axial CH3 forms. Consequently, the charged headgroups come close enough 
(within 2.83A) to partially shield the electrostatic forces of the two species as the carbonyl oxygen 
moves over the ring. In terms of the pharmacophore and bioactive conformation, this configuration is 
unacceptable.
4.3.4 Anatoxin-a and its analogues
Anatoxin is now a well established probe for investigating the nAChRs of both muscle and 
brain. Among its many attributes are its stereospecificity, extreme agonist potency (see sections
2.3.5.4 and 3.3.3.4), semi-rigid structure and the amenability of its functional sidechain to chemical 
modification. As such the structural analogues of anatoxin are numerous and have made the 
structure the focus of extensive structure-activity relationships (SARs) at both muscle and brain 
nAChR sites. A series of eighteen analogues of anatoxin, assessed for their nicotinic pharmacology 
at peripheral (Swanson e ta i 1991) and neuronal (Wonnacott e ta ! 1991) sites (Table 4.7), provided 
the opportunity to attempt to correlate observed affinities with possible conformations of these 
ligands. As such, these carbonyl, alcohol, amide and N-methylated derivatives were modelled and a 
summary of the pharmacological profiles of these derivatives is given in table 4.7. Also modelled 
were analogues (Thomas et al 1994), designed specifically to determine the absolute cis or trans 
configuration of the carbonyl group in the enone system and the effects on biological activity.







(+)anatoxin-a AnTx -c=o -c h3 3.5+1.1 x1 O'9 3.8±2.1x10'7
Dihydroanatoxin H2AnTx -c=o -ch3 2.7±1.0x1 O'8 1.2±0.5x10‘6
Anatoxinic acid methyl ester AnTx-ME -c=o -o ch3 3.7±1.3x1 O'8 2.6±0.7x1 O'6
Anatoxinal AnTxal -c=o -H 9.0±2.0x10'7 >2x1 O’4
a-Hydroxyanatoxin AnTxaOH -c=o -CH2OH 2.6±1.5x10‘6 >2x1 O’4
Alcohols
Anatoxin(10S)alcohol AnTx-(S)ol -C-OH-H -ch3 6.5±0.5x1 O'7 6.5±2.0x10'5
Anatoxin(10R)alcohol AnTx-(R)ol -C-H -o h -ch3 4.6±0.9x10‘6 >2x1 O’4
Noranatoxinol AnTx-Norol -C-OH-H -H 2.5±0.5x10'5 >2x1 O'4
Anatoxin-10-methyl alcohol AnTx-mol -C-OH -(-CH3)2 1.5±2.8x10'4
Amides
Anatoxinic acid isoxazolide AnTx-isox -C=0 -N O (C H 2)3 cyclic 3.6±1.0x10‘8 4.0±0.2x10'5
Anatoxinic acid methoxyamide AnTx-NOMe -C=0 -nh-o c h3 4.1±1.0x10‘8 3.1 ±0.7x1 O’5
Anatoxinic acid dimethylamide AnTx-Me2N -C=0 -N(CH3)2 1.9±1.0x10‘6 1,3±0.5x1 O'5
Anatoxinal-O-methyl oxime AnTx-MeOX -c=n o c h3 -H 1.8±0.9x1 O'6 7.5±3.0x10'5
N-methylated
N-methylanatoxin Me-AnTx -C=0 -c h3 2.6±0.5x10‘6 2x1 O'4
N-dimethylanatoxin Me2-AnTx -C=0 -c h3 2.0±0.3x1 O'6 7.5±3.5x1 O’5
N-methylanatoxinic acid methyl ester Me-AnTx-ME -c=o -OCH3 1.2±0.3x1 O'5 >2x1 O’4
(1 OS)-N-methylanatoxinol Me-AnTx-(S)ol -C-OH-H -ch3 >2x1 O'4 >2x1 O'4
(1 OR)-N-methylanatoxinol Me-AnTx-(R)ol -C-H-OH -ch3 >2x1 O'4 >2x1 O’4
N.V-dimethylanatoxinol Me-AnTx-mol -C-OH-CHg -ch3 >2x1 O'4 >2x1 O’4
(+)AnTx
Table 4.7: Sidechain structure and inhibition binding parameters for anatoxin anologues. Values for the inhibition of ligand binding were taken from Wonnacott et 
al (1991), where anatoxin analogues were assessed in competition binding assays on rat P2 membranes using [3H](-)-nicotine and [125l]abungarotoxin according to the 
method of Rapier ef a/ (1990). Ki values were calculated using the relationship Kj=IC50/( 1 +[L]/Kd). The synthesis of the analogues have been described elsewhere 
(Sardina et al 1989; Howard et al 1990).
129
4.3.4.1 Carbonyls - In the case of all these structures the accepted pharmacophore points 
suggested by Beers and Reich (1970), namely the quaternary nitrogen and carbonyl dipole, were 
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conformation for AnTx has been suggested to be where the carbonyl moiety of the enone system is 
either cis (chair or boat: Hacksell & Mellin 1989: Koskinen & Rapoport 1985: Witkop & Brossi 1984), 
or trans (chair: Hacksell & Mellin 1989). As activity resides in the (+) form of AnTx, all derivatives 
were built as the (+) isomer and manipulated to achieve boat and chair conformations, (which 
included (-)anatoxin) - total energy values for the minimum energy conformations are given in table 
4.8. As can be seen chair forms are preferred, with the carbonyl in the trans position (0 -180°) - the 
decreased stability of boat forms can be attributed to steric crowding.
Table 4.8
Boat Chair
E  (kcal/mol) N - 0  (A ) r ) E  (kcal/mol) N - 0  (A ) <j> f  )
(+)AnTx 49.399 4.06 178.84 48.405 3.75 -179.22
(-)AnTx 49.398 4.06 -178.86 48.406 3.75 179.25
H2AnTx 41.746 4.21 -174.49 41.228 3.26 -156.63
AnTx-ME 37.121 4.06 178.87 36.333 3.74 -179.37
AnTxal 57.134 4.13 179.27 56.319 3.83 -179.37
AnTx-aOH 68.710 4.05 175.13 67.817 3.75 176.98
The relatively small distances between nitrogen and carbonyl oxygen, in both chair and boat low 
energy forms of the carbonyls, suggest the cis conformation might better fit these pharmacophore 
points. This was born out by subjecting the torsion angle defined by C=C-C=0 (see inset of figure
4.4) in each analogue to dihedral driver calculations and monitoring the energy variation (Figure 
4.4a) and the effects on the Beers-Reich distance (Figure 4.4b) introduced by these changes. 
Although energies were generally higher in the cis position, N-0 distances were better fulfilled, being 
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Figure 4.4: Comparison of carbonyl 
analogues of (+)anatoxin using 
computational chemistry. Intermediate 
conformations of chair forms of each 
structure, including (-)anatoxin, were 
explored by rotation of the dihedral angle, 
(C=C-C=0) indicated on the core structure 
(★), in 20° increments, with minimisation at 
each step (see section 4.2.4). Changes to 
(a) the total energy (kcal/mol), and (b) the 
Beers-Reich distance (A) were monitored. 
Graphs represent calculations performed 
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achieved by boat conformations (4.72±0.02A for all derivatives). As the cationic and hydrogen-bond 
acceptor moiety are prerequisites for the model of the pharmacophore interacting with the receptor, 
their spatial displacement (distance apart) is important and should fulfil the basic criteria laid down 
by other active ligands, even if there is some energetic cost. With this in mind, the bioactive 
conformations of AnTx and its carbonyl derivatives are probably (+) boat, c/'s, as the Beers-Reich 
pharmacophore distance is fulfilled, despite the energy penalty incurred - although the cis position is 
a local minimum in every case. Energy penalties incurred in achieving the distances are shown 
(Table 4.9) for boat and chair structures.
Table 4.9
Boat (cis-> trans) Chair (cis-> trans)
A E
(kcal/mol)




A  N -0
(A )
(+)AnTx 5.903 0.64 6.636 0.79
(*)AnTx 6.108 0.65 6.528 0.79
H2AnTx 2.442 0.54 2.686 1.14
AnTx-ME 1.044 0.64 1.190 0.77
AnTxal 1.141 0.61 4.388 0.74
AnTx-aOH 4.063 0.66 10.123 0.82
Differences in N-0 distance between cis and trans for (+) and (-) AnTx are similar in boat and chair 
forms but, as can be seen from figure 4.4b, in orientations where the enone carbonyl lies in between 
cis and trans, the distances are quite different (up to 1.4A at -60°) which may partially contribute to 
the differences in activity (Table 4.7).
Removal of conjugation in the azabicyclononene ring (H2AnTx) reduces the potential energy of the 
structure by some 6.782 kcal/mol (chair, trans), radically reducing the stresses imposed on the 
structure through the rotation of the carbonyl group which originate from large torsion energies (inset 




The lowest global minimum energy conformation among the carbonyls is seen in AnTx-ME which is 
12.277 and 12.073 kcal/mol lower in energy than the respective (+)boat and (+)chair conformers of 
AnTx. The main differences occur in the electrostatic energy which is roughly 14.6 kcal/mol lower in 
AnTx-ME in which the pi system of C=0 is more delocalised being associated with the additional 
oxygen.
4.3.4.2 Alcohols - Primary (AnTx-norol), secondary (AnTx-(S)ol and AnTx-(R)ol), and tertiary 
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AnTx (Table 4.10). Chair conformations were slightly favoured. Rotation of the dihedral angle (which 
specified the OH group as the anionic centre - see inset of figure 4.5), revealed at least three local 
energy minima for each analogue (Figure 4.5a), but the torsional barriers between these were 
relatively small (Chair conformations: largest = 5.656 kcal/mol (AnTx-(R)-ol), smallest = 0.133 
kcal/mol (AnTx-mol)), due largely to the absence of the conjugated carbonyl. Beers-Reich distances 
varied more widely among the alcohols than the carbonyls partly due to the longer O-H bond, and 
were better fulfilled in boat conformations (not shown) being 4.85±0.02A in the cis position, though 









48.277 4.03 -118.76 
48.038 4.24 142.85 
48.776 3.97 -123.50 
48.143 4.12 161.34
46.919 3.44 -120.72 
46.842 3.37 -121.68 
47.564 3.53 -137.92 
47.509 3.46 -138.23
Consequently bioactive conformations are likely to be those in the higher energy saddles where the 
OH group is approximately cis with respect to the C=C bond of the ring. Interestingly, the double 
methylated AnTx-mol appears not to sterically inhibit the rest of the structure to any significant 
extent, and the extra methyl bulks do not adversely alter the observed distances between nitrogen 
and oxygen atoms. Absence of the pi electrons associated with the carbonyl dipole create a weaker 
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Figure 4.5: Comparison of alcohol 
analogues of (+)anatoxin using 
computational chemistry. Intermediate 
conformations of chair forms of each 
structure were explored by rotation of the 
dihedral angle (C=C-C-0) indicated on the 
core structure (★) in 2 0° increments, with 
minimisation at each step (see section
4.2.4). Changes to (a) the total energy 
(kcal/mol), and (b) the Beers-Reich 
distance (A) were monitored. Graphs 
represent calculations performed on the 
lowest energy twist, chair conformers.
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with these structures (Table 4.7). The hydrophobic nature of the substituent groups allied to the 
sidechain will also greatly influence the electronegative character of the hydroxyl.
4.3.4.3 Amides - Global minima were observed for all these analogues, (where a nitrogen is 
attached to the carbonyl - inset 10), in the chair conformers, except AnTx-MeOX which slightly 
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In the case of AnTx-Me2N, AnTx-NOMe and AnTx-isox the pi electrons associated with the carbonyl 
will be more delocalised due to the proximity of the nitrogen with its lone pair of electrons. AnTx- 
MeOX, which has the C=0 substituted by a nitrogen juxtaposed with an oxygen atom, will have 
similarly well dispersed electronegative character. Each analogue introduces charged bulk around 
the hydrogen bond acceptor moiety, yet this does not seem to affect activity too adversely (Table 
4.7), with AnTx-isox and AnTx-NOMe being only some 10 times less active than the parent (+)AnTx. 
In each of the analogues case, this bulk can be directed away from the nitrogen cationic head 
because of the flexibility of the amide-bonded side chain, including the cyclic AnTx-isox. The energy 
barriers to rotation between cis and trans forms (Figure 4.6a) are relatively small compared to the 
carbonyl analogues for example, the largest being for AnTx-MeOX in the chair form (22.5 kcal/mol). 
Several energy minima can be observed for the tricyclic AnTx-isox due to a number of chiral centres 
in the side chain and the saturated nature of the five membered ring system. A pseudo-chair 
arrangement of the amine ring is preferred. Beers-Reich distances for these species are acceptable 
for the pharmacophore model in chair, cis conformations (Figure 4.6b), though there are obviously 
significant attractive forces as the amide side chains pass over the azabicyclononene ring as 
distances reduce towards ~3A in chair conformations in all but AnTx-MeOX. It is the boat forms 
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Figure 4.6: Comparison of amide
analogues of (+)anatoxin using 
computational chemistry. Intermediate 
conformations of chair forms of each 
©  | structure were explored by rotation of the
|\|___________1 ___ dihedral angle (C=C-C=X) indicated on the
- core structure (★) in 20° increments, with
minimisation at each step (see section
4.2.4). Changes to (a) the total energy 
(kcal/mol), and (b) the Beers-Reich 
distance (A) were monitored. Graphs 
represent calculations performed on the 
lowest energy twist, chair conformers.
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It is therefore difficult to assess bioactive conformation when so many electron-rich species are 
present in the sidechain, as the electronegative character is diffuse, unlike the directional dipole 
associated with the carbonyl group of other analogues. These analogues are useful in that they 
provide information regarding the extent and directionality of the electronegative character required 
for activity at one receptor subtype or another, and additionally probe the accessible volume of the 
binding pocket.
4.3.4.4 N-methylated anatoxins - Addition of one methyl unit to the nitrogen of (+)AnTx (inset 11) 
incurs an energy penalty of 13.901 kcal/mol in the global energy minimum conformer, and 22.661 
kcal/mol in the dimethylated structure (Table 4.12). This energy increase was found to be similar for 
the methylation of other analogues.
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Me*AnTx 62.306 (R) 48.405 13.901
DiMe-AnTx 71.066 48.405 22.661
Me-AnTx-ME 50.323 (R) 36.333 13.999
Me-AnTx-(S)-ol 60.117 (R) 46.842 13.275
Me-AnTx-(R)-ol 60.877 (R) 47.442 13.435
Me-AnTx-mol 69.605 (R) 49.970 19.635
Commensurate with (+)AnTx, the mono- and di-methylated forms (inset 11) prefer a chair, trans 
conformation with the methyl preferably in an R configuration about the chiral nitrogen. The energy 
barriers to conversion between trans and cis forms (Figure 4.7a) are only as pronounced as in the 
non-methylated structures. There is obvious steric clash of the bulky methyls associated with Me- 
AnTx-mol which increases the energy of the system by about 8 kcal/mol above the comparative 
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Figure 4.7: Comparison of N-methylated 
analogues of (+)anatoxin using 
computational chemistry. Intermediate 
conformations of chair forms of each 
structure were explored by rotation of the 
dihedral angle indicated on the core 
structures (★) in 20° increments, with 
minimisation at each step (see section
4.2.4). Changes to (a) the total energy 
(kcal/mol), and (b) the Beers-Reich 
distance (A) were monitored. Graphs 
represent calculations performed on the 
lowest energy twist, chair conformers with 










distance significantly more or less favourable in any case (Figure 4.7b). It therefore looks as though 
the principle results of N-methylation are an inevitable decrease in stability and added bulk around 
an important pharmacophore point. Otherwise, the conformations are essentially the same as for the 
non-methylated analogues implying that the bioactive forms will be the same. Biological activity of 
these same analogues (Table 4.7) is reduced by at least 100-fold in nearly every case. If the 
bioactive conformations are the same as the non-methylated molecules then this reduction in activity 
may be exclusively attributable to interference with the volume, and extent over which the positive 
charge is distributed around the nitrogen.
4.3A5 Alkyl-modified sidechain analogues - Approaches to determine the bioactive conformation 
of (+)AnTx, by restricting movement around the acetyl sidechain, were invoked through the addition 







derivatives, designated HomoAnTx, PropylAnTx and IsopropylAnTx (inset 12), have been assessed 
for their biological potency (see sections 2.3.5.4 and 3.3.3.4) and the likely bioactive conformations 
modelled.
Chair conformations of all analogues were the most stable, and, as with the parent (+)AnTx, the 
trans configuration of the enone dihedral (see inset of figure 4.8) was favoured (Table 4.13).
Table 4.13
Chair, trans Chair, c is Boat, trans Boat, cis
E  (kcal/mol) N -0  (A ) E (kcal/mol) N -0  (A) E  (kcal/mol) N -0  (A ) E (kcal/mol) N -0  (A)
HomoAnTx 48.067 3.74 53.482 4.53 48.786 4.05 53.510 4.69
PropylAnTx 50.167 3.74 55.825 4.55 50.900 4.05 55.799 4.71
IsopropylAnTx 51.887 3.71 57.099 4.55 52.395 4.02 56.528 4.71
The difference in energy between trans chair and boat forms was not significant (0.653±0.103 
kcal/mol) so both forms should be well populated. Trans conformers were some 5.428±0.182 
kcal/mol (chair) and 4.585±0.328 kcal/mol (boat) lower in energy than corresponding cis forms, 
which are roughly 1 kcal/mol less than that observed for (+)AnTx (6.636 kcal/mol (chair), 5.903 
kcal/mol (boat)), a difference attributable to the extra bulk of the additional methine/methylene units. 
The increased hydrophobic bulk a  to the carbonyl carbon has no significant influence on the 
preference for trans as deviations from the mean energy are small. The enone moiety (C=C-C=0)
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adopts a very planar arrangement in global minima of all analogues (-178.82±0.26°) - the crystal 
structure of AnTx.HCI (Koskinen and Rapoport 1985) is distorted by -18°. All other conformations 
explored by dihedral driver calculations of the enone moiety (Figure 4.8a) increased the energy of 
each system.
Beers-Reich distances are best fulfilled by boat, cis structures (Table 4.13) whereas in trans 
configurations (especially chair), these pharmacophore points are in close proximity (Figure 4.8b), 
though with an obvious energetic advantage. Given the small energy barriers to overcome in 
converting from chair to boat, probably the most likely bioactive conformations exist as chair, cis and 
boat, cis.
4.3.4.6 Conformationally constrained analogues - A more radical attempt to ascertain the 









locked analogues of anatoxin. These structures include two cis analogues (HydroxyAnTx and 
HeteroAnTx), and an epoxide (EpoxyAnTx) - see inset 13 - also synthesised by Paul Brough.
The crystal structure of HydroxyAnTx reveals the cis configuration reinforced through the presence 
of a hydrogen bond (Brough et al 1992). Although this conformation exists as the crystal form, and 
as a local energy minimum, as revealed by bond breaking and dihedral driver calculations (Figure 
4.8a), the energetically preferred conformer is trans - chair forms being the most stable (Table 4.14).
Table 4.14
Chair, trans Chair, c is Boat, trans Boat, cis
E  (kcal/mol) N -0  (A) E  (kcal/mot) N -0  (A) E (kcal/mol} N -0  (A ) E (kcal/mol) N -0  (A)
HydroxyAnTx 28.764 3.61 30.799 4.54 30.486 3.98 32.517 4.74
EpoxyAnTx 203.174 4.19 205.600 4.70 207.913 4.11 - -
HeteroAnTx - - 43.255 4.49 - - 44.668 4.56
HydroxyAnTx appears to be the most stable structure among AnTx and its analogues. The 19.639 
kcal/mol lower potential energy of HydroxyAnTx relative to (+)AnTx can be explained by the 25.558 
kcal/mol difference in electrostatic energy of the global energy minima forms of the two structures. 
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Figure 4.8: Comparison of alkyl-modified 
sidechain analogues and
conformationally constrained analogues 
of (+)anatoxin using computational 
chemistry. Intermediate conformations of 
chair forms of each structure were explored 
by rotation of the dihedral angle (C=C- 
C=0) indicated on the core structure (★) in 
20° increments, with minimisation at each 
step (see section 4.2.4). Changes to (a) the 
total energy (kcal/mol), and (b) the Beers- 
Reich distance (A), were monitored. 
Graphs represent calculations performed 
on the lowest energy twist, chair 
conformers.
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EpoxyAnTx is an extremely unstable structure induced by the proximity of the two electronegative 
centres. The lowest energy structure exists as a chair, trans form (Table 4.14) with significant 
contributions to the instability being due to high bend energies. Rotation of the carbonyl, and epoxide 
orientation, have little effect on stability, though the cis arrangement conforms best to the 
pharmacophore distance (Figure 4.8b).
HeteroAnTx is a tricyclic derivative of AnTx with little conformational freedom. The addition of the 
methylated pyrazole ring mimics the cis conformation of the enone carbonyl in AnTx with the 
electron-rich nitrogen substituting for the carbonyl oxygen. This extra ring makes for a structure 
which is more stable than AnTx, having an energy value of 43.255 kcal/mol and an N-N distance of 
4.49A in its lowest energy, chair form. Rigorous conformational restriction or the extra bulk may 
account for its poor activity (see section 2.3.5.4).
4.4 Discussion
In order to validate the correlation of structural conformation and biological activity, an 
assumption of this study has been that a search would be made for the optimal, static 
pharmacophore which is initially presented to the receptor. Although other conformations pertinent to 
the later stages of interaction between ligand and receptor might be relevant to functional activity 
and therefore should not to be ignored, for the purposes of simplifying the conformational searching 
the preceeding, static pharmacophore was assumed. The pharmacophore model proposed by Beers 
and Reich in 1970 seems to have stood the test of time. The model has more recently been 
corroborated using a distance geometry method (Sheridan et al 1986) and, given its indisputable 
integrity, though remaining largely unrefined, was used as a guide in this project to explore the 
effects of structural alterations and to aid the search for bioactive conformations.
Although the proposed pharmacophore models (see section 1.5) appear adequate to justify some of 
the 3-dimensional structural requirements of many nicotinic agonists, they are incomplete as they do 
not explain the activity of analogues of certain established nicotinic agonists. This is perhaps not 
surprising given the alterations to the ground state, electronic character and innumerable other 
physicochemical parameters associated with even very subtle structural modifications. Another 
contributory factor to this stagnation of the model may be the conflict that is often observed between 
the conformational preferences of the isolated and receptor bound ligand. For instance 1H-NMR 
studies reveal that the conformation adopted by acetylcholine when bound to the receptor is quite 
distinct to that found in either the solid state or those predominant in solution (see below: Behling et 
al 1988). The bound conformation of a ligand represents a pharmacophore mode perhaps different 
to that the receptor must initially be confronted with and which determines whether interaction is 
going to take place. Although the flexibility of acetylcholine presents an exception to the rule among 
the otherwise semi-rigid nicotinic agonists, this observation highlights complications in the attempted 
derivation of a pharmacophore model from conformation searches in more than one environment. 
These observations do then bring into perspective the existence of several pharmacophore modes, 
each of which is associated with a particular receptor state, be it resting, activated, or one of the 
many desensitised states.
4.4.1 Acetylcholine
Following template forcing of the crystal structure of ACh onto the conformation assumed by 
c/'s, chair anatoxin-a, a lower energy structure was obtained which also overlaid very well with the 
more potent AnTx. The new conformation was not highly strained but was by no means the most 
stable conformer the structure can assume (see Figure 4.1). The distance between the nitrogen and 
oxygen centres was well within the limits defined for the Beers-Reich pharmacophore, and the 
torsion angles (see section 4.3.1, inset 2) agreed well with those quoted for the crystal and solution 
conformations of ACh (Behling et al 1988), which adopt a gauche arrangement about the N-C-C-0 
backbone. In order to attain a good fit with the AnTx template, the ACh molecule adopts an extended 
conformation, whereas it is reported that when bound to the nicotinic receptor of Torpedo the 
molecule is in a bent (trans, relative to the N-C-C-0 backbone) conformation in which the oxygens 
are adjacent and the methyl groups form an uninterrupted hydrophobic surface over the rest of the
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molecule (Behling et at 1988). This conformation also exists for the molecule when it is bound to 
lipid. Behling and co-workers speculated that the receptor bound conformation of ACh may be 
dictated by a generally hydrophobic environment in which there is also adequate provision for the 
interaction of the charged centres with complementary receptor points. Both the hydrophobic and 
hydrophilic 'surfaces' of the molecule must interact with regions of the receptor suggesting that the 
whole molecule is virtually 'consumed' when bound, which would require the provision of a 
substantial binding pocket to accommodate both the length of the molecule and its various 
interacting groups.
Directionality of the lone pair of the carbonyl oxygen was comparable to that of the template AnTx 
molecule. Little discrepancy was observed between the relative volumes occupied by ACh and 
AnTx, with only the methyl groups associated with the quaternary ammonium extending beyond the 
space occupied by AnTx - this space is however occupied by the methyls associated with the N- 
methylated forms of AnTx. Notably, N-methylated analogues of AnTx (both Me-AnTx and Me2-AnTx - 
Table 4.7) are less potent than ACh (Table 2.3) which could indicate that in order for methylation 
around the nitrogen centre to be accommodated in the binding pocket there must be a certain 
degree of flexibility in the ligand structure. This flexibility is largely absent in AnTx but among the 
piperazines, for example, inversion of the cyclohexane-like ring may give sufficient flexibility.
Relative to many other nicotinic agonists, ACh has only moderate potency at the neuronal receptors 
studied here. This may be a consequence of a series of factors, though the increased flexibility of 
this structure must dictate its potency to a large extent. Energy barriers to interconversion between 
some conformers are relatively small (Figure 4.1) so isomerisation may occur readily at room 
temperature - conversely, in the analogous acyclic analogue of AMP.Mel (see below: McGroody et 
al 1994), energy barriers to interconversion are high (~19kcal/mol) restricting the number of 
conformers at room temperature. The more conformational states that are accessible at room 
temperature the less dominant the bioactive species becomes and consequently less opportunities 
arise for interaction of the bioactive conformer with the receptor.
4.4.2 Nicotine
Preferred orientations of the pyrolidine and pyridine ring systems of nicotine modelled in this 
study corroborated those reported from NMR and quantum mechanical data (Pullman et al 1971). 
The methyl and pyridine group favoured a trans arrangement. The cis isomer was susceptible to 
steric effects associated with the bulky N-methyl group creating energetic differences between the 
syn and anti forms, though these effects were not apparent in the trans isomer. It might be expected 
that given the small energetic difference between syn and anti forms of the trans isomer, and the 
relatively small energy barrier to rotation of the rings between syn and anti forms, then rotation of the 
rings may be promiscuous event and thus both forms might be equally populated.
Strangely, the stereoselectivity exhibited in favour of the (-) enantiomer by the [3H]-(-)-nicotine 
labelled receptor is not explained by differences in the distance between the charged centres, for the 
separation of these atoms in both (+) and (-) isomers of nicotine are identical in the lower energy syn
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and anti forms, although distances more acceptable to the pharmacophore model were evident for 
syn forms. Therefore, handedness of the molecule (i.e. volume displacement of the molecule relative 
to the functional groups) could be a more important determinant of potency at [3H]-(-)-nicotine 
labelled, than [125l]aBgt labelled, receptors. This stereoselectivity is not exhibited by the [125l]cxBgt- 
labelled (a7-containing) receptor indicative of geometrical differences in the binding sites of these 
two receptors. Overlap of the carbon skeletons of (+)nicotine and (+)AnTx was better than that seen 
for (-)nicotine, although the RMS fit for the nitrogen centres alone was better for (-)nicotine (see 
section 4.3.2, inset 5). Orientation of the N-methyl group relative to the rest of the carbon skeleton 
may determine the relative inactivity of the (+) isoform nicotine.
Addition of a methyl group to the pyrrolidine nitrogen of nicotine decreases the stability of the 
structure considerably, especially in the trans isomer. Besides dispersing the positive charge 
associated with the cationic headgroup, this introduction creates steric clash between the hydrogens 
of the respective ring systems making interconversion between isomers much more energetically 
expensive, although relatively insignificant changes occur to the N(+)-N(-) distance. Methylation of 
nornicotine to nicotine increases potency, and is tolerated in nicotine monomethiodide. The 
pyrrolidine and pyridine rings of the nicotine skeleton are given greater flexibility over, say AnTx, due 
to the rotatable bond which connects the ring systems. This greater degree of relative flexibility may 
contribute to toleration of N-methylation in nicotine, as is seen with acetylcholine.
The absence of a directional dipole in nicotine seems not to denigrate the potency of this ligand. 
Much like the benzene ring of DMPP, the electronic character of the pyridine ring is probably diffuse 
though with an electronegative hotspot. Nicotine and DMPP are structurally quite similar in that their 
ring systems do not lie in the same plane, and the presence of a large delocalised electron cloud 
associated with the unsaturated ring. The fact that the carbonyl of AMP.Mel can be substituted with 
an unsaturated ring system which bestows greater potency on DMPP, the presence of a similar ring 
in the potent nicotine structure, and the greater than 100-fold loss of potency following substitution of 
the carbonyl with hydroxyl groups in AnTx (Table 4.7), lends less credence to the requirement for 
the formation of a hydrogen bond in the interaction between receptor and ligand, and supports the 
importance of some form of hydrophobic interaction in the site. We have already seen that possible 
alterations to the extent of the dipole in the Homo-, Propyl- and Isopropyl-AnTx derivatives does not 
seem to effect biological affinity of activity, thus could conclude that the dipole is not a prerequisite of 
the pharmacophore, and much less so is the extent of the charge separation associated with it. This 
is consistent with the presence of many hydrophobic residues in or around the binding pocket and 
with the absence of hydrogen bonding candidates in the receptor.
4.4.3 Piperazine-based compounds
All conformations of boat and chair forms were surveyed by rotation of the sidechain (either 
acetyl or benzene group) hinged to the six-membered, piperazine ring. Global minima occur at 
angles that maximise orbital overlap (i.e. 0° and 180° for acetyl-containing AMP analogues, and 90° 
and 270° for DMPP). As mentioned above, DMPP may be fortunate in its possession of a benzene 
ring which provides a cloud of delocalised electrons in place of the discrete dipole of AMP. The
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presence of this hydrophobic ring bestows greater potency upon this piperazine compound relative 
to its analogues which possess a hydrogen bond accepting group (see sections 2.3.5.3 and 3.3.3.3). 
The torsional energy barrier for rotation of the benzene ring is roughly 3kcal/mol less than for the 
acetyl (AMP) analogues, thus if the bioactive conformation, which maximises either the hydrophobic 
or possible hydrogen binding interaction, requires these sidechains to be other than in the local 
energy minimum, then the energy penalty incurred through rotation of the benzene ring will be less 
than a similar alteration to the acetyl sidechain. The hydrophobic interaction between the benzene 
ring and receptor binding residues is also likely to be more vague than that associated with the 
directional dipole, which forms a hydrogen bond with an orbital containing an unshared pair of 
electrons, (i.e. at ±60° from the plane defined by the carbonyl carbon and its substituents for the sp2- 
hybridised orbitals of a carbonyl oxygen). Therefore, perhaps the bioactive conformer of DMPP is 
attained through a smaller deviation from its global minimum energy conformation, whereas the 
same may not be true of the acetyl analogues which would thus incur a larger energy penalty. A 
consequence of the absence of a discrete electronegative centre in DMPP permits some flexibility in 
the measurement of the Beers-Reich distance and indeed, although this distance is some 0.7A 
longer on average than for the AMP analogues (Figure 4.3b), deviations are small indicating that in 
the majority of conformations explored a pi electron system is apparently appropriately placed for 
interaction with the receptor. Substitution of the benzene of DMPP with the acetyl-like sidechain in 
AMP.Mel increases the global minimum energy by some 12kcal/mol, the result of an increase in the 
electrostatic energy. It would appear this increase in electrostatic character, although in the form of a 
carbonyl, destabilises the structure enough to reduce potency.
Differences in the energetics of desolvation of ligands which interact with the nicotinic receptor could 
play a significant part in the observed potencies. Substitution of functional groups with those that 
increase the number of hydrogen bonds to water should, all other effects being constant, 
conceivably decrease the potency of a ligand as more energy is required to strip the hydration shell 
prior to binding. Such extrapolations cannot confidently be made as other intramolecular changes 
may also influence the binding reaction (see below). However, McGroddy and co-workers (1994) 
have performed molecular dynamics conformational searches of hydrated forms (i.e. in the presence 
of some 499 water molecules) of AMP.Mel and its less potent, acyclic derivative HTED (N,N,N,N'- 
tetramethyl-A/-acetylethylenediamine iodide). They demonstrate that AMP.Mel and HTED show 
relatively similar functions for the interaction between water molecules and their carbonyl oxygen 
and quaternary amine nitrogen. Flexibility of the HTED N-C-C-N(+) backbone tends to vary the 
extent of solvation, though conformers which are more compact shield the charged species (C=0(8- 
) and N(+)) reducing the number of water molecules participating in the formation of the hydration 
shell - these more compact molecules do not however conform particularly well to the Beers-Reich 
distance, a finding consistent with the need for an extended conformation of acetylcholine. The 
solvation shell of AMP.Mel is less extensive than any of the HTED structures that conform to the 
Beers-Reich criteria, by some 3-5 water molecules on average - the differences are largely due to 
the replacement of the methyls of HTED by methylene groups in AMP.Mel. These differences in 
solvation energy suggest that more energy may be required to desolvate HTED compared to 
AMP.Mel, an observation that could be extended to other nicotinic ligands though, given the
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relatively similar sizes of agonists, this contribution to differences in biological potency may not be as 
significant as variations in intramolecular interactions. Additionally, the more water molecules there 
are in the primary solvation shell of a particular conformation of a molecule the greater the entropic 
energy deficit incurred, which could influence the proportions of different conformers in solution and 
therefore available to interact with the receptor. The loss of entropic energy on binding would be a 
more important consideration for flexible molecules such as ACh, but may be less so for the majority 
of structurally rigid nicotinic agonists. The primary hydration shell of DMPP would feasibly contain a 
larger number of water molecules than would that of the AMP analogues. This should favour the 
binding of AMP over DMPP to the receptor though unfortunately this is not the case as electrostatic 
differences in these molecules must overshadow the desolvation issue.
In the same study involving AMP.Mel (McGroddy et al 1994) it has been demonstrated that although 
AMP.Mel maintains rigidity around the quaternary amine due to stable solvation, the ring undergoes 
significant dynamics at the acetyl end. The sp2 hybridisation of the amide nitrogen favours a planar 
conformation with a bond angle of 120°. These authors observe that upon molecular dynamics 
simulations most of the trajectory is populated by approximate half-chair ring conformations in which 
this amide nitrogen at the acetyl end of the molecule is in the same plane as the methylene groups of 
the ring. Other deviations at the acetyl end of the ring produced chair and twist boat conformations. 
The comparatively rigid quaternary amine remains out of the plane of the methylene groups 
throughout the simulation. Ring structures of cyclohexane are not reported to favour these 
conformations adopted by AMP.Mel, thus the piperazines used in this study may populate unusual 
ring conformations due to quaternisation of one of the nitrogens and the planarity of the other. It is 
conceivable that AMP.HCI is less rigid around its quaternary amine and therefore less able to keep 
the quaternary amine out of the plane of the ring methylenes. This disposition of the electropositive 
centre out of the plane of the hydrogen bond accepting group may be responsible for the lower 
potency of AMP.HCI relative to AMP.Mel (and possibly DMPP). Additionally, although AMP.HCI is 
generally very stable and has comparable Beers-Reich distance to AMP.Mel, the volume around the 
quaternary nitrogen may be insufficient to occupy the binding pocket and the extra methyl may be 
required to disperse the electropositive charge.
Molecular dynamics calculations and experimental determinations of the conformation of HTED in 
solution (McGroddy et al 1993b & c), identify the trans conformer of the carbonyl as being most 
stable, with a translcis equilibrium constant of greater than 4. However, it has been suggested from 
19F NMR experiments that only the less stable c/s conformer of the carbonyl of HTED is able to 
interact with the nAChR from Torpedo electroplaque (McGroddy et al 1993a). This reflects 
observations with bound and unbound conformations of acetylcholine. In this current study there 
was little or no preference for the c/'s or trans orientation of the acetyl sidechain in the semi-rigid 
cyclic equivalent AMP.Mel, or even AMP.HCI. It is likely that with more flexible molecules, such as 
HTED and acetylcholine, the receptor is able to recognise conformations which closely approximate 
to the ideal pharmacophore and once initiated in the binding reaction these ligands are forced to 
undergo conformational reorientations such that interactions with the complementary receptor points 
are maximised and the new conformer stabilised. This is probably the difference between the
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observed conformations for solution and receptor bound states of flexible ligands. The extent of 
these reorientations determine the energy of binding and are reflected in the ligand's potency. More 
rigid molecules such as AnTx must be close to the optimum pharmacophore model, for its potency 
suggests little or no structural reorientation on binding, if large conformational changes were 
necessary then they would be energetically expensive for this rigid structure and therefore costly in 
terms of increase in binding energy. AnTx should therefore remain the principal line of attack in 
determining the requisite features of the nicotinic pharmacophore.
In a study conducted on a series of carbamyl analogues of potent nicotinic agonists containing 
piperadine and piperazine structures (Spivak et al 1989a), the effect of having an NH2 or CH3 group 
a  to the carbonyl moiety was assessed. These structures, which are structurally highly homologous 
to the piperazines used in this study, included AMP.Mel and isoarecolone methiodide (a structure 
which resembles AMP.Mel except that the nitrogen at the acetyl end of the ring is replaced by an 
unsaturated carbon atom). Interestingly, substitution of the CH3 group by NH2 in the synthesis of 
carbamyl analogues, reduced their potency at the frog neuromuscular junction (Spivak e ta l 1989a). 
The presence of the NH2 in these molecules, which may have the effect of donating hydrogen bonds 
to water thus raising the energy barrier for desolvation that precedes receptor binding (see above), 
was predicted to confer a constant reduction in potency of the carbamyl analogues relative to the 
acetyl. However, the effect of this replacement was not constant for these structures the discrepancy 
being more likely due to intramolecular changes. Carbamyl analogues demonstrate a less negative 
electrostatic potential about the carbonyl oxygen, most probably due to the introduction of the 
electronegative NH2 group which disperses the negative character of this group. Thus these results 
tend to support a role for the acetyl-like methyl group of the piperazines in accentuating the dipole of 
the carbonyl, and also for providing essential hydrophobic bulk around the carbonyl carbon. Notably, 
if the acetyl-like methyl is removed from AnTx (AnTxal in table 4.7) there is a significant reduction in 
potency.
4.4.4 Anatoxin-a: a template ligand for the nicotinic pharmacophore
The recent nicotinic pharmacophore model of Hacksell and Mellin (1989) was derived by re­
examination of an Active Analogue Approach to generate a model which derived from novel potent 
nicotinic agonists. These authors examined the features of agonist conformations that explain the 
stereoselective actions of the receptor, using (+)AnTx as the central focus of the investigation. While 
the bioactive conformation of AnTx remains controversial (Witkop & Brossi 1984: Koskinen & 
Rapoport 1985: Hacksell & Mellin 1989), both the c/s, boat and c/s, chair conformers meet the 
requirements of the Beers-Reich pharmacophore and have consequently been suggested to 
represent the bioactive state (Witkop & Brossi 1984: Koskinen & Rapoport 1985). The c/s 
conformers do not comply with the pharmacophore model generated through the active analogue 
approach (Hacksell & Mellin 1989) and do not explain the activity profiles of other AnTx analogues. 
Therefore the trans, chair conformation has also been proposed by these latter authors to represent 
the bioactive state. We determined that such a fundamental discrepancy in determining the likely 
bioactive conformation of this important ligand could be addressed more directly through the 
synthesis of analogues which might stabilise either the c/s or trans conformation, and/or the
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conformation of the ring system. We have attempted to integrate the structural and biological 
relationships derived from these synthetic analogues with observations of other AnTx analogues.
Boat or chair conformation?
The conformational studies undertaken in this project reveal that anatoxin and many of its less 
radically modified analogues could feasibly flip easily between boat and chair conformations of the 
seven-membered ring, with the exception of the sterically crowded N-methylated derivatives (see 
below). Chair conformers were favoured by about 1 kcal/mol over the corresponding boat conformers 
in the global minimum energy conformations of the carbonyls, though this varied depending on the 
complexity of the sidechain modification. In general, most of this energy difference is accounted for 
by the difference in torsion energy between the two forms. However, among the carbonyls, these 
conformations were insufficient to fulfil the Beers-Reich distance criteria. In order for the chair 
conformations to conform to this model an energy penalty is incurred creating instability among the 
structures. Thus it may be that although chair conformations are energetically preferable the boat 
conformation may be the dominant bioactive form for most of the anatoxin analogues. Koskinen & 
Rapoport (1985) have suggested that the solution conformation of AnTx.HCI in D20  is in the 
energetically preferred twist-chair form, and indeed all other evidence from experimental (i.e. X-ray, 
U.V., I.R. and N.M.R.) and theoretical sources (see Thompson et al 1992) corroborate this.
The N-methylated forms of the anatoxin analogues expectedly prefer to assume the chair 
conformation due the steric crowding associated with the extra bulk. N-methylation profoundly 
decreases the potency of anatoxin and its analogues (Table 4.7: Wonnacott et al 1992). This 
decrease may be a consequence of greater charge distribution about the cationic headgroup, an 
unacceptable increase in volume in the same area, or due to the instability of the boat conformation 
(i.e. N,N-dimethyl AnTx is unable to adopt a boat conformation). The latter speculation would favour 
a bioactive conformation for anatoxin whereby the seven-membered ring would adopt the boat 
conformation. Variation in the electronic environment of the nitrogen centre may have a significant 
effect on overall conformation (Koskinen & Rapoport 1985), though this study found that methylation 
had little effect on the energetic profiles of analogues besides an expected relative increase in the 
energy of the structures.
Cis or trans orientation of the enone carbonyl?
The conformation of the enone system of AnTx is reported to adopt a trans orientation in the 
solid state (AnTx.HCI), a cis orientation in MO calculations, and is more freely rotating in solution 
(Koskinen & Rapoport 1985). In this project all global energy minimum conformations of anatoxin 
and its analogues were oriented with the dihedral close to 180° - the trans isomer was found to be 
favoured by around 6kcal/mol in both boat and chair conformations of anatoxin itself, and although 
the energy difference varied, this pattern was repeated for all of the analogues. The requirement for 
planar restriction of the enone system of AnTx through conjugation, is evident from the poorer 
activity of dihydroanatoxin. Koskinen & Rapoport (1985) determined the cis conformer to be 
0.75kcal/mol lower in energy than its trans isomer. The energy difference observed between cis and 
trans conformers in this study were attributable to intramolecular coulombic effects. In the less stable
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cis isomer of the anatoxin structure itself, non-bonded attractive interactions between the partial 
negative charge on the carbonyl oxygen and the positively charged hydrogen atoms associated with 
the nitrogen centre, most probably account for the increased instability - the same is probably true of 
the boat conformers. These nuclei are further apart in the cis conformer explaining the increase in 
coulombic energy. Support for the increased stability of the trans configuration is much evident from 
various other geometry optimisation methods, ( i.e. molecular mechanical and molecular orbital 
methods: see Thompson et al 1992).
The difference in energy between cis and trans forms, although not considerable, may infer the 
predominance of the trans form in the population. An interesting result from studies of the I.R. 
spectrum of AnTx in CHCI3 (Koskinen & Rapoport 1985) indicate the presence of both cis and trans 
populations of AnTx, although the proportions were not quantitatively determined. The N.O.e. 
difference spectrum of AnTx in CDCI3 suggests that both cis and trans conformations are 
significantly populated (Koskinen & Rapoport 1985), though Spivak and co-workers (1980) infer that 
the cis conformation represents a 'considerable proportion1 of the mixed population. It is probable 
that intramolecular electrostatic effects of the agonist molecule may be attenuated to some extent at 
the nicotinic receptor binding site, as the pharmacophore model implies that the nitrogen and 
carbonyl oxygen atoms interact with complementary receptor points which would thus smother the 
electrostatic effects of the ligand. Coulombic interactions may also be attenuated by polar solvents, 
thus the NMR data obtained for the AnTx conformations in CDCI3 may mimic to a certain extent the 
situation at the level of receptor recognition/interaction. If the intramolecular electrostatic interactions 
are neglected from in vacuo calculations, then the energy difference between the cis and trans 
conformer, especially of the chair conformation, becomes almost insignificant. Thus, either the cis or 
trans orientation of the enone moiety may be the conceivable bioactive conformation.
Thompson and co-workers (1992) made a search of the crystallographic data base using the 1- 
acetyl-1-cyclohexene sub-structure as a geometrically equivalent structure to part of the ring system 
of AnTx in order to deduce the incidence of cis and trans orientations in energetically stable 
conformations. They discovered that six out of the seven extracted structures possessed a trans 
configuration, the seventh being locked in the cis orientation due to an internal hydrogen bond. The 
average dihedral angle for the enone function among these structures was 175.9°, planarity similar 
to that observed for our derived minimum energy conformations, and for the AnTx structures 
generated by Thompson and co-workers (1992), although generally more planar than the angle 
found in the AnTx.HCI crystal (-162.7°: Koskinen & Rapoport 1985). A trans configuration of the 
enone moiety (175.4°) in the crystal conformation of the N-acetyl derivative of AnTx is also reported 
(see Thompson et al 1992), the seven-membered ring being in the chair conformation. Although the 
enone function retained its conjugation using the torsional parameters described in the 
HYPERCHEM forcefield, it appears to have been insufficient to permit the slight twisting of this 
function, as would be expected from any steric interactions.
The conformational flexibility of the acetyl sidechain of AnTx and its analogues appears to depend 
on the extent of the electrostatic interaction between the partial negative charge of the oxygen and
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the positively charged hydrogen atoms of the nitrogen centre. Thompson and co-workers (1992), 
using the semi-empirical MO program MOPAC, observed how the energy of each conformation of 
AnTx, where the acetyl group was subjected to dihedral driver calculations, was mirrored by the 
distance between the nitrogen and oxygen atoms (i.e. if the distance increases then so does the 
energy of the system).
Other observations of AnTx and its relatives
Pyridohomotropane (PHT: Figure 2.1), like the anatoxin analogues, loses affinity when 
methylated, though we have already seen that it seems the presence of methyl groups around the 
nitrogen centre is essential for conferring activity to agonists such as DMPP (see above and section 
2.3.5.3), isoarecolone methiodide and ferruginine methiodide (Spivak et al 1983: Figure 2.1). The 
effect of N-methylation in AnTx may be due to a destabilisation of the AnTx skeleton, as was 
suggested by Kofuji and co-workers (1990), and consequent destabilisation of the cis conformation 
of AnTx. These observations have been used to support the view that the bioactive conformation of 
AnTx is represented by the cis and not the trans form (Kofuji et al 1990). Although PHT has poor 
activity even with the hydrogen bond accepting group confined to the cis orientation, this, like our 
synthetic HeteroAnTx (see below), does not imply that inactivity is a direct consequence of a cis 
orientation, as other factors may also be contributing to the poor biological activity of these 
molecules. For instance the receptor essential volume described by Hacksell and Mellin (1989) may 
be impinged upon by the likes of PHT and HeteroAnTx, and indeed the same exclusive volume may 
prevent the effective interaction of the N-methylated AnTx analogues. A modification of the relative 
position of the methyl groups was implicated in the decrease in nicotinic potency that resulted from 
the reduction of isoarecolone methiodide to DMPP (Spivak et al 1986). Spivak and Albuquerque 
(1982) proposed that the displacement of the charged centre out of the carbonyl hydrogen bonding 
plane might contribute to potency of the secondary amine of AnTx, a displacement that could be 
exceeded in N-methylated AnTx analogues.
AnTx has the unusual advantage of being a secondary amine, and it can therefore achieve a 
stronger coulombic bond with the receptor than can the bulkier quaternary amines - the energy of 
the electrostatic interaction between ligand and receptor depends inversely upon the distance 
between the cationic headgroup and anionic site of the receptor.
Although not formally overlaid, the (+) and (-) forms of anatoxin clearly demonstrated the quite 
different volumes they would occupy in the receptor binding site. No energetic difference, or 
difference in the distance between the pharmacophore points, was apparent for these two 
molecules. The reason for the inactivity of the (-) isomer must therefore lie solely with the geometric 
configuration of the remainder of the molecule. The handedness of the molecule must be 
incompatible with the receptor binding site, which may result from either the volume requirements 
not being satisfied, or from the placement of otherwise crucial groups for the binding reaction on the 
wrong side of the molecule. The same must be true, at least in part, for the stereoisomers of nicotine 
(see above)
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Synthetic analogues and the cis/trans conformation of the enone
Conformational studies investigating the influence of methine or methylene units upon the 
conformation of the enone system proved to be inconclusive though the trans arrangement was the 
lowest energy configuration. Extension of the alkyl sidechain did not appear to distort the 
conformation of the anatoxin skeleton, and the energy barrier to rotation between cis and trans 
arrangement remains essentially unchanged relative to the parent. No preference was observed for 
the boat or chair conformation. These observations are consistent with the retention of biological 
activity by these analogues. Whether it is the hydrophobic nature of these sidechains, their weaker 
influence on the ground state conformation, or their greater flexibility over previous anatoxin 
analogues (Swanson eta l 1991: Wonnacott et al 1991) which makes them tolerable is unclear.
The more conformationally constrained analogues (HydroxyAnTx, EpoxyAnTx and HeteroAnTx) all 
have very poor biological activity, a consequence which cannot be wholly attributed to the pseudo- 
cis orientation of the carbonyl in HydroxyAnTx, or its equivalent in HeteroAnTx, neither to 
conformation adopted in the Epoxide. Inactivity in these species is most likely due to several factors 
among them unfavourable intramolecular electrostatic interactions, (especially in the epoxide), the 
introduction of too much steric bulk in sensitive regions, and unreasonable constraints on the 
conformation of the molecules as a whole.
5 General discussion
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The techniques applied in this study have been used to generate biological and structural 
descriptors for existing and novel ligands of the neuronal nicotinic receptors. Collation of this data 
has provided the opportunity to correlate the activity of these molecules with the differences and 
similarities between their structural attributes. As a result of these comparative studies we have 
made attempts, (using rationally designed synthetic analogues of a potent nicotinic agonist), to 
probe the model of the pharmacophore for the nicotinic receptor in order to ascertain the specific 
structural requirements of active ligands. It is hoped that this study has developed this structural 
model, and as a result will provide greater insight into the essential requirements of the receptor 
binding pocket of the nicotinic receptor in terms of volume constraints, the choice and relative 
orientation of potential charged centres partaking in the interaction (be they on the a  subunit or 
those adjacent to it), and other information not available at present but which would provide pointers 
to refine the 3-dimensional structure of the neuronal nicotinic receptor.
5.1 Features of the pharmacophore of active nicotinic agonists
Before a model of an optimum active molecule can evolve, consistent, reliable data on the 
activity of a series of such ligands must be generated. In this study activity indicators were generated 
from two distinct biological systems (viz. the receptor binding assay and the functional oocyte 
expression system). Although these systems are both consistent and reliable within their 
experimental limitations, their output is representative of the biological situation unique to it. For 
instance, whereas the receptor binding assays may regard aspects of the pharmacophore model 
which are important in stabilising the desensitised state, the functional responses of the a l  
homomer could be a result of additional features of active ligands which are perhaps less important 
in the initial recognition but are realised only in the proceeding activation, as well as desensitisation, 
events. Thus the determination of a truly complete pharmacophore model can only be derived 
through consideration of structural elements of the activating molecules which induce the complex 
sequence of interacting processes responsible for activity. However, in order for an agonist to be 
effective the recognition barrier must first be overcome, therefore all molecules which either bind to, 
activate or subsequently desensitise the receptor must possess common structural features which 
allow them to access the receptor. The way in which these features are presented determines 
whether one molecule is more potent than another.
Cationic head
A centre of positive charge is a prerequisite of all nicotinic agonists. It would appear, however, 
that this centre is very sensitive to the nature of the groups over which the charge is dispersed, even 
among homologous structures. We have seen that N-methylation of the cationic head in nicotine and 
anatoxin diminishes activity, most significantly in the latter case, whereas among piperazine ring 
based structures N-methylation is essential for activity. Activity as a function of successive 
methylation shows no consistent trend among bi- and tri-cyclic agonists - the ferruginines are 
structural analogues of anatoxin yet methylation among them defies simple order. These differential 
effects on potency of the juxtaposition of methyl groups and the sensitive nitrogen centre may be a
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consequence of many effects: for example, N-methylation may redistribute and/or disperse the 
positive charge (consequently altering the separation distance of the charged centres), increase the 
bulk about this indispensable region, displace the charged head relative to the plane defined by the 
hydrogen bond accepting group, for example, alter the ground state of the carbon skeleton, stabilise 
particular conformations through increased solvation, besides inducing more subtle electrostatic 
effects. It is apparent that particular carbon skeletons are more suited to N-methylation. It may be 
that more flexible molecules, such as acetylcholine and the piperazines in this study, require to be N- 
methylated in order to be active and for this cationic head to be removed out of the plane defined by 
the hydrogen bond accepting group, or its substitute. More rigid systems such as anatoxin do not 
tolerate the effects due to N-methylation, though as little or no difference was observed in the 
conformations of methylated and non-methylated structures this is unlikely to be a consequence of 
reorientation of the basic carbon skeleton.
Structural similarity is not sufficient to explain potency. The electrostatic potential pattern of the 
interacting groups must also be considered. Anatoxin reveals a very high positive potential (140-160 
kcal) about the ammonium head (Yao 1991). Binding of this region to the receptor is coulombic, 
therefore decreases in the positive potential should have the effect of weakening the interaction and 
reducing potency. This is clearly observable among the N-methyl and N-dimethyl anatoxin 
analogues which exhibit a dispersal, and therefore reduction, in the positive potential for the Van der 
Waals surfaces in this region (Yao 1991).
Hydrogen bond acceptor group
The function of the carbonyl oxygen as a hydrogen bond acceptor was incorporated as a 
critical element of the pharmacophore for nicotinic ligands by Beers and Reich (1970). This 
functional group is regarded to be of secondary importance in the recognition reaction given, a) that 
a hydrogen bond has not been proved to occur in the ligand-receptor interaction and, b) the 
incidence of auxiliary forms, (although it appears as a carbonyl oxygen in many agonists it is also 
represented by a phenolic or alcoholic OH, or an amine group (see Gund & Spivak 1991)). In more 
extreme cases this hydrogen bond accepting group appears to be present but irrelevant. For 
example in DMPP, although an amine group is present its near proximity to the cationic head (i.e. 
across the piperazine ring) probably excludes it as an important interacting species, it being 
overshadowed by the delocalised electron cloud of the benzene ring which may be an important 
hydrophobic interaction site.
Areas of high electron density, and lowest electrostatic potentials (0-40 kcal), are seen about the 
carbonyl group in anatoxin (Yao 1991). Although not ubiquitous among the nAChR agonists, if 
present, the more extreme the charge separation of the dipole the greater should be the hydrogen 
bonding strength and potency. However, it appears that the area of low potential requires to be 
consistent, and the greater the deviance from this value the lower the potency of the anatoxin 
analogue (Yao 1991). Thus possession of a permanent, directional dipole does not appear to be 
critical.
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Hydrogen bonding is not the only determinant of potency in this region, the acetyl-like methyl present 
in many agonists must also play an important role in the binding. Its presence in the potent anatoxin 
structure suggests a role in determining the electrostatic character of the carbonyl oxygen, and/or its 
occupation of a specific hydrophobic niche in the receptor binding cavity. In many of the anatoxin 
analogues which have probed the character of this region of the molecule (Swanson et al 1991: 
Wonnacott et al 1991) substitution of this methyl with charged species had a detrimental effect on 
activity. For example, the CH30- and (CH3)2N- group, while donating electrons which may enhance 
the hydrogen bonding of the carbonyl, may be of an inappropriate size or charge to fit a hydrophobic 
niche occupied by the methyl. In our attempts to restrict the enone conformation of the anatoxin 
molecule methine or methylene units were added to this region. Affinity and activity of these 
structures at both of the nAChRs studied were comparable to the parent and may even have 
increased affinity. Such alterations to the structure in the synthesis of Homo- Propyl- and Isopropyl- 
anatoxin would probably have insignificant effects on the electrostatic potential of the carbonyl group 
relative to the parent structure, but quite obviously would impinge on the space and hydrophobic 
environment around the atom a  to the carbonyl carbon. Additional to the coulombic interaction, (and 
possible hydrogen bonding), hydrophobic interactions may therefore also be an important feature of 
the pharmacophore and determinant of potency. The anatoxin structure may provide appropriate 
orientation of the acetyl-like methyl such that this interaction is effective and contributory to the 
binding reaction. However, given that some of the alkyl modified sidechain analogues of anatoxin 
retain and may enhance potency, it is feasible that this interaction has not been fully exploited in 
anatoxin and is realised only when the sidechain is extended in these analogues. However, it may 
be that this interaction has been overexploited in IsopropylAnTx which exhibits a hooked dose 
response curve. The perturbation of the receptor structure that occurs on activation in the case of 
this molecule may become exaggerated resulting in conversion to, or increased stabilisation of, a 
desensitised state.
Three dimensional structure
Nicotinic receptors, especially the [3H]-(-)-nicotine labelled receptor in this study, demonstrate 
selectivity in favour of certain stereoisomers of particular ligands - most extremely nicotine and 
anatoxin. Although functional groups are identical for stereoisomers their relative orientations are 
important in their recognition by the receptor as a result of the configuration of the carbon skeleton. It 
appears the receptor is capable of recognising handedness in certain activating ligands suggesting 
that among the semi-rigid agonists at least possession of the basic functional groups is insufficient 
for activity. Thus the absolute configuration of carbon atoms that make up the rigid structural 
skeleton must be such that interacting groups are appropriately presented to the receptor to 
maximise the interaction. Flexible molecules overcome the problem of not presenting the correct 
rigid conformation of the carbon skeleton through their ability to more easily interconvert between 
different conformers, though their effective interaction with the receptor may mean a more induced fit 
forced by the functional groups of the receptor, which is energetically expensive and thus reflects the 
reduced potencies of the less rigid ligands.
5.2 Residues important in the formation of the receptor binding pocket
Potential complementary amino acid residues for the cationic headgroup of activating ligands 
are not forthcoming among those residues identified by photolabelling ligands directed at the region 
of the nAChR a  subunit around cysteines 192 and 193 (see section 1.4.3.1), or the region crucial to 
the interaction of the potent abungarotoxin molecule (see section 1.4.4). This suggests the area for 
such long-range charge-charge interactions may only be present at the interface between a  and 
other subunits (see below). Affinity labelling and site-directed mutagenesis has identified, (besides 
the two adjacent disulphide-linked cysteines at a192 and a193), at least four aromatic residues in 
the a  subunit sequence of the receptor which directly affect ligand binding and receptor function 
(see section 1.4.3.4). Three of these four residues are tyrosines (Tyr93, Tyr190 and Tyr198) and 
each stabilises the cationic headgroup of the agonist as determined by the binding of 
phenyltrimethylammonium (PTMA: Aylwin et al 1994) and tetramethylammonium (TMA: Sine et al 
1994). Each also contributes equally to the binding energy (Sine et al 1994). The exact nature of 
these contributions are, however, not equivalent for while replacement of Tyr with Phe, Trp or Ser 
reduces the apparent affinity of ACh the severity of the reduction is dependent both on the position 
and chemical nature of the substitution. For Tyr93 and Tyr190 the hydroxyl is essential for activity, 
yet it is the aromatic facet of the Tyr198 sidechain which appears to be important (Aylwin et al 1994: 
Sine et al 1994). The significance of the hydroxyl groups may be their ability to form a salt bridge- 
type interaction with the ammonium group of the ligand - this would require that the pKa of this group 
be reduced by the local environment around it so that a significant portion of the anionic tyrosinate 
form exists (Aylwin eta11994). The covalent interaction of lophotoxin with Tyr190 (Abramson et al 
1989) supports the nucleophilic state of this residue. Likewise the aromatic portion of Tyr198 could 
interact with the ligand cation, but could equally likely provide a region of hydrophobic interaction. 
This latter residue, and possibly the aromatic of Tyr190, have been suggested to maintain the 
disposition of the tyrosine triad either through direct interaction with the neighbouring tyrosines, or 
via local residues of the binding pocket (Sine et al 1994).
These aromatics (including Trp149) presently provide the only plausible sites in the receptor a  
subunits for interaction with nicotinic ligands. The strong presence of these aromatic groups is 
consistent with the provision of a hydrophobic environment in which interactions could occur 
between the cation of nicotinic ligands and the n  electrons of the aromatic ring. Additionally, 
hydrophobic interactions would accommodate the conjugated systems which appear in so many 
nicotinic agonists, including the unsaturated ring systems which substitute for the discreet potential 
hydrogen bond accepting group in certain agonists (e.g. DMPP). It is likely that the cation-7c electron 
interaction diminishes rapidly with distance, and that the hydrophobic effect would be still weaker 
given the requirement for close contact to displace water from the interacting surfaces. The ability of 
the alkyl-modified sidechain variants of anatoxin to interact with the receptor as effectively as the 
parent structure supports the provision of a relatively hydrophobic environment in the binding site, 
and indicates the space constraints associated with this region. The participation of aromatics in the 
binding of nicotinic ligands to the receptor is consistent with the affinity demonstrated by quaternary 
ammonium groups for aromatic rings of synthetic macrocycles (see section 1.4.3.4) and with the 
nature of the acetylcholinesterase binding site.
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It must be stressed that the role of the residues identified on the a  subunit in the binding reaction is 
likely to be a contributory one, in that they probably do not represent the complete picture of the 
binding site. Acidic residues also contribute to the binding of ACh and the fact that candidates are 
found in the 5 and 7 subunits supports the notion of a binding site formed at the interface of adjacent 
nicotinic subunits. For instance in the region 8164-224 there are some 6 aspartates and 5 
glutamates. In this same region of the Torpedo ACh receptor the crosslinker S-(2- 
glycylaminoethyl)dithio-2-pyridine (GCP), attached by a disulphide bond to Cys192 or Cys193, forms 
an amide bond with aspartate or glutamate residues. Given the length of this crosslinker (0.9nm fully 
extended) this puts an important acidic residue within 0.9nm of the a  subunit binding site disulphide, 
providing a possible site for coulombic charge-charge interaction with the cationic centre of nicotinic 
ligands. Of the 12 acidic residues in this region the most functionally important appears to be 6 
Asp180, which when neutralised, (by mutation to Asn of the homologous residue in mouse muscle), 
decreased affinity of the receptor for ACh by some 100-fold (Czajkowski et al 1993). Only mutation 
of one other acidic residue in this region, SGIu189, significantly affected function (a 10-fold reduction 
in affinity of ACh), whereas mutation of the ten other acidic residues in this 8164-224 segment did 
not have such profound effects. However, 8Asp165 and 8Glu182 of the Torpedo receptor, have 
been confirmed to be labelled by the same GCP crosslinker that reacts with SAsp180, but not 8 
Asp189 (Czajkowski & Karlin 1995). It is therefore probable that 8Asp180 contributes directly to the 
binding of ACh, though the functional roles of SAsp165 and SGIu182, which also lie within 0.9nm of 
Cys192 and 193, remain unclear.
The holistic model of the binding site for interacting nicotinic ligands emerging from such crosslinking 
experiments appears to be consistent with the residues SAsp165, 8Asp180 and SGIu182 facing a  
Cys192 and 193 across a water-filled cavity between a  and 8 subunits. The reduction in binding 
affinity observed on neutralisation of 8Asp180 could quite feasibly result from the removal of the 
electrostatic interaction between the carboxylate of this residue and the cationic group of ACh, 
though structural perturbations can not be discounted - 8Asp165 and SGIu182 are probably not in 
such close proximity to the ammonium group of the ligand. Of these three residues, only SAsp180 is 
identically conserved among aligned sequences of the 8 ,7  and e subunits on muscle-type receptor 
(Czajkowski eta! 1993).
The evidence that the ACh binding site contains both acidic and aromatic residues supports findings 
which indicate a negative electrostatic potential associated with the site in the Torpedo receptor 
(Stauffer & Karlin 1994). Assuming that the long-range attractive coulombic interaction between 
anionic and cationic centres, as might be present in the binding reaction between nicotinic ligand 
and receptor, would be sensitive to ionic strength, these authors assessed the reaction rates of 
charged methanethiosulphonates with the cysteine residues in the binding site. Analysis of rate 
constants provided evidence consistent with the ACh binding site containing either two or three 
negative charges which would account for the three acidic residues labelled by GPC (Czajkowski & 
Karlin 1995). An electrostatic potential of -80mV at the binding site, (which includes a contribution of 
-30mV from the Cys thiols), substantiates the existence of anionic residues in the binding cavity and
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strengthens the involvement of some long-range electrostatic contribution to the binding of ligand to 
the receptor.
Our current understanding of the amino acid residues which contribute to the formation of the 
nicotinic receptor agonist binding site implicates the involvement of residues from different, adjacent 
subunits and thus supports an inter-subunit location for the site. It appears that ligands bind in some 
form of crevice in which there is provision for either charge-charge or cation-rc electron interaction 
with the cationic headgroup of the nicotinic agonist, hydrophobic and other salt bridge-type 
interactions. An inter-subunit site may provide opportunity for more pronounced and/or less 
energetically expensive structural perturbation upon binding given that ligand accommodation will 
directly rearrange the tertiary structure of two protein chains at each binding site. The most likely 
reason for maintaining a cationic ammonium group in the structure of agonist molecules of the 
nAChR is likely to be for the fulfilment of a long-range coulombic interaction in the binding cavity, 
which probably represents the most significant reaction between ligand and receptor. The subsidiary 
interactions between the other functional groups of the ligand and residues present in the binding 
site could determine the intimacy of the association between ligand and surrounding receptor milieu, 
thus determining factors such as potency and efficacy. For instance, although many structural 
features may be common to many agonists which demonstrate disparate biological activities, these 
same features must alter in the way they are presented to the binding site residues, due to factors 
such as steric clash, volume displacement, extent of electrostatic potential, carbon skeleton and so 
on. It is the prioritisation of these factors which will generate a better understanding of the complex 




The determinations of the structural model of the nicotinic pharmacophore and receptor 
binding site are processes that are mutually exclusive, thus if further progress is to be made in the 
elucidation of the structure of these models then close, simultaneous attention must be paid to the 
results of structural modifications to both.
•  As regards the nicotinic pharmacophore, the ligand that is potentially the most informative is 
anatoxin-a. Its rigidity restricts the number of possible conformations, thus the effects of 
structural modification should be more easily quantifiable, reducing the complications common to 
more flexible structures whose conformations are more readily influenced by even minor 
modifications to the skeleton. Perseverance with the type of sidechain modifications around the 
important carbonyl moiety carried in this project are essential if the bioactive conformation of this 
ligand is to be determined and used as a benchmark in the design of future ligands. It will be 
important to determine whether IsopropylAnTx is actually manifesting subtype selectivity - 
functional data for this ligand at the a l  receptor is required to extrapolate the competition 
binding observations. The series of extensively modified sidechain analogues of anatoxin 
studied previously (Swanson et al 1991: Wonnacott et al 1991) possibly introduced too many 
electrostatic modifications to the structure making interpretation difficult, besides which all had 
the effect of reducing potency considerably compared to the parent compound. Our slightly more 
rational, less complex approach should remain the angle of attack as further modification of the 
structure in this same region may produce an anatoxin-a analogue that has both selectivity for a  
7-containing receptors, and the potential to be an affinity ligand. This would provide a selective 
receptor handle to facilitate probing receptor function especially in the complicated system of the 
brain. Such a tool is lacking at present in the nicotinic receptor field, although a recent report (De 
Fiebre et al 1995) that a derivative of anabasiene (a structure closely related to nicotine) exhibits 
selective agonist action at the neuronal nicotinic a7  receptor is encouraging. It also appears that 
a-conotoxin Imi is able to selectively antagonise the a7 and a9 homomeric receptors (Johnson 
et al 1995). Cytisine, a ligand not covered in this study, like anatoxin-a is a very potent and rigid 
nicotinic agonist, and given the extensive evidence regarding its sensitivity to the presence of 
different p subunits in the heterooligomeric nAChR complex, could prove to be an equally 
valuable tool in the determination of the pharmacophore and the binding site.
•  The structural limitations and physicochemical nature of the interacting groups in the receptor 
binding pocket would complement the derivation of a pharmacophore model. Definition of a 
complementary receptor point to the cationic headgroup of interacting ligands remains 
unresolved - 5Asp180 is a strong candidate, though a7 lacks an equivalent residue in this 
position (see section 1.4.3.5). Also, given the substitutable nature of the carbonyl group in many 
ligands speculation that the formation of a hydrogen bond is crucial for activity seems tenuous. 
The complementary receptor points for these interactions could be explored through 
mutagenesis of receptor residues that are either labelled by photosensitive probes or 
crosslinking agents, or are implicated to be in the vicinity of the bound ligand. Emphasis should 
be placed not only on the anionic residues but also the on the many aromatic amino acids
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present in the potential binding site as observations with the piperazine structures and novel 
anatoxin-a analogues indicate the involvement of hydrophobic interactions in the binding of the 
ligand. The combination of site-directed mutagenesis and the analysis of functional 
consequences of the changes both through competition binding and receptor expression studies 
in the oocyte, would provide some insight into the interactions that may take place at the 
recognition and transduction levels.
Although theoretical, the calculations of computational chemistry are becoming increasingly 
accurate and therefore no less emphasis should be placed on the use of such methods to derive 
structural models of both agonist conformations and possible receptor binding site models, and 
indeed the docking of the ligand to the receptor. Although the molecular modelling carried out in 
this project was informative, the more rigorous approaches of molecular dynamics calculations 
in the presence of water molecules would represent both a more physiologically accurate picture 
and reveal more subtle structural perturbations providing a picture of the predominant forms of 
the structure available for binding. Most importantly, there is a need to compare structural and 
physicochemical attributes through extensive superposition studies of many structurally and 
biologically diverse potential bioactive conformations of molecules. This would provide crucial 
information regarding the volume limitations about the basic pharmacophore points, flexibility of 
the Beers-Reich distance, handedness, physicochemical character of functional groups and 
many other attributes important to active ligands.
It is increasingly evident that the a7 homomeric receptor does not represent native aBgt- 
sensitive receptors found in situ. It may therefore be prudent to continue expression studies but 
with the a7 subunit in the presence of other a  or p subunits cloned. This would create an 
important extra dimension to this study for as well as representing a more physiological situation 
it would investigate the influence of heterologous neighbouring subunits on the formation of the 
binding site, an important issue given the lack of potential interacting amino acid residues from 
the a  subunit.
5.4 Publications and communications resulting from this work
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Arsenicals have been used to explore the role of vicinal cysteines in enzymes, such as
.. ■ - i
dihydrolipoamide dehydrogenase [Stevenson et al., 1978; Danson et al. 1986; Danson et ah 
4d&7]. Arsenical reagents are attractive because bifunctional reagents can be generated to 
study residues in the vicinity of the vicinal cysteines. As a prerequisite to adopting such an
approach to studying the agonist binding site of nAChR, it is necessary to establish that the
monofunctional arsenical interacts with the receptor. Pike & Loring [1992] and Rossant et
al [4994] have shown that this is the case for immunoisolated nAChR from chicken brain
labelled with J^Hfagonists. Here we report that [3H]cytisine binding to rat brain membranes 
is prevented by reduction and reaction with />aminophenyldichloroarsine (APA; for 
structure see insert, Fig. 2) in a manner consistent with a specific modification of the pair of 
vicinal cysteines in the a  subunit.
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